

THE UNIVERSITY of EDINBURGH

Edinburgh Research Explorer

Proteome profile of peripheral myelin in healthy mice and in a neuropathy model

Citation for published version:

Siems, SB, Jahn, O, Eichel, MA, Kannaiyan, N, Wu, L-MN, Sherman, D, Kusch, K, Hesse, D, Jung, RB, Fledrich, R, Sereda, MW, Rossner, MJ, Brophy, P & Werner, HB 2020, 'Proteome profile of peripheral myelin in healthy mice and in a neuropathy model', eLIFE. https://doi.org/10.7554/eLife.51406

Digital Object Identifier (DOI):

10.7554/eLife.51406

Link: Link to publication record in Edinburgh Research Explorer

Document Version: Peer reviewed version

Published In: eLIFE

General rights

Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

Take down policy The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer content complies with UK legislation. If you believe that the public display of this file breaches copyright please contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and investigate your claim.





24 Hills Road, P 01223 855346 Cambridge W elifesciences.org CB2 1JP T @elife_sciences

FOR PEER REVIEW - CONFIDENTIAL

Proteome profile of peripheral myelin in healthy mice and in a neuropathy model

Tracking no: 27-08-2019-TR-eLife-51406R2

Impact statement: Comprehensive compendium of myelin proteins in the peripheral nervous system and method to address molecular diversity of myelin sheaths in health and disease.

Competing interests: No competing interests declared

Author contributions:

Sophie Siems: Sophie B. Siems performed all experiments not specified otherwise, conducted statistical analysis, contributed to analysis and interpretation of data. Olaf Jahn: Olaf Jahn performed proteome analysis, contributed to analysis and interpretation of data. Maria Eichel: Maria A. Eichel performed teased fiber labeling and microscopy. Nirmal Kannaiyan: Nirmal Kannaiyan performed bioinformatic analysis of RNA-Seq data. Lai Man Wu: Lai Man N. Wu performed histological analysis. Diane Sherman: Diane L. Sherman performed histological analysis. Kathrin Kusch: Kathrin Kusch provided unpublished reagents. Dörte Hesse: Dörte Hesse contributed to proteome analysis. Ramona Jung: Ramona B. Jung performed biochemical purification of myelin. Robert Fledrich: Robert Fledrich provided an unpublished RNA-Seq dataset. Michael Sereda: Michael W. Sereda provided an unpublished RNA-Seq dataset. Moritz Rossner: Moritz J. Rossner supervised bioinformatic analysis of RNA-Seq data. Peter Brophy: Peter J. Brophy supervised histological analysis. Hauke Werner: Hauke B. Werner conceived, designed and directed the study, analyzed and interpreted data and wrote the article.

Funding:

Deutsche Forschungsgemeinschaft (DFG): Hauke B. Werner, WE 2720/2-2; Deutsche Forschungsgemeinschaft (DFG): Hauke B. Werner, WE 2720/4-1; Deutsche Forschungsgemeinschaft (DFG): Hauke B. Werner, WE 2720/5-1; Deutsche Forschungsgemeinschaft (DFG): Moritz J. Rossner, RO 4076/3-2; Wellcome: Peter Brophy, 0842424 The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Data Availability:

All data generated or analysed during this study are included in the manuscript and supporting files. This includes the mass spectrometry proteomics data. Source data files have been provided for Figures 1, 3 and 5. Additional to being provided in the source data files, mass spectrometry proteomics data have been deposited to the PRIDE/ProteomeXchange Consortium with dataset identifier PXD015960 and are available to the reviewers. Please use username: reviewer94825@ebi.ac.uk and password: C5r5SVMi. Upon acceptance of the manuscript, we will notify PRIDE support to make the dataset publicly available.

Ethics:

Human Subjects: No Animal Subjects: Yes Ethics Statement: All animal work conformed to United Kingdom legislation (Scientific Procedures) Act 1986 and to the University of Edinburgh Ethical Review Committee policy; Home Office project license No. P0F4A25E9.

Information for reviewers (full submissions):

eLife aims to publish work of the highest scientific standards and importance in all areas of the life and biomedical sciences, from the most basic and theoretical work through to translational, applied and clinical research. Articles must be methodologically and scientifically rigorous, ethically conducted, and objectively presented according to the appropriate community standards.

You will be asked for a general assessment and a summary of any major concerns (ideally in fewer than 500 words), as well as a list of any minor comments (optional). You will also have the opportunity to comment on the statistical rigour of the work (optional).

In your general assessment, please articulate what is exciting and whether the work represents a significant contribution. Please note our guidelines about requests for additional work:

- 1. We will only request new work, such as experiments, analyses, or data collection, if the new data are essential to support the major conclusions. The authors must be able to do any new work in a reasonable time frame (additional work should be conducted and written up within two months); otherwise, we will usually reject the manuscript.
- 2. Any requests for new work must fall within the scope of the current submission and the technical expertise of the authors.

Our goal is to make peer review constructive and collaborative: after the reviews have been submitted independently, there is an online discussion between the reviewers in which each reviewer will see the identity of the other reviewers.

eLife Sciences Publications, Ltd is a limited liability non-profit nonstock corporation incorporated in the State of Delaware, USA with company number 5030732, and is registered in the UK with company number FC030576 and branch number BR015634 at the address 24 Hills Road, Cambridge, CB2 1JP.

eLife Sciences Publications, Ltd is a limited liability non-profit nonstock corporation incorporated in the State of Delaware, USA with company number 5030732, and is registered in the UK with company number FC030576 and branch number BR015634 at the address 24 Hills Road, Cambridge, CB2 1JP.

,

Proteome profile of peripheral myelin in healthy mice and in a neuropathy model

Sophie B. Siems^{1,7}, Olaf Jahn^{2,7}, Maria A. Eichel¹, Nirmal Kannaiyan³, Lai Man N. Wu⁴, Diane L. Sherman⁴, Kathrin Kusch¹, Dörte Hesse², Ramona B. Jung¹, Robert Fledrich^{1,5}, Michael W. Sereda^{1,6}, Moritz J. Rossner³, Peter J. Brophy⁴, Hauke B. Werner^{1,*}

Affiliations

1

2

15

16

21 22 ¹Department of Neurogenetics, Max Planck Institute of Experimental Medicine, 37075 Göttingen, Germany

²Proteomics Group, Max Planck Institute of Experimental Medicine, 37075 Göttingen, Germany ³Department of Psychiatry and Psychotherapy, University Hospital, LMU Munich, 80336 Munich, Germany

⁴Centre for Discovery Brain Sciences, University of Edinburgh, Edinburgh, EH16 4SB, UK

23 24 25 26

⁵Institute of Anatomy, University of Leipzig, 04103 Leipzig, Germany

27 28 ⁶Department of Clinical Neurophysiology, University Medical Center, 37075 Göttingen, Germany ⁷These authors contributed equally to this work

29

30 * Corresponding author

- 31 Dr. Hauke Werner
- 32 Max Planck Institute of Experimental Medicine
- 33 Department of Neurogenetics
- 34 Hermann-Rein-Str. 3
- D-37075 Göttingen, Germany 35
- Tel.: +49 (551) 3899-759; Fax.: +49 (551) 3899-758 36
- 37 E-mail: Hauke@em.mpg.de
- 38

39 Key words

40 Schwann cell, peripheral nervous system (PNS), myelin proteome, neuropathy, Charcot-

41 Marie-Tooth disease (CMT4F), periaxin (PRX), MCT1/SLC16A1, demyelination, axon 42 degeneration, transcriptome

43

44 Word and figure count

- 45 Abstract 149 words; Introduction/results/discussion 4786 words
- 46 6 main figures; 2 figure supplements; 2 main tables; 4 source data files
- 47 48

49 ABSTRACT

50

51 Proteome and transcriptome analyses aim at comprehending the molecular profiles of the 52 brain, its cell-types and subcellular compartments including myelin. Despite the relevance of 53 the peripheral nervous system for normal sensory and motor capabilities, analogous 54 approaches to peripheral nerves and peripheral myelin have fallen behind evolving technical 55 standards. Here we assess the peripheral myelin proteome by gel-free, label-free mass-56 spectrometry for deep quantitative coverage. Integration with RNA-Sequencing-based 57 developmental mRNA-abundance profiles and neuropathy disease genes illustrates the utility 58 of this resource. Notably, the periaxin-deficient mouse model of the neuropathy Charcot-59 Marie-Tooth 4F displays a highly pathological myelin proteome profile, exemplified by the 60 discovery of reduced levels of the monocarboxylate transporter MCT1/SLC16A1 as a novel 61 facet of the neuropathology. This work provides the most comprehensive proteome resource 62 thus far to approach development, function and pathology of peripheral myelin, and a 63 straightforward, accurate and sensitive workflow to address myelin diversity in health and 64 disease. 65

66

67 INTRODUCTION

68

69 The ensheathment of axons with myelin enables rapid impulse propagation, a prerequisite 70 for normal motor and sensory capabilities of vertebrates (1,2). This is illustrated by 71 demyelinating neuropathies of the Charcot-Marie-Tooth (CMT) spectrum, in which mutations 72 affecting myelin genes as MPZ, PMP22, GJB1 and PRX impair myelin integrity and reduce 73 the velocity of nerve conduction in the peripheral nervous system (PNS) (3). 74 Developmentally, myelination by Schwann cells in peripheral nerves is regulated by axonal 75 neuregulin-1 (4,5) and the basal lamina (6-8) that is molecularly linked to the abaxonal 76 Schwann cell membrane via integrins and the dystroglycan complex (9–12). In adulthood, 77 the basal lamina continues to enclose all axon/myelin-units (13), probably to maintain myelin. 78 Beyond regulation by extracellular cues, myelination involves multiple proteins mediating 79 radial sorting of axons out of Remak bundles, myelin membrane growth and layer 80 compaction (14–18). For example, the lg-domain containing myelin protein zero (MPZ; also 81 termed P0) mediates adhesion between adjacent extracellular membrane surfaces in 82 compact myelin (19). At their intracellular surfaces, myelin membranes are compacted by the 83 cytosolic domain of MPZ/P0 together with myelin basic protein (MBP; previously termed P1) 84 (20,21). Not surprisingly, MPZ/P0 and MBP were early identified as the most abundant 85 peripheral myelin proteins (22,23).

86

87 A system of cytoplasmic channels through the otherwise compacted myelin sheath remains 88 non-compacted throughout life, i.e. the adaxonal myelin layer, paranodal loops, Schmidt-89 Lanterman incisures (SLI), and abaxonal longitudinal and transverse bands of cytoplasm 90 termed bands of Cajal (14,24,25). Non-compacted myelin comprises cytoplasm, cytoskeletal 91 elements, vesicles and lipid-modifying enzymes, and thus numerous proteins involved in 92 maintaining the myelin sheath. The cytosolic channels probably also represent transport 93 routes toward Schwann cell-dependent metabolic support of myelinated axons (26-31).

94

95 Considering that Schwann cells constitute a major proportion of the cells in the PNS, 96 oligonucleotide microarray analyses have been used for mRNA abundance profiling of total 97 sciatic nerves (32,33). Indeed, these systematic approaches allowed the identification of 98 novel myelin constituents including non-compact myelin-associated protein (NCMAP/MP11) 99 (34). Notwithstanding that the number of known peripheral myelin proteins has grown in 100 recent years, a comprehensive molecular inventory has been difficult to achieve because 101 applications of systematic ('omics') approaches specifically to Schwann cells and peripheral 102 myelin remained comparatively scarce, different from studies addressing oligodendrocytes 103 and CNS myelin (35–40). One main reason may be that the available techniques were not

104 sufficiently straightforward for general application. For example, the protein composition of 105 peripheral myelin was previously assessed by proteome analysis (41). However, at that time 106 the workflow of sample preparation and data acquisition (schematically depicted in Figure 107 **1A**) was very labor-intense and required a substantial amount of input material; yet the depth 108 of the resulting datasets remained limited. In particular, differential myelin proteome analysis 109 by 2-dimensional fluorescence intensity gel electrophoresis (2D-DIGE) requires considerable 110 hands-on-time and technical expertise (41,42). While this method is powerful for the 111 separation of proteoforms (43), it typically suffers from under-representation of highly basic 112 and transmembrane proteins. It thus allows comparing the abundance of only few myelin 113 proteins rather than quantitatively covering the entire myelin proteome. Because of these 114 limitations and an only modest sample-to-sample reproducibility, 2D-DIGE analysis of myelin, 115 although unbiased, has not been commonly applied beyond specialized laboratories.

116

117 The aim of the present study was to establish a straightforward and readily applicable 118 workflow to facilitate both comprehensive knowledge about the protein composition of 119 peripheral myelin and systematic assessment of differences between two states, e.g., 120 pathological alterations in a neuropathy model. The major prerequisites were the biochemical 121 purification of myelin, its solubilization with the detergent ASB-14 and the subsequent 122 automated digestion with trypsin during filter-aided sample preparation (FASP). The tryptic 123 peptides were fractionated by liquid chromatography and analyzed by mass spectrometry for 124 gel-free, label-free quantitative proteome analysis. More specifically, we used nano-flow 125 ultra-performance liquid chromatography (nanoUPLC) coupled to an electrospray-ionization 126 guadrupole time-of-flight (ESI-QTOF) mass spectrometer with ion mobility option, providing 127 an orthogonal dimension of peptide separation. The utilized data-independent acquisition 128 (DIA) strategy relies on collecting data in an alternating low and elevated energy mode 129 (MS^E); it enables simultaneous sequencing and quantification of all peptides entering the 130 mass spectrometer without prior precursor selection (reviewed in (44,45)). With their highduty cycle utilized for the acquisition of precursor ions, MS^E-type methods are ideally suited 131 132 to reliably quantify proteins based on peptide intensities. Notably, these methods do not 133 involve the use of spectral libraries in the identification of proteins, different from other DIA 134 strategies. Instead, the achieved high-complexity fragmentation spectra are deconvoluted 135 before submission to dedicated search engines for peptide and protein identification (46.47). In the MS^E mode, this deconvolution involves precursor-fragment ion alignment solely on the 136 137 basis of chromatographic elution profiles; on top, drift times of ion mobility-separated precursors are used in the high-definition (HD)MS^E mode. An expansion of the latter referred 138 to as the ultra-definition (UD)MS^E mode, additionally implements drift time-dependent 139 140 collision energy profiles for more effective precursor fragmentation (48,49).

141

142 Indeed, compared to the previously used manual handling and in-gel digestion, the current 143 workflow (schematically depicted in Figure 1A) is considerably less labor-intense, and 144 automated FASP increases sample-to-sample reproducibility. Moreover, differential analysis 145 by quantitative mass spectrometry (MS) facilitates reproducible quantification of hundreds 146 rather than a few distinct myelin proteins. Together, the present workflow increases the 147 efficacy of assessing the peripheral myelin proteome while shifting the main workload from 148 manual sample preparation and gel-separation to automated acquisition and processing of 149 data. We propose that comprehending the expression profiles of all myelin proteins in the 150 healthy PNS and in myelin-related disorders can contribute to advancing our understanding 151 of the physiology and pathophysiology of peripheral nerves.

152

153 **RESULTS**

154

155 **Purification of peripheral myelin**

156 We biochemically enriched myelin as a light-weight membrane fraction from pools of sciatic 157 nerves dissected from mice at postnatal day 21 (P21) using an established protocol of 158 discontinuous sucrose density gradient centrifugation (41,50), in which myelin membranes 159 accumulate at the interface between 0.29 and 0.85 M sucrose. By immunoblotting, proteins 160 specific for both compact (MPZ/P0, MBP, PMP2) and non-compact (PRX) myelin were 161 substantially enriched in the myelin fraction compared to nerve lysates (Figure 1B). 162 Conversely, axonal (NEFH, KCNA1) and mitochondrial (VDAC) proteins and a marker for the 163 Schwann cell nucleus (KROX20/EGR2) were strongly reduced in purified myelin. Together, 164 these results imply that biochemically purified peripheral myelin is suitable for systematic 165 analysis of its protein composition.

166

167 **Proteome analysis of peripheral myelin**

168 It has long been difficult to accurately quantify the most abundant myelin proteins both in the 169 CNS (PLP, MBP, CNP (51)) and the PNS (MPZ/P0, MBP, PRX; this work), probably owing to 170 their exceptionally high relative abundance. For example, the major CNS myelin constituents 171 PLP, MBP and CNP comprise 17, 8 and 4% of the total myelin protein, respectively (51). We 172 have recently provided proof of principle (52) that the mass spectrometric quantification of 173 these high-abundant myelin proteins is accurate and precise when data are acquired in the 174 MS^E data acquisition mode and proteins are quantified according to the TOP3 method, i.e. if 175 their abundance values are obtained based on the proven correlation between the average 176 intensity of the three peptides exhibiting the most intense mass spectrometry response and 177 the absolute amount of their source protein (53,54). Using data acquisition by MS^E we 178 confirmed that CNP constitutes about 4% of the total CNS myelin proteome and that the abundance of CNP in myelin from mice heterozygous for the Cnp gene (Cnp^{WT/null}) compared 179 180 to wild-type mice is 50.7% (±0.4%), in agreement with the halved gene dosage and gel-181 based guantification by silver staining or immunoblotting (52).

182

When applying the MS^E mode to PNS myelin, we quantified 351 proteins with a false discovery rate (FDR) of <1% at peptide and protein level and an average sequence coverage of 35.5% (**Figure 1-source data 1**). While MS^E (labeled in orange in **Figure 1C**) indeed provided a dynamic range of more than four orders of magnitude and thus quantitatively covered the exceptionally abundant myelin proteins MPZ/P0, MBP and PRX, the number of quantified proteins appeared limited when spectral complexity was deconvoluted solely on the basis of chromatographic elution profiles. Accordingly, by using the UDMS^E mode, which

190 comprises ion mobility for additional peptide separation as well as drift time-specific collision 191 energies for peptide fragmentation, proteome coverage was increased about three-fold (1078 192 proteins quantified; average sequence coverage 34.3%; Figure 1-source data 1). However, 193 the dynamic range of UDMS^E (labeled in blue in **Figure 1C**) was found to be somewhat compressed compared to that of MS^E, which can be considered an expectable feature of 194 195 traveling wave ion mobility devices (55), where the analysis of pulsed ion packages leads to 196 a temporal and spatial binning of peptides during ion mobility separation. Indeed, this 197 manifests as a ceiling effect for the detection of exceptionally intense peptide signals, which 198 results in an underestimation of the relative abundance of MPZ/P0, MBP and PRX by 199 UDMS^E.

200

The complementary nature of the MS^E and UDMS^E data acquisition modes led us to 201 202 conclude that a comprehensive analysis of the myelin proteome that facilitates both correct 203 guantification of the most abundant proteins and deep guantitative coverage of the proteome 204 would require analyzing the same set of samples with two different instrument settings for MS^E and UDMS^E, respectively. Considering that instrument time is a bottleneck for the 205 routine differential proteome analysis of myelin from mutant mice, we aimed to combine the 206 207 strengths of MS^E and UDMS^E into a single data acquisition mode. Based on a gene ontology enrichment analysis for cellular components of the 200 proteins of highest and lowest 208 abundance from the UDMS^E dataset, we realized that the 'bottom' of the quantified proteome 209 210 is probably largely unrelated to myelin but dominated by contaminants from other subcellular 211 sources including mitochondria. We thus reasoned that for a myelin-directed data acquisition 212 mode, proteome depth may be traded in for a gain in dynamic range and devised a novel 213 method referred to as dynamic range enhancement (DRE)-UDMS^E, in which a deflection lens 214 is used to cycle between full and reduced ion transmission during mass spectrometric scanning. Indeed, DRE-UDMS^E quantified an intermediate number of proteins in PNS myelin 215 216 (554 proteins; average sequence coverage 30.6%; Figure 1-source data 1) while providing 217 an intermediate dynamic range (labeled in green in Figure 1C). We thus consider DRE-UDMS^E as the data acquisition mode of choice most suitable for routine differential myelin 218 219 proteome profiling (see below).

220

Overall, we found a high reproducibility between replicates and even among the different data acquisition modes as indicated by Pearson's correlation coefficients for protein abundance in the range of 0.765-0.997 (**Figure 1-supplement 1**). When comparing the proteins identified in PNS myelin using the three data acquisition modes, we found a very high overlap (**Figure 1D**). We also found a high overlap (**Figure 1E**) between the proteins identified in the present study by UDMS^E and those detected in previous proteomic 227 approaches to PNS myelin (41,42), thus allowing a high level of confidence. Together, the 228 three data acquisition modes exhibit distinct strengths in the efficient quantification of 229 exceptionally abundant proteins (MS^E), establishing a comprehensive inventory (UDMS^E) 230 and gel-free, label-free differential analysis of hundreds of distinct proteins (DRE-UDMS^E) in 231 peripheral myelin (see **Figure 1A**). Yet, analyzing the same set of samples by different 232 modes may not always be feasible in all routine applications when considering required 233 instrument time.

234

235 Relative abundance of peripheral myelin proteins

236 Considering that MS^E provides the high dynamic range required for the quantification of the 237 most abundant myelin proteins, we calculated the relative abundance of the 351 proteins identified in myelin by MS^E (Figure 1-source data 1). According to quantitative assessment 238 239 of this dataset, the most abundant PNS myelin protein, myelin protein zero (MPZ/P0), 240 constitutes 44% (+/-4% relative standard deviation (RSD)) of the total myelin protein (Figure 241 2). Myelin basic protein (MBP), periaxin (PRX) and tetraspanin-29 (CD9) constitute 18% (+/-242 1% RSD), 15% (+/-1%) and 1% (+/-0.2%) of the total myelin protein, respectively (Figure 2). For MPZ/P0 and MBP, our quantification by MS^E is in agreement with but specifies prior 243 244 estimations upon gel-separation and protein labeling by Sudan-Black, Fast-Green or 245 Coomassie-Blue, in which they were judged to constitute 45–70% and 2–26% of the total 246 myelin protein, respectively (22,56-58). However, gel-based estimates of the relative 247 abundance of myelin proteins were not very precise with respect to many other proteins. 248 including those of high molecular weight. Indeed, periaxin was identified as a constituent of 249 peripheral myelin after the advent of gradient SDS-PAGE gels (59), which allowed improved 250 migration of large proteins into gels. The present MS^E-based quantification of myelin proteins 251 also extends beyond and partially adjusts an earlier mass spectrometric approach (41). 252 Indeed, the current approach identified and quantified more myelin proteins, probably owing 253 to improved protein solubilization during sample preparation and higher dynamic range of the 254 used mass spectrometer. By MS^E, known myelin proteins (**Table 1**) collectively constitute 255 over 85% of the total myelin protein (Figure 2) while proteins not yet associated with myelin 256 account for the remaining 15% of the total myelin protein.

257

258 Comprehensive compendium and comparison to the transcriptome

To systematically elucidate the developmental abundance profiles of the transcripts that encode peripheral myelin proteins (**Figure 3**), we used our combined proteome inventory of peripheral myelin (**Figure 1-source data 1**) to filter mRNA abundance data of all genes expressed in sciatic nerves. By this strategy, **Figure 3** displays only those transcripts of which the protein product was identified in peripheral myelin rather than all transcripts in the 264 nerve, thereby discriminating myelin-related mRNAs from other mRNAs such as those 265 present in peripheral axons, fibroblasts, immune cells etc. In this assessment we additionally 266 included PMP22 although it was not detected by MS as well as 45 proteins exclusively 267 identified by LC-MS of myelin separated by SDS-PAGE (Figure 1-source data 1). For 268 mRNA abundance profiles, we exploited a recently established RNA sequencing analysis 269 (RNA-Seq; platform Illumina HiSeq 2000) of sciatic nerves dissected form wild type Sprague 270 Dawley rats at embryonic day 21 (E21), P6, P18 and 6 months (60). RNA-Seq provides 271 reliable information about the relative abundance of all significantly expressed genes and is 272 thus not limited to those represented on the previously used oligonucleotide microarrays 273 (41). The raw data (accessible under GEO accession number GSE115930) were normalized 274 (Figure 3-source data 1) and standardized. When comparing the proteome and 275 transcriptome datasets, significant mRNA abundance was detected for all 1046 transcripts 276 for which an unambiguous unique gene identifier was found (Figure 3). 126 transcripts 277 displayed developmentally unchanged abundance levels, i.e., abundance changes below a 278 threshold of 10% coefficient of variation (Figure 3B; Figure 3-source data 1).

279

280 By fuzzy c-means clustering, those 920 transcripts that showed developmental abundance 281 changes were grouped into 5 clusters (Figure 3A; Figure 3-source data 1). Among those, 282 one cluster corresponds to an mRNA-abundance peak coinciding with an early phase of 283 myelin biogenesis (cluster 'P6-UP'), which includes the highest proportion of known myelin 284 proteins (Table 1) such as MPZ/P0, MBP, PRX, cyclic nucleotide phosphodiesterase (CNP), 285 fatty acid synthase (FASN), myelin-associated glycoprotein (MAG), proteolipid protein 286 (PLP/DM20), cell adhesion molecule-4 (CADM4/NECL4), connexin-29 (GJC3), claudin-19 287 (CLDN19) and CKLF-like MARVEL-transmembrane domain containing protein-5 (CMTM5). 288 However, many known myelin proteins clustered together according to their mRNA-289 abundance peak coinciding with a later phase of myelination (cluster 'P18-UP'), including 290 peripheral myelin protein 2 (PMP2), tetraspanin-29 (CD9), tetraspanin-28 (CD81), connexin-291 32 (GJB1), plasmolipin (PLLP), junctional adhesion molecule-3 (JAM3), CD59 and 292 dystrophin-related protein-2 (DRP2). The proportion of known myelin proteins was lower in 293 the clusters corresponding to mRNA-abundance peaks in adulthood (clusters 'late-UP', 'U-294 shaped'). Yet, a considerable number of transcripts displayed abundance peaks at the 295 embryonic time-point (cluster 'Descending'), including carbonic anhydrase 2 (CA2), cofilin-1 296 CFL1), tubulin beta-4 (TUBB4b) and band 4.1-protein B (EPB41L3). Generalized, the 297 clusters were roughly similar when comparing previous oligonucleotide microarray analysis 298 of mouse sciatic nerves (41) and the RNA-Seq analysis of rat sciatic nerves (this study); yet, 299 the latter provides information on a larger number of genes and with a higher level of 300 confidence. Together, clustering of mRNA abundance profiles allows categorizing peripheral301 myelin proteins into developmentally co-regulated groups.

302

303 When systematically assessing the proteins identified in myelin by gene ontology (GO)-term 304 analysis, the functional categories over-represented in the entire myelin proteome included 305 cell adhesion, cytoskeleton and extracellular matrix (labeled in turquoise in Figure 4). When 306 analyzing the clusters of developmentally co-expressed transcripts (from **Figure 3**), proteins 307 associated with the lipid metabolism were particularly enriched in the P6-UP and P18-UP 308 clusters, while those associated with the extracellular matrix (ECM) were over-represented in 309 the U-shaped and Descending clusters (Figure 4). For comparison, known myelin proteins 310 (Table 1) were over-represented in the P6-UP and P18-UP clusters (Figure 4). Together, 311 our proteome dataset provides comprehensive in-depth coverage of the protein constituents 312 of peripheral myelin purified from the sciatic nerves of wild type mice, and comparison to the 313 transcriptome allows identifying developmentally co-regulated and functional groups of 314 myelin proteins. Our data thus supply a solid resource for the molecular characterization of 315 myelin and for discovering functionally relevant myelin proteins.

316

317 Neuropathy genes encoding myelin proteins

318 Heritable neuropathies can be caused by mutations affecting genes preferentially expressed 319 in neurons, Schwann cells or both (3,61-63). To systematically assess which neuropathy-320 causing genes encode peripheral myelin proteins, we compared our myelin proteome 321 dataset with a current overview about disease genes at the NIH National Library of Medicine 322 at https://ghr.nlm.nih.gov/condition/charcot-marie-tooth-disease#genes. Indeed, 31 myelin 323 proteins were identified to be encoded by a proven neuropathy gene (Table 2), a 324 considerable increase compared to eight disease genes found in a similar previous approach 325 (41). Notably, this increase is owing to both the larger size of the current myelin proteome 326 dataset (Figure 1E) and the recent discovery of numerous neuropathy genes by the 327 widespread application of next generation sequencing.

328

329 Pathological proteomic profile of peripheral myelin in a neuropathy model

The results presented thus far were based on analyzing myelin of healthy wild type mice; yet we also sought to establish a straightforward method to systematically assess myelin diversity, as exemplified by alterations in a pathological situation. As a model we chose mice carrying a homozygous deletion of the periaxin gene ($Prx^{-/-}$) (26,64). Periaxin (PRX) is the third-most abundant peripheral myelin protein (**Figure 2**) and scaffolds the dystroglycan complex in Schwann cells. $Prx^{-/-}$ mice represent an established model of Charcot-Marie-Tooth disease type 4F (65–67). Aiming to assess the myelin proteome, we purified myelin from pools of sciatic nerves dissected from $Prx^{-/-}$ and control mice at P21. Upon SDS-PAGE separation and silver staining the band patterns appeared roughly similar (**Figure 5A**), with the most obvious exception of the absence of the high-molecular weight band constituted by periaxin in $Prx^{-/-}$ myelin. Yet, several other bands also displayed genotype-dependent differences in intensity. As expected, PRX was also undetectable by MS^E in $Prx^{-/-}$ myelin, in which most of the total myelin protein was constituted by MPZ/P0 and MBP (**Figure 5B**; **Figure 5-source data 1**).

344

Upon differential analysis by DRE-UDMS^E (Figure 5-source data 2), multiple proteins 345 346 displayed genotype-dependent differences as visualized in a heatmap displaying those 40 347 proteins of which the abundance was reduced or increased with the highest statistical 348 significance in *Prx^{-/-}* compared to control myelin (**Figure 5C**). For example, the abundance of 349 the periaxin-associated dystrophin-related protein 2 (DRP2) was strongly reduced in Prx^{-/-} 350 myelin, as previously shown by immunoblotting (9). Notably, the abundance of multiple other 351 proteins was also significantly reduced in *Prx^{-/-}* myelin, including the extracellular matrix 352 protein laminin C1 (LAMC1; previously termed LAMB2), the laminin-associated protein 353 nidogen (NID1), Ig-like cell adhesion molecules (CADM4, MAG), the desmosomal junction 354 protein desmin (DES), cytoskeletal and cytoskeleton-associated proteins (EPB41L3, MAP1A, 355 CORO1A, SPTBN1, various microtubular and intermediate filament monomers), the 356 monocarboxylate transporter MCT1 (also termed SLC16A1) and the MCT1-associated (68) 357 immunoglobulin superfamily protein basigin (BSG, also termed CD147). On the other hand, 358 proteins displaying the strongest abundance increase in *Prx^{-/-}* myelin included immune-359 related proteins (LGALS3, LYZ2, CTSD), cytoskeletal and cytoskeleton-associated proteins 360 (CAPG, CORO1C, CNN3, several myosin heavy chain subunits), peroxisomal enzymes (CAT, HSD17B4, MDH1) and known myelin proteins (PLLP/plasmolipin, CRYAB, 361 362 GJB1/CX32). For comparison, the abundance of the marker proteolipid protein (PLP/DM20) 363 (69) and the periaxin-associated integrin beta-4 (ITGB4) (12) in myelin was unaltered in Prx^{-/-} 364 myelin. Together, differential proteome analysis finds considerably more proteins and protein 365 groups to be altered in $Prx^{-/-}$ myelin than previously known (**Figure 5C. D-D**^{...}), probably 366 reflecting the complex pathology observed in this model (26,64).

367

368 The monocarboxylate transporter MCT1/SLC16A1 expressed by myelinating 369 oligodendrocytes (70,71) and Schwann cells (28,72) has been proposed to supply lactate or 370 other glucose breakdown products to axons, in which they may serve as substrate for the 371 mitochondrial production of ATP (73–75). In this respect it was striking to find the abundance 372 of MCT1 significantly reduced in peripheral myelin when PRX is lacking (Figure 5C), a result 373 that we were able to confirm by immunoblotting (Figure 5E) and immunolabeling of teased 374 fiber preparations of sciatic nerves (Figure 5F). Notably, reduced expression of MCT1 in 375 Slc16a1^{+/-} mice impairs axonal integrity at least in the CNS (70,76). The reduced abundance of MCT1 thus represents an interesting novel facet of the complex pathology in *Prx^{-/-}* mice. 376 377 Considering that the integrity of peripheral axons may be impaired in Prx^{-/-} mice, we 378 assessed their quadriceps nerves. Indeed, *Prx^{-/-}* mice displayed reduced axonal diameters, a 379 progressively reduced total number of axons and a considerable number of myelin whorls 380 lacking a visible axon (Figure 6), indicative of impaired axonal integrity (77). Yet we note that molecular or neuropathological features other than the reduced abundance of MCT1 381 382 probably also contribute to the axonopathy in *Prx^{-/-}* mice.

383

Together, gel-free, label free proteome analysis provides a cost- and time-efficient method that provides an accurate, sensitive tool to gain systematic insight into the protein composition of healthy peripheral myelin and its alterations in pathological situations. Indeed, gel-free proteome analysis is particularly powerful and comprehensive compared to 2D-DIGE; the workflow presented here appears readily applicable to other neuropathy models, thereby promising discovery of relevant novel features of their neuropathology.

390

391

392 DISCUSSION

393

394 We used gel-free, label-free quantitative mass spectrometry to assess the protein 395 composition of myelin biochemically purified from the sciatic nerves of wild-type mice, 396 thereby establishing a straightforward and readily applicable workflow to approach the 397 peripheral myelin proteome. The key to comprehensiveness was to combine the strengths of three data acquisition modes, i.e., MS^E for correct guantification of high-abundant proteins, 398 399 UDMS^E for deep guantitative proteome coverage including low-abundant proteins and DRE-400 UDMS^E for differential analysis. We suggest that DRE-UDMS^E provides a good compromise between dynamic range, identification rate and instrument run time for routine differential 401 402 myelin proteome profiling as a prerequisite for a molecular understanding of myelin 403 (patho)biology. We have also integrated the resulting compendium with RNA-Seq-based 404 mRNA abundance profiles in peripheral nerves and neuropathy disease loci. Beyond 405 providing the largest peripheral myelin proteome dataset thus far, the workflow is appropriate 406 to serve as starting point for assessing relevant variations of myelin protein composition, e.g., 407 in different nerves, ages, species and in pathological conditions. The identification of 408 numerous pathological alterations of myelin protein composition in the *Prx^{-/-}* neuropathy 409 model indicates that the method is well suited to assess such diversity.

410

411 Aiming to understand nervous system function at the molecular level, multiple 'omics'-scale 412 projects assess the spatio-temporal expression profiles of all mRNAs and proteins in the 413 CNS including oligodendrocytes and myelin (35-39). Yet, peripheral nerves are also 414 essential for normal sensory and motor capabilities. Prior approaches to the molecular 415 profiles of Schwann cells and PNS myelin thus far, however, were performed >8 years ago 416 (32–34,41,78–80), and the techniques have considerably advanced since. For example, 417 current gel-free, label-free mass spectrometry can simultaneously identify and quantify the 418 vast majority of proteins in a sample, thereby providing comprehensive in depth-information. 419 Moreover, RNA-Seq technology has overcome limitations of the previously used microarrays 420 for characterizing mRNA abundance profiles with respect to the number of represented 421 genes and the suitability of the oligonucleotide probes. The present compendium thus 422 provides high confidence with respect to the identification of myelin proteins, their relative 423 abundance and their developmental mRNA expression profiles. This view is supported by the 424 finding that over 80% of the total myelin proteome is constituted by approximately 50 425 previously known myelin proteins. We believe that the majority of the other identified proteins 426 represent low-abundant myelin-associated constituents in line with the high efficiency of 427 biochemical myelin purification. Doubtless, however, the myelin proteome also comprises

428 contaminants from other cellular sources, underscoring the need of independent validation429 for establishing newly identified constituents as true myelin proteins.

430

431 Do myelin proteins exist that escape identification by standard proteomic approaches? 432 Indeed, some proteins display atypically distributed lysine and arginine residues, which 433 represent the cleavage sites of the commonly used protease trypsin. The tryptic digest of 434 these proteins leads to peptides that are not well suited for chromatographic separation 435 and/or mass spectrometric detection/sequencing, as exemplified by the small hydrophobic 436 tetraspan-transmembrane myelin proteins MAL (81) and PMP22 (82). We can thus not 437 exclude that additional proteins with atypical tryptic digest patterns exist in peripheral myelin, 438 which would need to be addressed by the use of alternative proteases. Moreover, potent 439 signaling molecules including erbB receptor tyrosine kinases (83,84) and G-protein coupled 440 receptors (GPRs) (85-87) display exceptionally low abundance. Such proteins may be 441 identified when applying less stringent identification criteria, e.g., by requiring the sequencing 442 of only one unique peptide per protein. However, lower stringency would also result in 443 identifying false-positive proteins, which we wished to avoid for the purpose of the present 444 compendium. We note that a truly comprehensive spatio-temporally resolved myelin 445 proteome should preferentially also include systematic information about protein isoforms 446 and post-translational modifications, which still poses technical challenges.

447

448 Mutations affecting the periaxin (PRX) gene in humans cause CMT type 4F (65.88–90); the 449 neuropathology resulting from mutations affecting periaxin has been mainly investigated in 450 the *Prx^{-/-}* mouse model. Indeed, *Prx^{-/-}* mice display a progressive peripheral neuropathy 451 including axon/myelin-units with abnormal myelin thickness, demyelination, tomaculae, onion 452 bulbs, reduced nerve conduction velocity (64), reduced abundance and mislocalization of the 453 periaxin-associated DRP2 (9) and reduced internode length (26). Absence of SLIs (64) and 454 bands of Cajal (26) imply that the non-compact myelin compartments are impaired when 455 PRX is lacking. In the differential analysis of myelin purified from Prx^{-/-} and control mice we 456 find that the previously reported reduced abundance of DRP2 (9) represents one of the 457 strongest molecular changes in the myelin proteome when PRX is lacking. Notably, the 458 reported morphological changes in this neuropathy model (9,26,64) go along with alterations 459 affecting the abundance of multiple other myelin-associated proteins, including junctional, 460 cytoskeletal, extracellular matrix and immune-related proteins as well as lipid-modifying enzymes. Thus, the neuropathology in Prx^{--} mice at the molecular level is more complex 461 462 than previously anticipated. It is striking that the abundance of the monocarboxylate 463 transporter MCT1/SLC16A1 that may contribute to the metabolic supply of lactate from myelinating cells to axons (27–31) is strongly reduced in $Prx^{-/-}$ myelin. Considering that 464

465 MCT1 in Schwann cells mainly localizes to Schmidt Lanterman incisures (SLI) (28) and that 466 SLI are largely absent from myelin when PRX is lacking (64), the reduced abundance of 467 MCT1 in Prx^{-/-} myelin may be a consequence of the impaired myelin ultrastructure. Yet, considering that SLI are part of the cytosolic channels that may represent transport routes 468 469 toward Schwann cell-dependent metabolic support of myelinated axons, the diminishment of MCT1 may contribute to reduced axonal diameters or axonal loss in $Prx^{-/-}$ mice, probably in 470 471 conjunction with other molecular or morphological defects. Together, the in depth-analysis of 472 proteins altered in neuropathy models can contribute to an improved understanding of nerve 473 pathophysiology.

474

475 Compared to a previous approach (41), the number of proven neuropathy genes of which the 476 encoded protein is mass spectrometrically identified in peripheral myelin has increased four-477 fold from eight to 32 in the present study. This reflects both that the number of proteins 478 identified in myelin has approximately doubled and that more neuropathy genes are known 479 due to the common use of genome sequencing. We note that our compendium comprises 480 not only myelin-associated proteins causing (when mutated) demyelinating CMT1 (e.g., 481 MPZ/P0, NEFL, PMP2) or intermediate CMT4 (GDAP1, NDRG1, PRX) but also axonal 482 CMT2 (RAB7, GARS, HSPB1). Yet, the expression of genes causative of CMT2 is not 483 necessarily limited to neurons, as exemplified by the classical myelin protein MPZ/P0. 484 Indeed, a subset of MPZ-mutations causes axonal CMT2I or CMT2J (91–95), probably 485 reflecting impaired axonal integrity as consequence of a mutation primarily affecting 486 Schwann cells. We also note that the nuclear EGR2/KROX20 causative of demyelinating 487 CMT1D has not been mass spectrometrically identified in myelin, reflecting that Schwann cell 488 nuclei are efficiently removed during myelin purification.

489

While morphological analysis of peripheral nerves by light and electron microscopy is routine in numerous laboratories, systematic molecular analysis has been less straightforward. Using the sciatic nerve as a model, we show that systematic assessment of the myelin proteome and the total nerve transcriptome are suited to determine comprehensive molecular profiles in healthy nerves and in myelin-related disorders. Myelin proteome analysis can thus complement transcriptome analysis in assessing development, function and pathophysiology of peripheral nerves.

497

498 **MATERIALS AND METHODS**

499

500 Mouse models

501 Prx^{-/-} mice (64) were kept on c57Bl/6 background in the animal facility of the University of 502 Edinburgh (United Kingdom). Genotyping was by PCR on genomic DNA using the forward 503 primers 5'-CAGATTTGCT CTGCCCAAGT and 5'-CGCCTTCTAT CGCCTTCTTGAC in 504 combination with reverse primer 5'-ATGCCCTCAC CCACTAACAG. The PCR yielded a 0.5 505 kb fragment for the wildtype allele and a 0.75 kb product for the mutant allele. The age of 506 experimental animals is given in the figure legends. All animal work conformed to United 507 Kingdom legislation (Scientific Procedures) Act 1986 and to the University of Edinburgh 508 Ethical Review Committee policy; Home Office project license No. P0F4A25E9.

509

510 Myelin purification

A light-weight membrane fraction enriched for myelin was purified from sciatic nerves of mice by sucrose density centrifugation and osmotic shocks as described (41,52). Myelin accumulates at the interface between 0.29 and 0.85 M sucrose. *Prx*^{-/-} and wild type control C57BI/6 mice were sacrificed by cervical dislocation at postnatal day 21 (P21). For each genotype, myelin was purified as three biological replicates (n=3); each biological replicate representing a pool of 20 sciatic nerves dissected from 10 mice. Protein concentration was determined using the DC Protein Assay Kit (Bio-Rad).

518

519 Filter-aided sample preparation for proteome analysis

520 Protein fractions corresponding to 10 µg myelin protein were dissolved and processed 521 according to a filter-aided sample preparation (FASP) protocol essentially as previously 522 described for synaptic protein fractions (96) and as adapted to CNS myelin (52,97). Unless 523 stated otherwise, all steps were automated on a liquid-handling workstation equipped with a 524 vacuum manifold (Freedom EVO 150, Tecan) by using an adaptor device constructed in-525 house. Briefly, myelin protein samples were lysed and reduced in lysis buffer (7 M urea, 2 M 526 thiourea. 10 mM DTT. 0.1 M Tris pH 8.5) containing 1% ASB-14 by shaking for 30 min at 527 37°C. Subsequently, the sample was diluted with ~10 volumes lysis buffer containing 2% 528 CHAPS to reduce the ASB-14 concentration and loaded on centrifugal filter units (30 kDa 529 MWCO, Merck Millipore). After removal of the detergents by washing twice with wash buffer 530 (8 M urea, 10 mM DTT, 0.1 M Tris pH 8.5), proteins were alkylated with 50 mM 531 iodoacetamide in 8 M urea, 0.1 M Tris pH 8.5 (20 min at RT), followed by two washes with 532 wash buffer to remove excess reagent. Buffer was exchanged by washing three times with 533 50 mM ammonium bicarbonate (ABC) containing 10 % acetonitrile. After three additional 534 washes with 50 mM ABC/10% acetonitrile, which were performed by centrifugation to ensure

535 quantitative removal of liquids potentially remaining underneath the ultrafiltration membrane, 536 proteins were digested overnight at 37°C with 400 ng trypsin in 40 µl of the same buffer. 537 Tryptic peptides were recovered by centrifugation followed by two additional extraction steps 538 with 40 µl of 50 mM ABC and 40 µl of 1% trifluoroacetic acid (TFA), respectively. Aliquots of 539 the combined flow-throughs were spiked with 10 fmol/µl of yeast enclase-1 tryptic digest 540 standard (Waters Corporation) for quantification purposes and directly subjected to analysis 541 by liquid chromatography coupled to electrospray mass spectrometry (LC-MS). A pool of all 542 samples was injected at least before and after any sample set to monitor stability of 543 instrument performance.

544

545 Mass spectrometry

546 Nanoscale reversed-phase UPLC separation of tryptic peptides was performed with a 547 nanoAcquity UPLC system equipped with a Symmetry C18 5 µm, 180 µm × 20 mm trap 548 column and a HSS T3 C18 1.8 µm, 75 µm × 250 mm analytical column (Waters Corporation) 549 maintained at 45°C. Injected peptides were trapped for 4 min at a flow rate of 8 µl/min 0.1% 550 TFA and then separated over 120 min at a flow rate of 300 nl/min with a gradient comprising 551 two linear steps of 3-35% mobile phase B in 105 min and 35-60% mobile phase B in 15 min, 552 respectively. Mobile phase A was water containing 0.1% formic acid while mobile phase B 553 was acetonitrile containing 0.1% formic acid. Mass spectrometric analysis of tryptic peptides 554 was performed using a Synapt G2-S quadrupole time-of-flight mass spectrometer equipped 555 with ion mobility option (Waters Corporation). Positive ions in the mass range m/z 50 to 2000 556 were acquired with a typical resolution of at least 20.000 FWHM (full width at half maximum) and data were lock mass corrected post-acquisition. UDMS^E and DRE-UDMS^E analyses 557 558 were performed in the ion mobility-enhanced data-independent acquisition mode with drift 559 time-specific collision energies as described in detail by Distler et al. (48,49). Specifically, for 560 DRE-UDMS^E a deflection device (DRE lens) localized between the quadrupole and the ion 561 mobility cell of the mass spectrometer was cycled between full (100% for 0.4 sec) and 562 reduced (5% for 0.4 sec) ion transmission during one 0.8 sec full scan. Continuum LC-MS 563 data were processed for signal detection, peak picking, and isotope and charge state 564 deconvolution using Waters ProteinLynx Global Server (PLGS) version 3.0.2 (47). For 565 protein identification, a custom database was compiled by adding the sequence information 566 for yeast enclase 1 and porcine trypsin to the UniProtKB/Swiss-Prot mouse proteome and by 567 appending the reversed sequence of each entry to enable the determination of false 568 discovery rate (FDR). Precursor and fragment ion mass tolerances were automatically 569 determined by PLGS 3.0.2 and were typically below 5 ppm for precursor ions and below 10 570 ppm (root mean square) for fragment ions. Carbamidomethylation of cysteine was specified 571 as fixed and oxidation of methionine as variable modification. One missed trypsin cleavage

was allowed. Minimal ion matching requirements were two fragments per peptide, five
fragments per protein, and one peptide per protein. The FDR for protein identification was set
to 1% threshold.

575

576 Analysis of proteomic data

577 For each genotype (*Prx*^{-/-} and wild type control mice sacrificed at P21), biochemical fractions 578 enriched for PNS myelin were analyzed as three biological replicates (n=3 per condition); 579 each biological replicate representing a pool of 20 sciatic nerves dissected from 10 mice. The 580 samples were processed with replicate digestion and injection, resulting in four technical 581 replicates per biological replicate and thus a total of 12 LC-MS runs per condition to be 582 compared, essentially as previously reported for CNS myelin (36,97). The freely available 583 software ISOQuant (www.isoquant.net) was used for post-identification analysis including 584 retention time alignment, exact mass and retention time (EMRT) and ion mobility clustering, 585 peak intensity normalization, isoform/homology filtering and calculation of absolute in-sample 586 amounts for each detected protein (48,49,98) according to the TOP3 quantification approach 587 (53,54). Only peptides with a minimum length of seven amino acids that were identified with 588 scores above or equal to 5.5 in at least two runs were considered. FDR for both peptides and 589 proteins was set to 1% threshold and only proteins reported by at least two peptides (one of 590 which unique) were quantified using the TOP3 method. The parts per million (ppm) 591 abundance values (i.e. the relative amount (w/w) of each protein in respect to the sum over 592 all detected proteins) were log2-transformed and normalized by subtraction of the median 593 derived from all data points for the given protein. Significant changes in protein abundance 594 were detected by moderated t-statistics essentially as described (96,97) across all technical 595 replicates using an empirical Bayes approach and false discovery (FDR)-based correction for 596 multiple comparisons (100). For this purpose, the Bioconductor R packages "limma" (101) 597 and "q-value" (102) were used in RStudio, an integrated development environment for the 598 open source programming language R. Proteins identified as contaminants (e.g. components 599 of blood or hair cells) were removed from the analysis. Proteins with ppm values below 100 600 which were not identified in one genotype were considered as just above detection level and 601 also removed from the analysis. The relative abundance of a protein in myelin was accepted 602 as altered if both statistically significant (q-value <0.05). Pie charts, heatmaps and volcano 603 plots were prepared in Microsoft Excel 2013 and GraphPad Prism 7. Pearson's correlation 604 coefficients derived from log2-transformed ppm abundance values were clustered and 605 visualized with the tool heatmap.2 contained in the R package gplots (CRAN.R-606 project.org/package=gplots). Only pairwise complete observations were considered to 607 reduce the influence of missing values on clustering behavior. The mass spectrometry 608 proteomics data have been deposited to the ProteomeXchange Consortium

609 (proteomecentral.proteomexchange.org) via the PRIDE partner repository (103) with the

- 610 dataset identifier PXD015960.
- 611

612 Gel electrophoresis and silver staining of gels

613 Protein concentration was determined using the DC Protein Assay kit (BioRad). Samples 614 were separated on a 12% SDS-PAGE for 1 h at 200 V using the BioRad system, fixated 615 overnight in 10% [v/v] acetic acid and 40 % [v/v] ethanol and then washed in 30% ethanol (2x 616 20 min) and ddH₂O (1x 20 min). For sensitization, gels were incubated 1 min in 0.012% [v/v]617 $Na_2S_2O_3$ and subsequently washed with ddH₂O (3x 20 sec). For silver staining, gels were 618 impregnated for 20 min in 0.2 % [w/v] AgNO₃ / 0.04% formaldehyde, washed with ddH₂O (3x 619 20 sec) and developed in 3% [w/v] Na_2CO_3 / 0.02% [w/v] formaldehyde. The reaction was 620 stopped by exchanging the solution with 5% [v/v] acetic acid.

621

622 Immunoblotting

623 Immunoblotting was performed as described (104,105). Primary antibodies were specific for 624 dystrophin-related-protein 2 (DRP2; Sigma; 1:1000), peripheral myelin protein 2 (PMP2; 625 ProteinTech Group 12717-1-AP; 1:1000), proteolipid protein (PLP/DM20; A431 (106); 626 1:5000), Monocarboxylate transporter 1 (MCT1/SLC16A1; (107); 1:1000), periaxin (PRX; 627 (59); 1:1000), sodium/potassium-transporting ATPase subunit alpha-1 (ATP1A1; 1:2000; 628 Abcam #13736-1-AP), myelin protein zero (MPZ/P0; (108); kind gift by J. Archelos-Garcia; 629 1:10.000), voltage-dependent anion-selective channel protein (VDAC; Abcam #ab15895; 630 1:1000), basigin (BSG/CD147; ProteinTech Group #ab64616; 1:1000), neurofilament H 631 (NEFH/NF-H; Covance #SMI-32P; 1:1000), voltage-gated potassium channel subunit A 632 member 1 (KCNA1; Neuromab #73-007; 1:1000), EGR2/KROX20 ((109); kind gift by D. 633 Meijer, Edinburgh; 1:1000) and myelin basic protein (MBP; 1:2000). To generate the latter 634 antisera, rabbits were immunized (Pineda Antikörper Service, Berlin, Germany) with the 635 KLH-coupled peptide CQDENPVVHFFK corresponding to amino acids 212-222 of mouse 636 MBP isoform 1 (Swisprot/Uniprot-identifier P04370-1). Anti-MBP antisera were purified by 637 affinity chromatography and extensively tested for specificity by immunoblot analysis of homogenate of brains dissected from wild-type mice compared to Mbp^{shiverer/shiverer} mice that 638 639 lack expression of MBP. Appropriate secondary anti-mouse or -rabbit antibodies conjugated 640 to HRP were from dianova. Immunoblots were developed using the Enhanced 641 Chemiluminescence Detection kit (Western Lightning® Plus, Perkin Elmer) and detected with 642 the Intas ChemoCam system (INTAS Science Imaging Instruments GmbH, Göttingen, 643 Germany).

644

645 Immunolabelling of teased fibers

646 Teased fibers were prepared as previously described (9,110). For each genotype, one male 647 mouse was sacrificed by cervical dislocation at P17. Immunolabelling of teased fibers was 648 performed as described (69). Briefly, teased fibers were fixed for 5 min in 4% 649 paraformaldehyde, permeabilized 5 min with ice-cold methanol, washed in PBS (3x 5 min) 650 and blocked for 1 h at 21°C in blocking buffer (10% horse serum, 0.25% Triton X-100, 1% 651 bovine serum albumin in PBS). Primary antibodies were applied overnight at 4°C in 652 incubation buffer (1.5% horse serum, 0.25% Triton X-100 in PBS). Samples were washed in 653 PBS (3x 5 min) and secondary antibodies were applied in incubation buffer (1 h, RT). 654 Samples were again washed in PBS (2x 5 min), and 4',6-diamidino-2-phenylindole (DAPI; 655 1:50 000 in PBS) was applied for 10 min at RT. Samples were briefly washed 2x with ddH₂O 656 and mounted using Aqua-Poly/Mount (Polysciences, Eppelheim, Germany). Antibodies were 657 specific for myelin-associated glycoprotein (MAG clone 513; Chemicon MAB1567; 1:50) and 658 MCT1/SLC16A1 (107). Secondary antibodies were donkey α-rabbit-Alexa488 (Invitrogen 659 A21206; 1:1000) and donkey α-mouse-Alexa555 (Invitrogen A21202; 1:1000). Labeled 660 teased fibers were imaged using the confocal microscope Leica SP5. The signal was 661 collected with the objective HCX PL APO lambda blue 63.0.x1.20. DAPI staining was excited 662 with 405 nm and collected between 417 nm - 480 nm. To excite the Alexa488 fluorophore an 663 Argon laser with the excitation of 488 nm was used and the emission was set to 500 nm -664 560 nm. Alexa555 was excited by using the DPSS561 laser at an excitation of 561 nm and 665 the emission was set to 573 nm - 630 nm. To export and process the images LAS AF lite and 666 Adobe Photoshop were used.

667

668 mRNA abundance profiles

669 Raw data were previously established (60) from the sciatic nerves of wild type Sprague 670 Dawley rats at the indicated ages (E21, P6, P18; n=4 per time point). Briefly, sciatic nerves 671 were dissected, the epineurium was removed, total RNA was extracted with the RNeasy Kit 672 (Qiagen), concentration and quality (ratio of absorption at 260/280 nm) of RNA samples were 673 determined using the NanoDrop spectrophotometer (ThermoScientific), integrity of the 674 extracted RNA was determined with the Agilent 2100 Bioanalyser (Agilent Technologies) and 675 RNA-Seq was performed using the Illumina HiSeq2000 platform. RNA-Seq raw data are 676 available under the GEO accession number GSE115930 (60). For the present analysis, the 677 fastqfiles were mapped to rattus norvegicus rn6 using Tophat Aligner and then quantified 678 based on the Ensemble Transcripts release v96. The raw read counts were then normalized 679 using the R package DESeq2. The normalized gene expression data was then standardized 680 to a mean of zero and a standard deviation of one, therefore genes with similar changes in 681 expression are close in the euclidian space. Clustering was performed on the standardized

- 682 data using the R package mfuzz. Transcripts displaying abundance differences of less than
- 683 10% coefficient of variation were considered developmentally unchanged.
- 684

685 Venn diagrams

686 Area-proportional Venn diagrams were prepared using BioVenn (111) at <u>www.biovenn.nl/</u>.

687

688 **GO-term**

For functional categorization of the myelin proteome the associated gene ontology terms were systematically analyzed on the mRNA abundance cluster using the Database for Annotation, Visualization and Integrated Discovery (DAVID; <u>https://david.ncifcrf.gov</u>). For comparison known myelin proteins according to literature were added.

693

694 Histological analysis

695 Prx⁻⁻ and control mice were perfused at the indicated ages intravascularly with fixative 696 solution (2.5% glutaraldehyde, 4% paraformaldehyde, 0.1 M sodium cacodylate buffer, pH 697 7.4). Quadriceps nerves were removed, fixed for 2 h at room temperature, followed by 18 h 698 at 4°C in the same fixative, postfixed in OsO₄, dehydrated a graded series of ethanol, 699 followed by propylene oxide and embedded in Araldite. All axons not associated with a 700 Remak bundle were counted and categorized as myelinated or non-myelinated. All myelin 701 profiles lacking a recognizable axon were counted. The total number of axons were counted 702 on micrographs of toluidine blue stained Araldite sections (0.5 µm) of quadriceps nerves. 703 Precise p-values for the quantitative comparison between Ctrl and Prx^{-/-} mice were: Total 704 number of axons (Figure 6B; Student's unpaired t-test): 2 mo p=0.01734; 4 mo p=2.1E-05; 9 705 mo p=0.007625; Number of myelinated axons (Figure 6C; Student's unpaired t-test): 2 mo 706 p=0.00444; 4 mo p=2.12E-05; 9 mo p=0.005766; Number of empty myelin profiles (Figure 707 **6D**; Student's unpaired t-test): 2 mo p=0.004445; 4 mo p=0.001461; 9 mo p=0.000695; 708 Axonal diameters (Figure 6E-G; two-sided Kolmogorow-Smirnow test): 2 mo p=2.20E-16; 4 709 mo p=2.20E-16; 9 mo p=2.20E-16.

- 710
- 711

ACKNOWLEDGMENTS

- We thank J. Archelos-Garcia and D. Meijer for antibodies, T. Buscham and J. Edgar for discussions, L. Piepkorn for support in data analysis, K.-A. Nave for support made possible by a European Research Council Advanced Grant ('MyeliNano' to K.-A.N.) and the International Max Planck Research School for Genome Science (IMPRS-GS) for supporting S.B.S.. FUNDING Our work is supported by the Deutsche Forschungsgemeinschaft (DFG; Grants WE 2720/2-2, WE 2720/4-1 and WE 2720/5-1 to H.B.W. and RO 4076/3-2 to M.J.R.) and the Wellcome Trust (Grant No 0842424 to P.J.B.). **CONFLICT OF INTEREST STATEMENT** The authors declare no conflict of interest.

- 731 **REFERENCES**
- 732
- 733 1. Weil M-T, Heibeck S, Töpperwien M, tom Dieck S, Ruhwedel T, Salditt T, et al. Axonal 734 Ensheathment in the Nervous System of Lamprey: Implications for the Evolution of Myelinating 735 Glia. J Neurosci [Internet]. 2018 Jul 18:38(29):6586–96. Available from: 736 http://www.jneurosci.org/lookup/doi/10.1523/JNEUROSCI.1034-18.2018 737 2. Hartline DK, Colman DR, Rapid Conduction and the Evolution of Giant Axons and Myelinated 738 Fibers. Curr Biol [Internet]. 2007 Jan;17(1):R29-35. Available from: 739 https://linkinghub.elsevier.com/retrieve/pii/S0960982206025231 740 3. Rossor AM, Polke JM, Houlden H, Reilly MM. Clinical implications of genetic advances in 741 Charcot-Marie-Tooth disease. Nat Rev Neurol [Internet]. 2013 Oct 10;9(10):562-71. Available 742 from: http://www.nature.com/articles/nrneurol.2013.179 743 Michailov G V. Axonal Neuregulin-1 Regulates Myelin Sheath Thickness. Science (80-) 4. 744 [Internet]. 2004 Apr 30;304(5671):700-3. Available from: 745 http://www.sciencemag.org/cgi/doi/10.1126/science.1095862 746 5. Taveggia C, Zanazzi G, Petrylak A, Yano H, Rosenbluth J, Einheber S, et al. Neuregulin-1 747 Type III Determines the Ensheathment Fate of Axons. Neuron [Internet]. 2005 Sep;47(5):681– 748 94. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0896627305006926 749 6. Chernousov MA, Yu W-M, Chen Z-L, Carey DJ, Strickland S. Regulation of Schwann cell 750 function by the extracellular matrix. Glia [Internet]. 2008 Nov 1;56(14):1498-507. Available 751 from: http://doi.wiley.com/10.1002/glia.20740 752 7. Petersen SC, Luo R, Liebscher I, Giera S, Jeong S-J, Mogha A, et al. The Adhesion GPCR 753 GPR126 Has Distinct, Domain-Dependent Functions in Schwann Cell Development Mediated 754 by Interaction with Laminin-211. Neuron [Internet]. 2015 Feb:85(4):755–69. Available from: 755 https://linkinghub.elsevier.com/retrieve/pii/S0896627314011660 756 8. Ghidinelli M, Poitelon Y, Shin YK, Ameroso D, Williamson C, Ferri C, et al. Laminin 211 inhibits 757 protein kinase A in Schwann cells to modulate neuregulin 1 type III-driven myelination. Emery 758 B, editor. PLOS Biol [Internet]. 2017 Jun 21;15(6):e2001408. Available from: 759 https://dx.plos.org/10.1371/journal.pbio.2001408 760 9. Sherman DL, Fabrizi C, Gillespie CS, Brophy PJ. Specific Disruption of a Schwann Cell 761 Dystrophin-Related Protein Complex in a Demyelinating Neuropathy. Neuron [Internet]. 2001 762 May;30(3):677-87. Available from: 763 https://linkinghub.elsevier.com/retrieve/pii/S0896627301003270 764 Masaki T, Matsumura K, Hirata A, Yamada H, Hase A, Arai K, et al. Expression of 10. 765 Dystroglycan and the Laminin- α 2 Chain in the Rat Peripheral Nerve during Development. Exp 766 Neurol [Internet]. 2002 Mar;174(1):109-17. Available from: 767 https://linkinghub.elsevier.com/retrieve/pii/S0014488601978562 768 11. Nodari A, Previtali SC, Dati G, Occhi S, Court FA, Colombelli C, et al. 6 4 Integrin and 769 Dystroglycan Cooperate to Stabilize the Myelin Sheath. J Neurosci [Internet]. 2008 Jun 770 25:28(26):6714-9. Available from: http://www.jneurosci.org/cgi/doi/10.1523/JNEUROSCI.0326-771 08.2008

772 Raasakka A, Linxweiler H, Brophy PJ, Sherman DL, Kursula P. Direct Binding of the Flexible 12. 773 C-Terminal Segment of Periaxin to β4 Integrin Suggests a Molecular Basis for CMT4F. Front 774 Mol Neurosci [Internet]. 2019 Apr 9;12. Available from: 775 https://www.frontiersin.org/article/10.3389/fnmol.2019.00084/full 776 13. Hess A, Lansing AI. The fine structure of peripheral nerve fibers. Anat Rec. 1953; 777 14. Sherman DL, Brophy PJ. Mechanisms of axon ensheathment and myelin growth. Nat Rev 778 Neurosci [Internet]. 2005 Sep;6(9):683–90. Available from: 779 http://www.nature.com/articles/nrn1743 780 15. Pereira JA, Lebrun-Julien F, Suter U. Molecular mechanisms regulating myelination in the 781 peripheral nervous system. Trends Neurosci [Internet]. 2012 Feb;35(2):123–34. Available from: 782 https://linkinghub.elsevier.com/retrieve/pii/S0166223611001937 783 Grove M, Brophy PJ. FAK Is Required for Schwann Cell Spreading on Immature Basal Lamina 16. 784 to Coordinate the Radial Sorting of Peripheral Axons with Myelination. J Neurosci [Internet]. 785 2014 Oct 1;34(40):13422–34. Available from: 786 http://www.jneurosci.org/cgi/doi/10.1523/JNEUROSCI.1764-14.2014 787 17. Monk KR, Feltri ML, Taveggia C. New insights on schwann cell development. Glia [Internet]. 788 2015 Aug;63(8):1376–93. Available from: http://doi.wiley.com/10.1002/glia.22852 789 18. Feltri ML, Poitelon Y, Previtali SC. How Schwann Cells Sort Axons. Neurosci [Internet]. 2016 790 Jun 16;22(3):252–65. Available from: 791 http://journals.sagepub.com/doi/10.1177/1073858415572361 792 Giese KP, Martini R, Lemke G, Soriano P, Schachner M. Mouse P0 gene disruption leads to 19. 793 hypomyelination, abnormal expression of recognition molecules, and degeneration of myelin 794 and axons. Cell [Internet]. 1992 Nov;71(4):565-76. Available from: 795 https://linkinghub.elsevier.com/retrieve/pii/009286749290591Y 796 20. Martini R, Mohajeri MH, Kasper S, Giese KP, Schachner M. Mice doubly deficient in the genes 797 for P0 and myelin basic protein show that both proteins contribute to the formation of the major 798 dense line in peripheral nerve myelin. J Neurosci. 1995; 799 21. Nawaz S, Schweitzer J, Jahn O, Werner HB. Molecular evolution of myelin basic protein, an 800 abundant structural myelin component. Glia [Internet]. 2013 Aug;61(8):1364–77. Available 801 from: http://doi.wiley.com/10.1002/glia.22520 802 22. Greenfield S, Brostoff S, Eylar EH, Morell P. PROTEIN COMPOSITION OF MYELIN OF THE 803 PERIPHERAL NERVOUS SYSTEM. J Neurochem [Internet]. 1973 Apr;20(4):1207-16. 804 Available from: http://doi.wiley.com/10.1111/j.1471-4159.1973.tb00089.x 805 23. Brostoff SW, Karkhanis YD, Carlo DJ, Reuter W, Eylar EH. Isolation and partial 806 characterization of the major proteins of rabbit sciatic nerve myelin. Brain Res [Internet]. 1975 807 Mar;86(3):449–58. Available from: 808 https://linkinghub.elsevier.com/retrieve/pii/0006899375908951 809 24. Nave K-A, Werner HB. Myelination of the Nervous System: Mechanisms and Functions. Annu 810 Rev Cell Dev Biol [Internet]. 2014 Oct 11;30(1):503-33. Available from: 811 http://www.annualreviews.org/doi/10.1146/annurev-cellbio-100913-013101 812 25. Kleopa KA, Sargiannidou I. Connexins, gap junctions and peripheral neuropathy. Neurosci Lett

813 [Internet]. 2015 Jun;596:27–32. Available from:

814 https://linkinghub.elsevier.com/retrieve/pii/S0304394014008453

- 815 26. Court FA, Sherman DL, Pratt T, Garry EM, Ribchester RR, Cottrell DF, et al. Restricted growth
 816 of Schwann cells lacking Cajal bands slows conduction in myelinated nerves. Nature [Internet].
 817 2004 Sep;431(7005):191–5. Available from: http://www.nature.com/articles/nature02841
- 81827.Beirowski B, Babetto E, Golden JP, Chen Y-J, Yang K, Gross RW, et al. Metabolic regulator819LKB1 is crucial for Schwann cell-mediated axon maintenance. Nat Neurosci [Internet]. 2014
- 820 Oct 7;17(10):1351–61. Available from: http://www.nature.com/articles/nn.3809
- Bomenech-Estevez E, Baloui H, Repond C, Rosafio K, Medard J-J, Tricaud N, et al.
 Distribution of Monocarboxylate Transporters in the Peripheral Nervous System Suggests
 Putative Roles in Lactate Shuttling and Myelination. J Neurosci [Internet]. 2015 Mar
 11;35(10):4151–6. Available from: http://www.jneurosci.org/cgi/doi/10.1523/JNEUROSCI.3534-
- 825 14.2015
- Kim S, Maynard JC, Sasaki Y, Strickland A, Sherman DL, Brophy PJ, et al. Schwann Cell OGlcNAc Glycosylation Is Required for Myelin Maintenance and Axon Integrity. J Neurosci
 [Internet]. 2016 Sep 14;36(37):9633–46. Available from:
- 829 http://www.jneurosci.org/cgi/doi/10.1523/JNEUROSCI.1235-16.2016
- 830 30. Gonçalves NP, Vægter CB, Andersen H, Østergaard L, Calcutt NA, Jensen TS. Schwann cell
 831 interactions with axons and microvessels in diabetic neuropathy. Nat Rev Neurol [Internet].
 832 2017 Mar 30;13(3):135–47. Available from: http://www.nature.com/articles/nrneurol.2016.201
- 83331.Stassart RM, Möbius W, Nave K-A, Edgar JM. The Axon-Myelin Unit in Development and834Degenerative Disease. Front Neurosci [Internet]. 2018 Jul 11;12. Available from:

835 https://www.frontiersin.org/article/10.3389/fnins.2018.00467/full

- 83632.Nagarajan R, Le N, Mahoney H, Araki T, Milbrandt J. Deciphering peripheral nerve myelination837by using Schwann cell expression profiling. Proc Natl Acad Sci [Internet]. 2002 Jun
- 838 25;99(13):8998–9003. Available from: http://www.pnas.org/cgi/doi/10.1073/pnas.132080999
- 839 33. Le N, Nagarajan R, Wang JYT, Araki T, Schmidt RE, Milbrandt J. Analysis of congenital
 840 hypomyelinating Egr2Lo/Lo nerves identifies Sox2 as an inhibitor of Schwann cell
 841 differentiation and myelination. Proc Natl Acad Sci [Internet]. 2005 Feb 15;102(7):2596–601.
- 842 Available from: http://www.pnas.org/cgi/doi/10.1073/pnas.0407836102

843 34. Ryu EJ, Yang M, Gustin JA, Chang L-W, Freimuth RR, Nagarajan R, et al. Analysis of

- 844 Peripheral Nerve Expression Profiles Identifies a Novel Myelin Glycoprotein, MP11. J Neurosci
 845 [Internet]. 2008 Jul 23;28(30):7563–73. Available from:
- 846 http://www.jneurosci.org/cgi/doi/10.1523/JNEUROSCI.1659-08.2008
- 35. Zhang Y, Chen K, Sloan SA, Bennett ML, Scholze AR, O'Keeffe S, et al. An RNA-Sequencing
 Transcriptome and Splicing Database of Glia, Neurons, and Vascular Cells of the Cerebral
 Cortex. J Neurosci [Internet]. 2014 Sep 3;34(36):11929–47. Available from:

850 http://www.jneurosci.org/cgi/doi/10.1523/JNEUROSCI.1860-14.2014

- 851 36. Patzig J, Erwig MS, Tenzer S, Kusch K, Dibaj P, Möbius W, et al. Septin/anillin filaments
- scaffold central nervous system myelin to accelerate nerve conduction. Elife. 2016;5:e17119.
- 853 37. Sharma K, Schmitt S, Bergner CG, Tyanova S, Kannaiyan N, Manrique-Hoyos N, et al. Cell

854 type- and brain region-resolved mouse brain proteome. Nat Neurosci [Internet]. 2015 Dec 855 2;18(12):1819–31. Available from: http://www.nature.com/articles/nn.4160 856 38. Thakurela S, Garding A, Jung RB, Müller C, Goebbels S, White R, et al. The transcriptome of 857 mouse central nervous system myelin. Sci Rep [Internet]. 2016 May 13;6(1):25828. Available 858 from: http://www.nature.com/articles/srep25828 859 39. Margues S, Zeisel A, Codeluppi S, van Bruggen D, Mendanha Falcao A, Xiao L, et al. 860 Oligodendrocyte heterogeneity in the mouse juvenile and adult central nervous system. 861 Science (80-) [Internet]. 2016 Jun 10;352(6291):1326-9. Available from: 862 http://www.sciencemag.org/cgi/doi/10.1126/science.aaf6463 863 40. De Monasterio-Schrader P, Jahn O, Tenzer S, Wichert SP, Patzig J, Werner HB. Systematic 864 approaches to central nervous system myelin. Cellular and Molecular Life Sciences. 2012. 865 41. Patzig J, Jahn O, Tenzer S, Wichert SP, de Monasterio-Schrader P, Rosfa S, et al. 866 Quantitative and Integrative Proteome Analysis of Peripheral Nerve Myelin Identifies Novel 867 Myelin Proteins and Candidate Neuropathy Loci. J Neurosci [Internet]. 2011 Nov 868 9;31(45):16369–86. Available from: 869 http://www.jneurosci.org/cgi/doi/10.1523/JNEUROSCI.4016-11.2011 870 42. Kangas SM, Ohlmeier S, Sormunen R, Jouhilahti E-M, Peltonen S, Peltonen J, et al. An 871 approach to comprehensive genome and proteome expression analyses in Schwann cells and 872 neurons during peripheral nerve myelin formation. J Neurochem [Internet]. 2016 873 Sep;138(6):830–44. Available from: http://doi.wiley.com/10.1111/jnc.13722 874 43. Kusch K, Uecker M, Liepold T, Möbius W, Hoffmann C, Neumann H, et al. Partial 875 Immunoblotting of 2D-Gels: A Novel Method to Identify Post-Translationally Modified Proteins 876 Exemplified for the Myelin Acetylome. Proteomes [Internet]. 2017 Jan 12;5(4):3. Available 877 from: http://www.mdpi.com/2227-7382/5/1/3 878 44. Neilson KA, Ali NA, Muralidharan S, Mirzaei M, Mariani M, Assadourian G, et al. Less label, 879 more free: Approaches in label-free quantitative mass spectrometry. Proteomics. 2011. 880 45. Distler U, Kuharev J, Tenzer S. Biomedical applications of ion mobility-enhanced data-881 independent acquisition-based label-free quantitative proteomics. Expert Rev Proteomics. 882 2014; 883 46. Geromanos SJ, Vissers JPC, Silva JC, Dorschel CA, Li GZ, Gorenstein M V., et al. The 884 detection, correlation, and comparison of peptide precursor and product ions from data 885 independent LC-MS with data dependant LC-MS/MS. Proteomics. 2009; 886 47. Li GZ, Vissers JPC, Silva JC, Golick D, Gorenstein M V., Geromanos SJ. Database searching 887 and accounting of multiplexed precursor and product ion spectra from the data independent 888 analysis of simple and complex peptide mixtures. Proteomics. 2009; 889 48. Distler U, Kuharev J, Navarro P, Tenzer S. Label-free guantification in ion mobility-enhanced 890 data-independent acquisition proteomics. Nat Protoc [Internet]. 2016 Apr 24;11(4):795-812. 891 Available from: http://www.nature.com/articles/nprot.2016.042 892 49. Distler U, Kuharev J, Navarro P, Levin Y, Schild H, Tenzer S. Drift time-specific collision 893 energies enable deep-coverage data-independent acquisition proteomics. Nat Methods 894 [Internet]. 2014 Feb 15;11(2):167–70. Available from:

895		http://www.nature.com/articles/nmeth.2767
896	50.	Larocca JN, Norton WT. Isolation of Myelin. Curr Protoc Cell Biol [Internet]. 2006
897		Dec;33(1):3.25.1-3.25.19. Available from: http://doi.wiley.com/10.1002/0471143030.cb0325s33
898	51.	Jahn O, Tenzer S, Werner HB. Myelin proteomics: Molecular anatomy of an insulating sheath.
899		Molecular Neurobiology. 2009.
900	52.	Erwig MS, Hesse D, Jung RB, Uecker M, Kusch K, Tenzer S, et al. Myelin: Methods for
901		Purification and Proteome Analysis. In: Methods in Molecular Biology [Internet]. 2019. p. 37-
902		63. Available from: http://link.springer.com/10.1007/978-1-4939-9072-6_3
903	53.	Silva JC, Gorenstein M V., Li G-Z, Vissers JPC, Geromanos SJ. Absolute Quantification of
904		Proteins by LCMS E. Mol Cell Proteomics [Internet]. 2006 Jan;5(1):144–56. Available from:
905		http://www.mcponline.org/lookup/doi/10.1074/mcp.M500230-MCP200
906	54.	Ahrné E, Molzahn L, Glatter T, Schmidt A. Critical assessment of proteome-wide label-free
907		absolute abundance estimation strategies. Proteomics. 2013;
908	55.	Dodds JN, Baker ES. Ion Mobility Spectrometry: Fundamental Concepts, Instrumentation,
909		Applications, and the Road Ahead. J Am Soc Mass Spectrom. 2019;
910	56.	Micko S, Schlaepfer WW. PROTEIN COMPOSITION OF AXONS and MYELIN FROM RAT
911		and HUMAN PERIPHERAL NERVES. J Neurochem [Internet]. 1978 May;30(5):1041–9.
912		Available from: http://doi.wiley.com/10.1111/j.1471-4159.1978.tb12397.x
913	57.	Smith ME, Curtis BM. FROG SCIATIC NERVE MYELIN: A CHEMICAL CHARACTERIZATION.
914		J Neurochem [Internet]. 1979 Aug;33(2):447–52. Available from:
915		http://doi.wiley.com/10.1111/j.1471-4159.1979.tb05174.x
916	58.	Whitaker JN. The protein antigens of peripheral nerve myelin. Ann Neurol [Internet].
917		1981;9(S1):56–64. Available from: http://doi.wiley.com/10.1002/ana.410090710
918	59.	Gillespie CS, Sherman DL, Blair GE, Brophy PJ. Periaxin, a novel protein of myelinating
919		schwann cells with a possible role in axonal ensheathment. Neuron [Internet]. 1994
920		Mar;12(3):497–508. Available from:
921		https://linkinghub.elsevier.com/retrieve/pii/0896627394902089
922	60.	Fledrich R, Abdelaal T, Rasch L, Bansal V, Schütza V, Brügger B, et al. Targeting myelin lipid
923		metabolism as a potential therapeutic strategy in a model of CMT1A neuropathy. Nat Commun
924		[Internet]. 2018 Dec 2;9(1):3025. Available from: http://www.nature.com/articles/s41467-018-
925		05420-0
926	61.	Pareyson D, Marchesi C. Diagnosis, natural history, and management of Charcot-Marie-Tooth
927		disease. Lancet Neurol [Internet]. 2009 Jul;8(7):654–67. Available from:
928		https://linkinghub.elsevier.com/retrieve/pii/S1474442209701103
929	62.	Baets J, De Jonghe P, Timmerman V. Recent advances in Charcot-Marie-Tooth disease. Curr
930		Opin Neurol [Internet]. 2014 Oct;27(5):532-40. Available from:
931		http://content.wkhealth.com/linkback/openurl?sid=WKPTLP:landingpage&an=00019052-
932		201410000-00006
933	63.	Brennan KM, Bai Y, Shy ME. Demyelinating CMT–what's known, what's new and what's in
934		store? Neurosci Lett [Internet]. 2015 Jun;596:14–26. Available from:
935		https://linkinghub.elsevier.com/retrieve/pii/S0304394015000725

- 64. Gillespie CS, Sherman DL, Fleetwood-Walker SM, Cottrell DF, Tait S, Garry EM, et al.
 937 Peripheral Demyelination and Neuropathic Pain Behavior in Periaxin-Deficient Mice. Neuron
 938 [Internet]. 2000 May;26(2):523–31. Available from:
- 939 https://linkinghub.elsevier.com/retrieve/pii/S0896627300811848
- 65. Guilbot A. A mutation in periaxin is responsible for CMT4F, an autosomal recessive form of
 64. Charcot-Marie-Tooth disease. Hum Mol Genet [Internet]. 2001 Feb 1;10(4):415–21. Available
 65. from: https://academic.oup.com/hmg/article-lookup/doi/10.1093/hmg/10.4.415
- 66. Berger P, Niemann A, Suter U. Schwann cells and the pathogenesis of inherited motor and
 sensory neuropathies (Charcot-Marie-Tooth disease). Glia [Internet]. 2006 Sep;54(4):243–57.
 Available from: http://doi.wiley.com/10.1002/glia.20386
- Marchesi C, Milani M, Morbin M, Cesani M, Lauria G, Scaioli V, et al. Four novel cases of
 periaxin-related neuropathy and review of the literature. Neurology [Internet]. 2010 Nov
 16;75(20):1830–8. Available from:
- 949 http://www.neurology.org/cgi/doi/10.1212/WNL.0b013e3181fd6314
- 950 68. Philp NJ, Ochrietor JD, Rudoy C, Muramatsu T, Linser PJ. Loss of MCT1, MCT3, and MCT4
 951 Expression in the Retinal Pigment Epithelium and Neural Retina of the 5A11/Basigin-Null
 952 Mouse. Investig Opthalmology Vis Sci [Internet]. 2003 Mar 1;44(3):1305. Available from:
 953 http://iovs.arvojournals.org/article.aspx?doi=10.1167/iovs.02-0552
- 954 69. Patzig J, Kusch K, Fledrich R, Eichel MA, Lüders KA, Möbius W, et al. Proteolipid protein
 955 modulates preservation of peripheral axons and premature death when myelin protein zero is
 956 lacking. Glia [Internet]. 2016 Jan;64(1):155–74. Available from:
- 957 http://doi.wiley.com/10.1002/glia.22922
- 960 11;487(7408):443–8. Available from: http://www.nature.com/articles/nature11314
- 961 71. Fünfschilling U, Supplie LM, Mahad D, Boretius S, Saab AS, Edgar J, et al. Glycolytic
 962 oligodendrocytes maintain myelin and long-term axonal integrity. Nature [Internet]. 2012 May
 963 29;485(7399):517–21. Available from: http://www.nature.com/articles/nature11007
- 964 72. Morrison BM, Tsingalia A, Vidensky S, Lee Y, Jin L, Farah MH, et al. Deficiency in
- 965 monocarboxylate transporter 1 (MCT1) in mice delays regeneration of peripheral nerves
 966 following sciatic nerve crush. Exp Neurol [Internet]. 2015 Jan;263:325–38. Available from:
 967 https://linkinghub.elsevier.com/retrieve/pii/S0014488614003549
- 968 73. Morrison BM, Lee Y, Rothstein JD. Oligodendroglia: Metabolic supporters of axons. Trends in969 Cell Biology. 2013.
- 970 74. Saab AS, Tzvetanova ID, Nave K-A. The role of myelin and oligodendrocytes in axonal energy
 971 metabolism. Curr Opin Neurobiol [Internet]. 2013 Dec;23(6):1065–72. Available from:
 972 https://linkinghub.elsevier.com/retrieve/pii/S0959438813001888
- 973 75. Rinholm JE, Bergersen LH. White matter lactate Does it matter? Neuroscience [Internet].
 974 2014 Sep;276:109–16. Available from:
- 975 https://linkinghub.elsevier.com/retrieve/pii/S0306452213008464
- 976 76. Jha MK, Lee Y, Russell KA, Yang F, Dastgheyb RM, Deme P, et al. Monocarboxylate

077		
977 078		transporter 1 in Schwann cells contributes to maintenance of sensory nerve myelination during
978 070		aging. Glia. 2019;
979 080	77.	Edgar JM, McLaughlin M, Werner HB, McCulloch MC, Barrie JA, Brown A, et al. Early
980 081		ultrastructural defects of axons and axon-glia junctions in mice lacking expression of Cnp1.
981 082	70	Glia. 2009;
982	78.	Verheijen MHG. Local regulation of fat metabolism in peripheral nerves. Genes Dev [Internet].
983		2003 Oct 1;17(19):2450–64. Available from:
984 085	70	http://www.genesdev.org/cgi/doi/10.1101/gad.1116203
985 086	79.	Buchstaller J. Efficient Isolation and Gene Expression Profiling of Small Numbers of Neural
986 087		Crest Stem Cells and Developing Schwann Cells. J Neurosci [Internet]. 2004 Mar
987 089		10;24(10):2357–65. Available from:
988		http://www.jneurosci.org/cgi/doi/10.1523/JNEUROSCI.4083-03.2004
989	80.	D'antonio M, Michalovich D, Paterson M, Droggiti A, Woodhoo A, Mirsky R, et al. Gene
990 001		profiling and bioinformatic analysis of Schwann cell embryonic development and myelination.
991 002		Glia [Internet]. 2006 Apr 1;53(5):501–15. Available from:
992	04	http://doi.wiley.com/10.1002/glia.20309
993 004	81.	Schaeren-Wiemers N, Bonnet A, Erb M, Erne B, Bartsch U, Kern F, et al. The raft-associated
994 005		protein MAL is required for maintenance of proper axon–glia interactions in the central nervous
995 006		system. J Cell Biol [Internet]. 2004 Aug 30;166(5):731–42. Available from:
996 007		http://www.jcb.org/lookup/doi/10.1083/jcb.200406092
997 000	82.	Adlkofer K, Martini R, Aguzzi A, Zielasek J, Toyka K V., Suter U. Hypermyelination and
998		demyelinating peripheral neuropathy in Pmp22-deficient mice. Nat Genet [Internet]. 1995
999		Nov;11(3):274–80. Available from: http://www.nature.com/articles/ng1195-274
1000	83.	Riethmacher D, Sonnenberg-Riethmacher E, Brinkmann V, Yamaai T, Lewin GR, Birchmeier
1001		C. Severe neuropathies in mice with targeted mutations in the ErbB3 receptor. Nature
1002		[Internet]. 1997 Oct;389(6652):725–30. Available from: http://www.nature.com/articles/39593
1003	84.	Woldeyesus MT, Britsch S, Riethmacher D, Xu L, Sonnenberg-Riethmacher E, Abou-Rebyeh
1004		F, et al. Peripheral nervous system defects in erbB2 mutants following genetic rescue of heart
1005		development. Genes Dev [Internet]. 1999 Oct 1;13(19):2538–48. Available from:
1006	05	http://www.genesdev.org/cgi/doi/10.1101/gad.13.19.2538
1007	85.	Ackerman SD, Luo R, Poitelon Y, Mogha A, Harty BL, D'Rozario M, et al. GPR56/ADGRG1
1008		regulates development and maintenance of peripheral myelin. J Exp Med [Internet]. 2018 Mar
1009	00	5;215(3):941–61. Available from: http://www.jem.org/lookup/doi/10.1084/jem.20161714
1010	86.	Monk KR, Oshima K, Jors S, Heller S, Talbot WS. Gpr126 is essential for peripheral nerve
1011		development and myelination in mammals. Development [Internet]. 2011 Jul 1;138(13):2673–
1012	07	80. Available from: http://dev.biologists.org/cgi/doi/10.1242/dev.062224
1013	87.	Monk KR, Naylor SG, Glenn TD, Mercurio S, Perlin JR, Dominguez C, et al. A G Protein-
1014		Coupled Receptor Is Essential for Schwann Cells to Initiate Myelination. Science (80-)
1015		[Internet]. 2009 Sep 11;325(5946):1402–5. Available from:
1016	00	http://www.sciencemag.org/cgi/doi/10.1126/science.1173474
1017	88.	Kabzinska D, Drac H, Sherman DL, Kostera-Pruszczyk A, Brophy PJ, Kochanski A, et al.

1018 Charcot-Marie-Tooth type 4F disease caused by S399fsx410 mutation in the PRX gene. 1019 Neurology [Internet]. 2006 Mar 14;66(5):745–7. Available from: 1020 http://www.neurology.org/cgi/doi/10.1212/01.wnl.0000201269.46071.35 1021 89. Baránková L, Šišková D, Hühne K, Vyhnálková E, Sakmaryová I, Bojar M, et al. A 71-1022 nucleotide deletion in the periaxin gene in a Romani patient with early-onset slowly progressive 1023 demyelinating CMT. Eur J Neurol [Internet]. 2008 Jun;15(6):548–51. Available from: 1024 http://doi.wiley.com/10.1111/j.1468-1331.2008.02104.x 1025 90. Tokunaga S, Hashiguchi A, Yoshimura A, Maeda K, Suzuki T, Haruki H, et al. Late-onset 1026 Charcot-Marie-Tooth disease 4F caused by periaxin gene mutation. Neurogenetics [Internet]. 1027 2012 Nov 1;13(4):359–65. Available from: http://link.springer.com/10.1007/s10048-012-0338-5 1028 91. Gallardo E, García A, Ramón C, Maraví E, Infante J, Gastón I, et al. Charcot-Marie-Tooth 1029 disease type 2J with MPZ Thr124Met mutation: clinico-electrophysiological and MRI study of a 1030 family. J Neurol [Internet]. 2009 Dec 22;256(12):2061–71. Available from: 1031 http://link.springer.com/10.1007/s00415-009-5251-y 1032 92. Leal A, Berghoff C, Berghoff M, Rojas-Araya M, Ortiz C, Heuss D, et al. A Costa Rican family 1033 affected with Charcot-Marie-Tooth disease due to the myelin protein zero (MPZ) p.Thr124Met 1034 mutation shares the Belgian haplotype. Rev Biol Trop [Internet]. 2014 Dec 1;62(4):1285. 1035 Available from: http://revistas.ucr.ac.cr/index.php/rbt/article/view/13473 1036 93. Tokuda N, Noto Y, Kitani-Morii F, Hamano A, Kasai T, Shiga K, et al. Parasympathetic 1037 Dominant Autonomic Dysfunction in Charcot-Marie-Tooth Disease Type 2J with the MPZ 1038 Thr124Met Mutation. Intern Med [Internet]. 2015;54(15):1919-22. Available from: 1039 https://www.jstage.jst.go.jp/article/internalmedicine/54/15/54 54.4259/ article 1040 94. Duan X, Gu W, Hao Y, Wang R, Wen H, Sun S, et al. A Novel Asp121Asn Mutation of Myelin 1041 Protein Zero Is Associated with Late-Onset Axonal Charcot-Marie-Tooth Disease, Hearing 1042 Loss and Pupil Abnormalities. Front Aging Neurosci [Internet]. 2016 Sep 22;8. Available from: 1043 http://journal.frontiersin.org/Article/10.3389/fnagi.2016.00222/abstract 1044 95. Fabrizi GM, Tamburin S, Cavallaro T, Cabrini I, Ferrarini M, Taioli F, et al. The spectrum of 1045 Charcot-Marie-Tooth disease due to myelin protein zero: An electrodiagnostic, nerve 1046 ultrasound and histological study. Clin Neurophysiol [Internet]. 2018 Jan;129(1):21-32. 1047 Available from: https://linkinghub.elsevier.com/retrieve/pii/S1388245717310854 1048 96. Ambrozkiewicz MC, Schwark M, Kishimoto-Suga M, Borisova E, Hori K, Salazar-Lázaro A, et 1049 al. Polarity Acquisition in Cortical Neurons Is Driven by Synergistic Action of Sox9-Regulated 1050 Wwp1 and Wwp2 E3 Ubiguitin Ligases and Intronic miR-140. Neuron [Internet]. 2018 1051 Dec;100(5):1097-1115.e15. Available from: 1052 https://linkinghub.elsevier.com/retrieve/pii/S0896627318308961 1053 97. Erwig MS, Patzig J, Stever AM, Dibaj P, Heilmann M, Heilmann I, et al. Anillin facilitates septin 1054 assembly to prevent pathological outfoldings of central nervous system myelin. Elife [Internet]. 1055 2019 Jan 23;8. Available from: https://elifesciences.org/articles/43888 1056 98. Kuharev J, Navarro P, Distler U, Jahn O, Tenzer S. In-depth evaluation of software tools for 1057 data-independent acquisition based label-free guantification. Proteomics [Internet]. 2015 1058 Sep;15(18):3140–51. Available from: http://doi.wiley.com/10.1002/pmic.201400396

1059	99.	Silva JC, Denny R, Dorschel C, Gorenstein M V., Li G-Z, Richardson K, et al. Simultaneous
1060		Qualitative and Quantitative Analysis of the Escherichia coli Proteome. Mol Cell Proteomics
1061		[Internet]. 2006 Apr;5(4):589–607. Available from:
1062		http://www.mcponline.org/lookup/doi/10.1074/mcp.M500321-MCP200
1063	100.	Kammers K, Cole RN, Tiengwe C, Ruczinski I. Detecting significant changes in protein
1064		abundance. EuPA Open Proteomics [Internet]. 2015 Jun;7:11–9. Available from:
1065		https://linkinghub.elsevier.com/retrieve/pii/S2212968515000069
1066	101.	Ritchie ME, Phipson B, Wu D, Hu Y, Law CW, Shi W, et al. limma powers differential
1067		expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res [Internet].
1068		2015 Apr 20;43(7):e47–e47. Available from:
1069		http://academic.oup.com/nar/article/43/7/e47/2414268/limma-powers-differential-expression-
1070		analyses-for
1071	102.	Storey JD. The positive false discovery rate: a Bayesian interpretation and the q -value. Ann
1072		Stat [Internet]. 2003 Dec;31(6):2013–35. Available from:
1073		http://projecteuclid.org/euclid.aos/1074290335
1074	103.	Vizcaíno JA, Csordas A, Del-Toro N, Dianes JA, Griss J, Lavidas I, et al. 2016 update of the
1075		PRIDE database and its related tools. Nucleic Acids Res [Internet]. 2016 Jan 4;44(D1):D447-
1076		56. Available from: https://academic.oup.com/nar/article-lookup/doi/10.1093/nar/gkv1145
1077	104.	Schardt A, Brinkmann BG, Mitkovski M, Sereda MW, Werner HB, Nave K-A. The SNARE
1078		protein SNAP-29 interacts with the GTPase Rab3A: Implications for membrane trafficking in
1079		myelinating glia. J Neurosci Res [Internet]. 2009 Nov 15;87(15):3465–79. Available from:
1080		http://doi.wiley.com/10.1002/jnr.22005
1081	105.	de Monasterio-Schrader P, Patzig J, Möbius W, Barrette B, Wagner TL, Kusch K, et al.
1082		Uncoupling of neuroinflammation from axonal degeneration in mice lacking the myelin protein
1083		tetraspanin-2. Glia. 2013;
1084	106.	Jung M, Sommer I, Schachner M, Nave KA. Monoclonal antibody O10 defines a
1085		conformationally sensitive cell- surface epitope of proteolipid protein (PLP): Evidence that PLP
1086		misfolding underlies dysmyelination in mutant mice. J Neurosci. 1996;16(24):7920–9.
1087	107.	Stumpf SK, Berghoff SA, Trevisiol A, Spieth L, Düking T, Schneider L V., et al. Ketogenic diet
1088		ameliorates axonal defects and promotes myelination in Pelizaeus-Merzbacher disease. Acta
1089		Neuropathol [Internet]. 2019 Jul 27;138(1):147–61. Available from:
1090		http://link.springer.com/10.1007/s00401-019-01985-2
1091	108.	Archelos JJ, Roggenbuck K, Scheider-Schaulies J, Linington C, Toyka K V., Hartung H-P.
1092		Production and characterization of monoclonal antibodies to the extracellular domain of P0. J
1093		Neurosci Res [Internet]. 1993 May 1;35(1):46–53. Available from:
1094		http://doi.wiley.com/10.1002/jnr.490350107
1095	109.	Darbas A, Jaegle M, Walbeehm E, van den Burg H, Driegen S, Broos L, et al. Cell autonomy of
1096		the mouse claw paw mutation. Dev Biol [Internet]. 2004 Aug;272(2):470-82. Available from:
1097		https://linkinghub.elsevier.com/retrieve/pii/S0012160604003616
1098	110.	Catenaccio A, Court FA. Teased Fiber Preparation of Myelinated Nerve Fibers from Peripheral
1099		Nerves for Vital Dye Staining and Immunofluorescence Analysis. In: Methods in Molecular

- 1100 Biology [Internet]. 2018. p. 329–37. Available from: http://link.springer.com/10.1007/978-1-
- 1101 4939-7649-2_21
- 1102111.Hulsen T, de Vlieg J, Alkema W. BioVenn a web application for the comparison and1103visualization of biological lists using area-proportional Venn diagrams. BMC Genomics1104[Internet]. 2008;9(1):488. Available from:
- 1105 http://bmcgenomics.biomedcentral.com/articles/10.1186/1471-2164-9-488
- 1106
- 1107

- 1108 FIGURE LEGENDS
- 1109
- 1110

1111 Figure 1. Proteome analysis of peripheral myelin

1112 (A) Schematic illustration of a previous approach to the peripheral myelin proteome (41) 1113 compared with the present workflow. Note that the current workflow allows largely automated 1114 sample processing and omits labor-intense 2-dimensional differential gel-electrophoresis, thereby considerably reducing hands-on time. Nano LC-MS analysis by data-independent 1115 1116 acquisition (DIA) using three different data acquisition modes provides efficient identification and guantification of abundant myelin proteins (MS^E; see Figure 2), a comprehensive 1117 inventory (UDMS^E; see **Figures 3-4**) and gel-free differential analysis of hundreds of distinct 1118 proteins (DRE-UDMS^E; see **Figure 5**). Samples were analyzed in three biological replicates. 1119

(B) Immunoblot of myelin biochemically enriched from sciatic nerves of wild-type mice at postnatal day 21 (P21). Equal amounts of corresponding nerve lysate were loaded to compare the abundance of marker proteins for compact myelin (MPZ/P0, MBP, PMP2), noncompact myelin (PRX), the Schwann cell nucleus (KROX20/EGR2), axons (NEFH, KCNA1) and mitochondria (VDAC). Blots show n=2 biological replicates representative of n=3 biological replicates. Note that myelin markers are enriched in purified myelin; other cellular markers are reduced.

1127 (C) Number and relative abundance of proteins identified in myelin purified from the sciatic nerves of wild-type mice using three different data acquisition modes (MS^E, UDMS^E, DRE-1128 UDMS^E). Note that MS^E (orange) provides the best information about the relative abundance 1129 of high-abundant myelin proteins (dynamic range of more than four orders of magnitude) but 1130 identifies comparatively fewer proteins in purified myelin. UDMS^E (blue) identifies the largest 1131 number of proteins but provides only a lower dynamic range of about three orders of 1132 magnitude. DRE-UDMS^E (green) identifies an intermediate number of proteins with an 1133 1134 intermediate dynamic range of about four orders of magnitude. Note that MS^E with very high 1135 dynamic range is required for the quantification of the exceptionally abundant myelin protein 1136 zero (MPZ/P0), myelin basic protein (MBP) and periaxin (PRX). ppm, parts per million.

(D) Venn diagram comparing the number of proteins identified in PNS myelin by MS^E,
 UDMS^E and DRE-UDMS^E. Note the high overlap of identified proteins.

- (E) Venn diagram of the proteins identified in PNS myelin by UDMS^E in this study compared
 with those identified in two previous approaches (41,42).
- 1141
- 1142
- 1143Figure 1-supplement 1. Clustered heatmap of Pearson's correlation coefficients for1144protein abundance comparing data acquisition modes.

The heatmap compares the log_2 transformed ppm protein abundance values to assess peripheral myelin purified from wild type mice using three data acquisition modes (MS^E , $UDMS^E$, DRE-UDMS^E). The inset shows the color key and the histogram for the values of the correlation coefficients. Note that the runs cluster with a high overall correlation (>0.75) into three conditions defined by the acquisition mode, in agreement with the experimental design. Among the samples analyzed by different acquisition modes, DRE-UDMS^E similarly correlates with both MS^E and UDMS^E, reflecting its intermediate nature.

11521153

1154 Figure 2. Relative abundance of peripheral myelin proteins

MS^E was used to identify and quantify proteins in myelin purified from the sciatic nerves of wild-type mice at P21; their relative abundance is given as percent with relative standard deviation (% +/- RSD). Note that known myelin proteins constitute >80% of the total myelin protein; proteins not previously associated with myelin constitute <20%. Mass spectrometric quantification based on 3 biological replicates per genotype with 4 technical replicates each (see **Figure 1-source data 1**).

- 1161
- 1162

1163 Figure 3. Developmental mRNA abundance profiles of myelin-associated genes

1164 (A) K-means clustering was performed for the mRNA profiles of those 1046 proteins in our 1165 myelin proteome inventory for which significant mRNA expression was found by RNA-Seg in 1166 the sciatic nerve of rats dissected at ages E21, P6, P18 and 6 months (M6). Note that this 1167 filtering strategy allows to selectively display the developmental abundance profiles of those 1168 transcripts that encode myelin-associated proteins rather than of all transcripts present in the 1169 nerve. Standardized mRNA abundance profiles are shown (n=4 biological replicates per 1170 age). Known myelin genes are displayed in red. For comparison, Pmp22 mRNA was 1171 included although the small tetraspan protein PMP22 was not mass spectrometrically 1172 identified due to its unfavorable distribution of tryptic cleavage sites. Normalized counts for all 1173 mRNAs including those displaying developmentally unchanged abundance are provided in

- 1174 **Figure 3-Source data 1**.
- 1175 **(B)** Numbers of mRNAs per cluster.
- 1176
- 1177

1178 Figure 4. Categorization of annotated protein functions

1179 All proteins identified in peripheral myelin by UDMS^E (turquoise) and the respective 1180 developmental expression clusters (**Figure 3**; shades of red) were analyzed for 1181 overrepresented functional annotations using gene ontology (GO) terms. The graph displays 1182 the percentage of proteins in each cluster that were annotated with a particular function. For 1183 comparison, known myelin proteins were annotated. n.o., not over-represented.

1184 1185

1186 Figure 5. Molecular analysis of myelin in the *Prx^{-/-}* mouse model of CMT4F

1187 **(A)** Myelin purified from sciatic nerves dissected from $Prx^{-/-}$ and control mice at P21 was 1188 separated by SDS-PAGE (0.5 µg protein load) and proteins were visualized by silver 1189 staining. Bands constituted by the most abundant myelin proteins (MPZ/P0, MBP, PRX) are 1190 annotated. Note that no band constituted by PRX was detected in $Prx^{-/-}$ myelin and that 1191 several other bands also display genotype-dependent differences in intensity. Gel shows n=2 1192 biological replicates representative of n=3 biological replicates.

(B) The relative abundance of proteins in myelin purified from Prx^{-/-} sciatic nerves as quantified by MS^E is given as percent with relative standard deviation (% +/- RSD). Note the increased relative abundance of MPZ/P0 and MBP compared to wild-type myelin (see **Figure 2**) when PRX is lacking. Mass spectrometric quantification based on 3 biological replicates with 4 technical replicates each (see **Figure 5-source data 1**).

- (C,D) Differential proteome analysis by DRE-UDMS^E of myelin purified from Prx^{-/-} and wild-1198 1199 type mice. Mass spectrometric quantification based on 3 biological replicates per genotype 1200 with 4 technical replicates each (see Figure 5-source data 2). (C) Top 40 proteins of which 1201 the abundance is reduced (blue) or increased (red) in peripheral myelin purified from Prx^{-/-} 1202 compared to wild-type mice with the highest level of significance according to the -log₁₀ 1203 transformed q-value (green). In the heatmaps, each horizontal line corresponds to the fold-1204 change (FC) of a distinct protein compared to its average abundance in wild-type myelin 1205 plotted on a log₂ color scale. Heatmaps display 12 replicates, i.e. 3 biological replicates per genotype with 4 technical replicates each. (D-D") Volcano plots representing genotype-1206 1207 dependent quantitative myelin proteome analysis. Data points represent quantified proteins in Prx^{-/-} compared to wild-type myelin and are plotted as the log2-transformed fold-change 1208 1209 (FC) on the x-axis against the -log10-transformed g-value on the y-axis. Stippled lines mark a 1210 -log10-transformed g-value of 1.301, reflecting a g-value of 0.05 as significance threshold. 1211 Highlighted are the datapoints representing the Top 10 proteins displaying highest zdist 1212 values (Euclidean distance between the two points (0,0) and (x,y) with $x = \log_2(FC)$ and y = -1213 log10(q-value) (red circles in **D**), immune-related proteins (purple circles in **D**ⁱ), proteins of 1214 the extracellular matrix (ECM; yellow circles in D") and known myelin proteins (blue circles in 1215 D""). n.d., not detected; n.g., no q-value computable due to protein identification in one 1216 genotype only. Also see Figure 5-supplement 1.
- 1217 **(E)** Immunoblot of myelin purified from $Prx^{-/-}$ and control sciatic nerves confirms the reduced 1218 abundance of DRP2, SLC16A1/MCT1, BSG and PMP2 in $Prx^{-/-}$ myelin, as found by

differential DRE-UDMS^E analysis (in Figure 5C,D). PRX was detected as genotype control;
PLP/DM20 and ATP1A1 serve as markers. Blot shows n=2 biological replicates per
genotype.

1222 **(F)** Teased fiber preparations of sciatic nerves dissected from $Prx^{-/-}$ and control mice 1223 immunolabelled for MAG (red) and SLC16A1 (green). Note that SLC16A1 co-distributes with 1224 MAG in Schmidt-Lanterman incisures (SLI) in control but not in $Prx^{-/-}$ nerves, in accordance 1225 with the reduced abundance of SLC16A1 in $Prx^{-/-}$ myelin (**Figure 5C-E**). Also note that, in 1226 $Prx^{-/-}$ myelin, SLI were largely undetectable by MAG immunolabeling.

1227

1228

Figure 5-supplement 1. Clustered heatmap of Pearson's correlation coefficients for protein abundance comparing genotypes.

1231 **(A)** The heatmap compares the \log_2 transformed ppm protein abundance values from the 1232 DRE-UDMS^E runs to assess peripheral myelin purified from wild type and *Prx*^{-/-} mice. The 1233 inset shows the color key and the histogram for the values of the correlation coefficients. 1234 Note that the runs cluster with a high overall correlation (>0.85) into two conditions defined 1235 by the genotype, in agreement with the experimental design.

- 1236 **(B)** Volcano plot representing genotype-dependent guantitative myelin proteome analysis. Data points represent quantified proteins in Prx^{-2} compared to wild-type myelin plotted as the 1237 1238 log2-transformed fold-change (FC) on the x-axis against the -log10-transformed g-value on 1239 the y-axis. Note the different axis scale compared to Figure 5D. Stippled line marks a -log10-1240 transformed q-value of 1.301, reflecting a q-value of 0.05 as significance threshold. 1241 Highlighted is the datapoint for PRX to illustrate that only trace amounts of PRX were detected when assessing *Prx^{-/-}* myelin. ATP2A1, ATP1A4 and PLCD1 were not detected in 1242 *Prx^{-/-}* myelin. 1243
- 1244
- 1245

1246 Figure 6. Progressive loss and reduced diameters of peripheral axons in *Prx^{-/-}* mice

1247 **(A-D)** Genotype-dependent quantitative assessment of light micrographs of toluidine-stained 1248 semi-thin sectioned quadriceps nerve dissected at 2, 4 and 9 months of age reveals

- 1249 progressive loss of peripheral axons in Prx^{-2} compared to control mice.
- (A) Representative micrographs. Arrows point at myelinated axons; asterisk denotes an
 unmyelinated axon; arrowhead points at a myelin whorl lacking a recognizable axon. Scale
 bars, 10 µm.
- 1253 **(B)** Total number of axons per nerve that are not associated with a Remak bundle.
- 1254 **(C)** Total number of myelinated axons per nerve.
- 1255 **(D)** Total number per nerve of myelin whorls that lack a recognizable axon.

- 1256 Mean +/ SD, n=3-4 mice per genotype and age; *P<0.05, **P<0.01, ***P<0.001 by Student's 1257 unpaired t-test.
- 1258 (**E-G**) Genotype-dependent assessment of myelinated axons shows a shift toward reduced 1259 axonal diameters in quadriceps nerves of $Prx^{-/-}$ compared to control mice at 2 months (**E**), 4 1260 months (**F**) and 9 months (**G**) of age. Data are presented as frequency distribution with 0.5 1261 µm bin width. ***, p<0.001 by two-sided Kolmogorow-Smirnow test. For precise p-values see
- 1262 methods section.
- 1263
- 1264

Figure 1-source data 1. Label-free quantification of proteins in wild-type PNS myelin fractions by three different data acquisition modes

1267 Identification and quantification data of detected myelin-associated proteins. Tryptic peptides 1268 derived from four technical replicates (replicate digestion and replicate injection) per three 1269 biological replicate (20 sciatic nerves pooled from 10 animals) were analyzed by LC-MS (12 1270 runs in total). Proteins (FDR < 1%; 2 peptides/protein) and peptides (FDR < 1%; ≥7 amino 1271 acids) were identified by database search against the UniprotKB/SwissProt mouse database 1272 using PLGS. Data were post-processed with the software package ISOQuant to calculate 1273 absolute in-sample amounts for each detected protein based on the TOP3 approach. 1274 Reported abundance values are defined as the relative amount of each protein in respect to 1275 the sum over all detected proteins (ppm: parts per million (w/w) of total protein). Typical 1276 contaminant proteins like keratins were filtered.

- 1277 \rightarrow sheet 1: protein identification details
- 1278 \rightarrow sheet 2: WT myelin proteome by MS^E
- 1279 \rightarrow sheet 3: WT myelin proteome by UD-MS^E
- 1280 \rightarrow sheet 4: WT myelin proteome by DRE UD-MS^E
- 1281 → sheet 5: 45 proteins additionally identified in WT myelin by 1D-gel-LC-MS
- 1282 1283

1284 Figure 3-source data 1. Normalized developmental mRNA abundance data

- 1285 \rightarrow sheet 1: normalized values for all individual 4 biological replicates per age
- 1286 \rightarrow sheet 2: normalized values for biological replicates averaged to give mean per age
- 1287 1288

1289Figure 5-source data 1. Label-free quantification of proteins in PNS myelin fractions1290from *Prx*^{-/-} mice by MSe

- 1291 Identification and quantification data of detected myelin-associated proteins. Tryptic peptides
- 1292 derived from four technical replicates (replicate digestion and replicate injection) per three

1293 biological replicate (20 sciatic nerves pooled from 10 animals) were analyzed by LC-MS (12 1294 runs in total). Proteins (FDR < 1%; 2 peptides/protein) and peptides (FDR < 1%; ≥7 amino 1295 acids) were identified by database search against the UniprotKB/SwissProt mouse database 1296 using PLGS. Data were post-processed with the software package ISOQuant to calculate 1297 absolute in-sample amounts for each detected protein based on the TOP3 approach. 1298 Reported abundance values are defined as the relative amount of each protein in respect to 1299 the sum over all detected proteins (ppm: parts per million (w/w) of total protein). Typical 1300 contaminant proteins like keratins were filtered.

- 1301 \rightarrow sheet 1: protein identification details
- 1302 \rightarrow sheet 2: *Prx*^{-/-} myelin proteome by MS^E
- 1303
- 1304

1305Figure 5-source data 2. Label-free quantification of proteins in PNS myelin fractions1306from WT and *Prx^{-/-}* mice by DRE-UDMSe

1307 Identification and quantification data of detected myelin-associated proteins by DRE-UDMSe. 1308 For each genotype, tryptic peptides derived from four technical replicates (replicate digestion 1309 and replicate injection) per three biological replicate (20 sciatic nerves pooled from 10 1310 animals) were analyzed by LC-MS (24 runs in total). Proteins (FDR < 1%; 2 peptides/protein) 1311 and peptides (FDR < 1%; \geq 7 amino acids) were identified by database search against the 1312 UniprotKB/SwissProt mouse database using PLGS. Data were post-processed with the 1313 software package ISOQuant to calculate absolute in-sample amounts for each detected 1314 protein based on the TOP3 approach. Reported abundance values are defined as the 1315 relative amount of each protein in respect to the sum over all detected proteins (ppm: parts 1316 per million (w/w) of total protein). Typical contaminant proteins like keratins were filtered. The 1317 -log10-transformed q-value was plotted against the log2-transformed fold change to obtain 1318 the volcano plot shown in Figure 5D. As no imputation of missing values was performed, 1319 proteins exclusive for only one of the conditions do not appear in the volcano plot, but are 1320 appended at the end of the list. Criteria for statistically significant regulation were as follows: 1321 fold change of at least 1.5 and q-value below 0.05.

- 1322 \rightarrow sheet 1: protein identification details
- 1323 \rightarrow sheet 2: comparison of WT vs. *Prx*^{-/-} myelin proteome by DRE-UDMS^E
- 1324
- 1325

Protein name	Gene	Reference	TMD	Cluster		
2-hydroxyacylsphingosine 1-beta-galactosyltransferase	Ugt8	Bosio et al., 1996	2	P6-up		
Syntrophin a1	Snta1	Fuhrmann-Stroissnigg et al., 2012	-	P18-up		
Annexin A2	Anxa2	Hayashi et al., 2007	-	Descending		
Band 4.1 protein B / 4.1B	Epb4113	Ivanovic et al., 2012	-	Descendin		
Band 4.1 protein G / 4.1G	Epb41l2	Ohno et al., 2006	-	P6-up		
Breast carcinoma-amplified sequence 1	Bcasl	Ishimoto et al., 2017	-	P6-up		
Cadherin 1/ E-Cadherin	Cdh1	Fannon et al., 1995	1	P18-up		
Carbonic anhydrase 2	Ca2	Cammer et al., 1987	-	Descendin		
Catenin a1	Ctnna1	Murata et al., 2006	-	U-shaped		
Catenin ß1	Ctnnb1	Fannon et al., 1995	-	Descendin		
Caveolin 1	Cavl	Mikol et al., 2002	1	P18-up		
CD9, tetraspanin 29	Cd9	Ishibashi et al., 2004	4	P18-p		
CD59A	Cd59a	Funabashi et al., 1994	1	P18-up		
CD47, integrin-associated signal transducer	Cd47	Gitik et al., 2011	5	P6-up		
CD81, tetraspanin 28	Cd81	Ishibashi et al., 2004	4	P18-up		
CD82, tetraspanin 27	Cd82	Chernousov et al., 2013	4	P18-up		
CD151, tetraspanin 24	Cd151	Patzig et al., 2011	4	P18-up		
Cell adhesion molecule 4/ NECL4	Cadm4	Spiegel et al., 2007	1	P6-up		
Cell division control protein 42	Cdc42	Benninger et al., 2007	-	P6-up		
Cell surface glycoprotein MUC18	Mcam	Shi et al., 1998	1	Descendin		
Ciliary neurotrophic factor	Cntf	Rende et al., 1992	-	Late-up		
CKLF-like MARVEL TMD-containing 5	Cmtm5	Patzig et al., 2011	4	P6-up		
Claudin-19	Cldn19	Miyamoto et al., 2005	4	P6-up		
Cofilin 1	Cfl1	Sparrow et al., 2012	-	Descendin		
Crystallin α2	Cryab	d'Antonio et al., 2006	-	P18-up		
Cyclic nucleotide phosphodiesterase	Cnp	Matthieu et al., 1980	-	P6-up		
Sarcoglycan δ	Sgcd	Cai et al., 2007	1	Late-up		
Dihydropyrimidinase related protein 1	Crmp1	d'Antonio et al., 2006	-	Descendin		
Disks large homolog 1	Dlg1	Cotter et al., 2010	-	Descendin		
Dynein light chain 1	Dynll1	Myllykoski et al. 2018	-	P6-up		
Dystroglycan	Dagl	Yamada et al, 1994	1	P6-up		
Dystrophin/DP116	Dmd	Cai et al., 2007	-	P6-up		
Dystrophin-related protein 2	Drp2	Sherman et al., 2001	-	P18-up		
E3 ubiquitin-protein ligase NEDD4	Nedd4	Liu et al., 2009	-	Descendin		
Ezrin	Ezr	Scherer et al., 2001	-	P6-up		
Fatty acid synthase	Fasn	Salles et al., 2002	-	P6-up		
Flotillin 1	Flot1	Lee et al., 2014	-	P18-up		
Gap junction B1 protein / Cx32	Gjbl	Li et al., 2002	4	P18-up		
Gap junction γ3 protein / Cx29	Gjc3	Li et al., 2002	1	P6-up		
Gelsolin	Gsn	Gonçalves et al., 2010	-	Late-up		
Glycogen synthase kinase 3ß	Gsk3b	Ogata et al., 2004	-	P6-up		
Integrin $\alpha 6$	Itga6	Nodari et al., 2008	1	P6-up		
Integrin aV	Itgav	Chernousov & Carey, 2003	1	Descendin		
Integrin ß1	Itgb1	Feltri et al., 2002	1	Descendin		
Integrin ß4	Itgb4	Quattrini et al., 1996	2	P18-up		
Junctional adhesion molecule C	Jam3	Scheiermann et al., 2007	1	P18-up		
Laminin α2	Lama2	Yang et al., 2005	-	P6-up		
Laminin α4	Lama4	Yang et al., 2005	-	Descendin		
Laminin ß1	Lamb1	LeBeau et al., 1994	-	Descendin		
Laminin B2	Lamb2	LeBeau et al., 1994	-	P18-up		
Laminin y1	Lamc1	Chen & Strickland, 2003	-	Descendin		
Membrane Palmitoylated Protein 6	Мррб	Saitoh et al., 2019	-	P6-up		
Microtubule-associated protein 1A	Mapla	Fuhrmann-Stroissnigg et al., 2012	-	P18-up		
Microtubule-associated protein 1B	Map1b	Fuhrmann-Stroissnigg et al., 2012	-	P6-up		
Mitogen-activated protein kinase 1/ ERK2	Mapk1	Mantuano et al., 2015	-	Descendin		
Mitogen-activated protein kinase 3/ ERK1	Mapk3	Mantuano et al., 2015	-	P18-up		
Moesin	Msn	Scherer et al., 2001	-	Unchanged		
Monocarboxylate transporter 1	Slc16a1	Domenech-Estevez et al., 2015	11	P18-up		

Myelin associated glycoprotein	Mag	Figlewicz et al., 1981	1	P6-up
Myelin basic protein	Mbp	Boggs, 2006	-	P6-up
Myelin protein 2	Pmp2	Trapp et al., 1984	-	P18-up
Myelin protein zero/ P0	Mpz	Giese et al., 1992	1	P6-up
Myelin proteolipid protein	Plp1	Garbern et al., 1997	4	P6-up
Myotubularin-related protein 2	Mtmr2	Bolino et al., 2004	-	P6-up
Noncompact myelin-associated protein	Ncmap	Ryu et al., 2008	1	P18-up
NDRG1, N-myc downstream regulated	Ndrg1	Berger et al., 2004	-	P18-uP
Neurofascin	Nfasc	Tait et al., 2000	2	P18-up
Nidogen 1	Nid1	Lee et al., 2007	-	Descending
P2X purinoceptor 7	P2rx7	Faroni et al., 2014	-	P6-up
Paxillin	Pxn	Fernandez-Valle et al., 2002	-	P6-up
Periaxin	Prx	Gillespie et al., 1994	-	P6-up
Plasmolipin	Pllp	Bosse et al., 2003	4	P18-up
Profilin 1	Pfn1	Montani et al., 2014	-	Descending
Lin-7 homolog C	Lin7c	Saitoh et al., 2017	-	P6-up
Rac1	Rac1	Benninger et al., 2007	-	U-Shaped
Radixin	Rdx	Scherer et al., 2001	-	Descending
RhoA	Rhoa	Brancolini et al., 1999	-	U-Shaped
Septin 2	Sept 2	Buser et al., 2009	-	Descending
Septin 7	Sept 7	Buser et al., 2009	-	U-Shaped
Septin 8	Sept 8	Patzig et al., 2011	-	P18-up
Septin 9	Sept 9	Patzig et al., 2011	-	P6-up
Septin 11	Sept 11	Buser et al., 2009	-	Descending
Sirtuin 2, NAD-dependent deacetylase	Sirt2	Werner et al., 2007	-	P18-up
Spectrin alpha chain, non-erythrocytic 1	Sptan1	Susuki et al., 2018	-	P18-up
Spectrin beta chain, non-erythrocytic 1	Sptbn1	Susuki et al., 2018	-	P18-up
Tight junction protein ZO-1	Tjp1	Poliak et al., 2007	-	P6-up
Tight junction protein ZO-2	Tjp2	Poliak et al., 2007	-	P6-up
Transferrin	Tf	Liu et al., 1990	2	Late-up
Vimentin	Vim	Triolo et al., 2012	-	Unchanged
Vinculin	Vcl	Beppu et al., 2015	-	Descending


Table 1. Known myelin proteins in the myelin proteome. Proteins mass-spectrometrically identified in peripheral myelin are compiled according to availability of prior references as myelin proteins. Given are the official gene name, one selected reference, the number of transmembrane domains (TMD) and the mRNA abundance profile cluster (see Figure 3).

Protein name	Gene name	OMIM#	Gene Locus	Neuropathy
Monoacylglycerol lipase ABHD12	ABHD12	613599	20p11.21	PHARC
Apoptosis-inducing factor 1	AIFM1	300169	Xq26.1	CMTX4, DFNX5
Na+/K+ -transporting ATPase $\alpha 1$	ATP1A1	182310	1p13.1	CMT2DD
Cytochrome c oxidase subunit 6A1	COX6A1	602072	12q24.31	CMTRID
Dystrophin-related protein 2	DRP2	300052	Xq22.1	CMTX
Dynactin subunit 1	DCTN1	601143	2p13.1	DHMN7B
Dynamin 2	DNM2	602378	19p13.2	CMT2M, CMTDIB
Cytoplasmic dynein 1 heavy chain 1	DYNC1H1	600112	14q32.31	CMT20, SMALED1
E3 SUMO-protein ligase	EGR2	129010	10q21.3	CMT1D, CMT3, CMT4E
Glycine-tRNA ligase	GARS (Gart)	600287	7p14.3	CMT2D, HMN5A
Gap junction B1 protein / Cx32	GJB1	304040	Xq13.1	CMTX1
Guanine nucleotide-binding protein B4	GNB4	610863	3q26.33	CMTDIF
Histidine triad nucleotide-binding protein 1	HINT1	601314	5q23.3	NMAN
Hexokinase 1	HK1	142600	10q22.1	CMT4G
Heat shock protein ß1	HSPB1	602195	7q11.23	CMT2F, DHMN2B
Kinesin heavy chain isoform 5A	KIF5A	602821	12q13.3	SPG10
Prelamin A/C	LMNA	150330	1q22	CMT2B1
Neprilysin	MME	120520	3q25.2	CMT2T, SCA43
Myelin protein zero/ P0	MPZ	159440	1q23.3	CHN2,CMT1B, CMT2I, CMT2J,CMT3, CMTDID, Roussy-Levy syndrome
Myotubularin-related protein 2	MTMR2	603557	11q21	CMT4B1
Alpha-N-acetylglucosaminidase	NAGLU (NAGA)	609701	17q21.2	CMT2V
NDRG1, N-myc downstream regulated	NDRG1	605262	8q24.22	CMT4D
Neurofilament heavy polypeptide	NEFH	162230	22q12.2	CMT2CC
Neurofilament light polypeptide	NEFL	162280	8p21.2	CMT2E, CMT1F, CMTDIG
Peripheral myelin protein 2	PMP2	170715	8q21.13	CMT1G
Peripheral myelin protein 22	PMP22	601907	17p12	CMT1A, CMT1E, CMT3, HNPP,
Ribose-phosphate pyrophosphokinase 1	PRPS1	311850	Xq22.3	Roussy-Levy syndrome Arts syndrome, CMTX5, DFNX1
Periaxin	PRX	605725	19q13.2	CMT4F, CMT3
Ras-related protein Rab 7a	RAB7A	602298	3q21.3	CMT2B
Septin 9	SEPT9	604061	17q25.3	HNA
Transitional ER-ATPase	VCP	601023	9p13.3	CMT2Y
Tryptophan-tRNA ligase, cytoplasmic	WARS	191050	14q32.32	HMN9
Tyrosine-tRNA ligase, cytoplasmic	YARS	603623	1p35.1	DI-CMTC


Table 2. Peripheral myelin proteins identified in PNS myelin involved in neuropathological diseases. Proteins massspectrometically identified in peripheral myelin were analyzed regarding the involvement of the ortholog human gene in neuropathological diseases. PMP22 was added, though it was not identified by MS analyses due to its unfavorable distribution of tryptic cleavage sites. CMT, Charcot-Marie-Tooth disease; DHMN, distal hereditary motor neuropathy; DI-CMTC, dominant intermediate CMTC; DFN, X-linked deafness; HMN, hereditary motor neuropathy; HSAN, hereditary sensory and autonomic neuropathy; HNA, hereditary sensory and autonomic neuropathy; OMIM, Online Mendelian Inheritance in Man; PHARC, polyneuropathy, hearing loss, ataxia, retinitis pigmentosa and cataract; SCA, spinocerebellar ataxia; SPG, spastic paraplegia.

1341

Siems et al., Figure 1



Α



Siems et al., Figure 2

% (+/- RSD)

0.06 0.01

0.05 0.01

0.04 0.00

0.04 0.01

0.04 0.00

0.04 0.01

0.03 0.00

0.03 0.00

0.03 0.00

0.02 0.00

0.02 0.00

0.02 0.00

0.02 0.01

0.02 0.00

0.02 0.00

0.02 0.00

0.02 0.00

0.02 0.00

0.01 0.00

0.01 0.00

0.01 0.00

0.01 0.03

0.01 0.00

0.01 0.00

15.39

Protein

RAC1

VCL

CA2

SEPT2

CFL1

CRYAB

MPP6

CAV1

SEPT7

GJC3

RDX

CDC42

PFN1

SEPT11

CRMP1

RHOA

MAPK3

MAPK1

CMTM5

JAM3


DYNLL1

CD59A


Others

EZR

LAMC1



Α														В		
P6-up														Cluste	r	#mRNA
mRNA-abundance (normalized)	Acaca Acat2 Adam10 Agps Appl1 Art3 Bcas1 Bdh1 Brox Cab39I	Cmtm5 Cnp Col15a1 Col1a1 Col1a2 Col28a1 Col4a2 Col6a1	•	Fam177a1 Far1 Far1 Fdft1 Fdps Fmnl2 Fscn1 Fut8 Gamt	Gng2 Gsk3b Gypc Hmgcs1	Letm1 Lin7c Lss M6pr Mag Map1b Map4 Map6 Mapre3 Mbp Mical1 Mlec	Mvk Myh14 Myo18a Naga Napb Ndufb7 Ndufs8 Nefl Nefm	P2rx7 Pdhb Pgls Plg Plp1 Pmp22 Pra2 Prkacb Prx Psmb6 Psmc3 Pura	Rcn1 Rer1	Tjp1 Tjp2 Tspan15 Tubb2a Ubl3 Ugt8					-up -up	132 203 186 154 245 126 1046
P18-up																
Bundance (normalized) Bundance (normalized)	Aldh1a7 Aldh3a2		1 Cavin3		Cryab Ctsd Cyb5a Cyb5r3 Ddah1 Decr1 Dmm1 Dpysl2 Drp2 Ech1 Eno2 Etfb Fam213a Fis1	Fkbp1a FInb Flot1 Gatm Gdi1 Glod4 Glu1 Gnao1 Gpi Hadh Hepacam Hibadh	Hibch Hk1 Hras Hsd17b10 Hsd17b11 Hsd17b12 Hsd17b4 Hspa12a Hspa2 Hspa2 Hgb4 Jam3 Jup Kit	Ldhb		Ndufs4 Ndufs7 Ndufv2 Nes Nfasc Nptn Ostf1 Pcolce Pdcd6ip Pfkm Phb Plec Plekb1 Pllp	Pmp2 Por Prdx5 Prelp Prkca Psmf1 Rab11b Rab12 Rab21 Rab22 Rab23 Rab43 Rab43	Rab5b Rab7a Rdh11 Reep5 Rida Rtkn Rth4 Rufy3 S100a6 Sacm11 Sbds Scarb2 Scp2 Sept8	Serpinf1 Sft2d2 Sfxn3 Sirt2 Slc16a1 Slc25a1 Slc2a1 Slc3a2 Slc4a2 Snta1 Sod2 Sparc Sptan1 Sptbn1	Stx12 Stxbp1 Sucla2	Tst Tubb4a Vat1l Vps26a Vps29 Vsnl1 Ywhaq	
Late-up																
S ¹ -	Actn3 Ahcy Akr1b1 Aldh2 Aldoa Aldoc Anpep Anxa1 Anxa3 Anxa7 Aoc3 Apoe Apoh Arl6ip5	Arpc4 Aspa Atp12a Atp1a3 Atp1b1 Atp2b2 Atp5f1d Atp5f1d Atp5v1g Bag3 Bag5 Bcam Blvrb C3	Cat	Cfh Cisd1 Ckm Ckmt1 Cntf1 Coro1a Cox4i1 Cox6c Cp Csrp1 Cst3 Dcn Dctn2	Des Dnajb4 Dnpep Dstn Dusp3 Dynll2 Echs1 Eef1a2 Ehd2 Ehd4 Eif4a2 Eno3 Entpd2 Ephx1	Esyt1 Etfa F13a1 Fabp4 Fam129b Fbx02 Fgg Flot2 Fn3krp G6pd Gfap Glud1 Gnai2 Gng3	Got2 Gpd1 Gpd1l Gpx3 Gpx4 Gsm Gstk1 Gstm1 Gstm2 Gstm3 Gstp1 Hadhb Hspa1l Hspb1	Idh3g Ivd Lap3 Lcp1 Lypla2 Lyz2 Macrod1 Mapt Mdh1 Me1 Mrc1 Myh11 Myh4 Myl2b	Myl6 Myl9 Ndufa5 Ndufa6 Ndufa8 Ndufb10 Ndufb3 Ndufb3 Ndufb3 Ndufb2 Npc2 Ogn Pacsin2 Pc Pcmt1	Pdha1 Pdlim5 Pebp1 Pfkp Pgam2 Picalm Pkm Plin1 Plin3 Pls3 Prnp Prnp Psmc6 Pygm	Rab18 Rab5c Rhob Rpl12 Rpl13a Rpl19 Rpl26 Rpl29 Rpl30 Rpl30 Rpl30 Rps14 Rps15 Rps25	Rras Rras2 Rtn1 S100b Sbspon Sdha Serpinb66 Serpinb66 Serpinb66 Serpinb67 Sfn Sic25a20 Sncg Sord Sri	Tppp3 Tsg101 Tuba1c	Uqcrb Vat1 Vwa5a Zc2hc1a		
U-shaped																
undance (normalized) 0 1:5	Acadl Acot7 Actb Actn1 Actn4 Adsl Ahsa1 Akr1a1	Atp5f1b Atp5mf Avil Cacybp Calm1 Camk2d Capza2 Cct4	Dnm3 Dpysl4 Dsp Dync1i2	Gclm Gnb1 Gng12 Gpx1 Hpcal1 Hsp90b1 Hspa12b Hspa8	Mat2a Mcts1 Ndufa12 Ndufa3 Ndufa4 Ndufs1 Nxn Pacsin1	Ppia Ppid Ppp1cb Ppp2r1b Ppp2r2a Prdx1 Prdx3 Prps1	Rack1 Ralb Rap1a Rap1b Rhoa Rhoc Rpl10 Rpl11	Rp123 Rp123a Rp124 Rp127 Rp127a Rp128 Rp13 Rp132	Rpl9 Rpn2 Rps11 Rps15a Rps20 Rps23 Rps24 Rps27a	Rps8 Rpsa S100a10 Sept7 Skp1 Slc25a24 Slc25a3 Slc25a4	Tomm70 Tpm3 Tuba4a Tubb3 Ube2d1 Uqcrc1 Vapa Vdac3)				



Anp32a Cnn2

Arhgap1 Cpne6

Arpc1b Cs

Cnn3

Cox6a1

Ctnna1

Anxa6

Ap2b1

Arpc5

Eno1

Erp29

Etf1

Fbn1

Fh

Fhl1

Ina


Kpna4

Lasp1

Ldha

Lxn

Lman2



Abce1 Apex1 Calu Col18a1 Dnajb11 Fermt2 Hist1h1a Ilk Lrrc59 Nid2 Pdia3 Psmb2 Rps17 Snd1 Tomm40 Ybx1 Acly Apoa1 Cand1 Сора Dnm1l Flna Hist1h1b Immt Lum Nipsnap1 Pdia6 Psmd13 Rps18 Snx6 Tubb1 Ykt6 Flnc lpo5 Tubb2b Ywhae Actr1b Arcn1 Capn5 Copb1 Dpysl3 Hist1h1e Mapk1 Nipsnap3b Pfn1 Psmd5 Rps19 Ssr1 Arf4 Tubb4b Ywhaz Mapre1 Actr2 Capza1 Cope Dpysl5 Fn1 Hist1h3a Nme1 Phb2 Psmd7 Rrbp1 Ssr3 lqgap1 Add3 Arf5 Islr Tubb5 Zc3hav1l Car2 Copg1 Dync1li1 Ganab Hist1h3b Marcks Nme2 Plcd1 Ptpa Sars Stip1 Agk Arf6 Cct2 Coro1c . Eef1d Gars Hmgb1 lsoc1 Mcam Nnt Postn Ran Sec22b Stx1b Tubb6 Aifm1 Aspn Cct3 Crmp1 Eef1g Glg1 Hnrnpa2b1ltgav Mthfd1 Npm1 Ppib Rap2a Sec23a Stxbp6 Tufm Ak2 Atp2a2 Cct5 Ctnnb1 Eif2s1 Glipr2 Hnrnpa3 ltgb1 Myadm Nras Ppic Rap2b Sec31a Surf4 Txndc5 Akap12 Uba1 Atp4a Cct6a Cttn Eif3b Glrx3 Hnrnpd Kif5a Myh10 Nsf Ppp1ca Rars Sec61a1 Syncrip Alad . Atp5f1a Cct7 Dad1 Eif4a1 Kif5c Nap11 Ola1 Rcn3 Sec61b Tcp1 Ube2i Gnai3 Hnrnpk Ppp1cc Alcam . Basp1 Cct8 Ddost Eif4h Gnas Hsp90aa1 Kpnb1 Nap1l4 Otub1 Prdx2 Rdx Sept2 Tgfbi Ube2n Aldh7a1 Bax Cfl1 Ddx1 Eif5a Gnb2 Hsp90ab1 Kras Ncam1 P4hb Prdx4 Rpl10a Sept11 Tln2 Usp5 Anp32b Bin1 Ckap4 Dlg1 Epb41l3 Gnb4 Hspa5 Lama4 Ncl Pa2g4 Prkaca Rpl31 Sept6 Tm9sf3 Vcl Anxa2 Bzw1 Ckap5 Dlst Eprs Gpd2 Hspd1 Lamb1 Nedd4 Pabpc1 Psma1 Rpl8 Serpinh1 Tmed2 Vcp Vdac1 Ap2a2 Fabp5 Nefh Pafah1b2 C1qbp Cnrip1 Dnaja1 Gpx7 Idh2 Lamc1 Psma5 Rpn1 Set Tmed9 Col14a1 Slk Ap2s1 Calr Dnaja2 Fam129a Hdlbp Ikbip Lpp Nid1 Pcyox1 Psma7 Rps10 Tmx1 Yars

Rpl35

Rpl4

Rpl5

Rpl6

Rpl7

Rpl7a

. Rps3

Rps3a

Rps4x

Rps5

Rps6

Rps6ka3 Thy1

Snx1

Snx2

Ssr4

Stoml2

TagIn2

Wdr1

Ybx3

Ywhab

Ywhag

Ywhah

Zyx

Rpl14

Rpl15

Rpl17

Rpl18

Rpl21

Rpl22

. Psma6

Ptges3

Rab39a

Rab6b

Rab8a

Rac1

Paics


Pcbp2

Pdia4


Pgam1


Pgk1


Phgdh




Siems et al., Figure 5











В





Α

Proteome profile of peripheral myelin in healthy mice and in a neuropathy model

Sophie B. Siems^{1,7}, Olaf Jahn^{2,7}, Maria A. Eichel¹, Nirmal Kannaiyan³, Lai Man N. Wu⁴, Diane L. Sherman⁴, Kathrin Kusch¹, Dörte Hesse², Ramona B. Jung¹, Robert Fledrich^{1,5}, Michael W. Sereda^{1,6}, Moritz J. Rossner³, Peter J. Brophy⁴, Hauke B. Werner^{1,*}

Affiliations

1

2

15

16

21 22 ¹Department of Neurogenetics, Max Planck Institute of Experimental Medicine, 37075 Göttingen, Germany

²Proteomics Group, Max Planck Institute of Experimental Medicine, 37075 Göttingen, Germany ³Department of Psychiatry and Psychotherapy, University Hospital, LMU Munich, 80336 Munich, Germany

⁴Centre for Discovery Brain Sciences, University of Edinburgh, Edinburgh, EH16 4SB, UK

23 24 25 26

⁵Institute of Anatomy, University of Leipzig, 04103 Leipzig, Germany

27 28 ⁶Department of Clinical Neurophysiology, University Medical Center, 37075 Göttingen, Germany ⁷These authors contributed equally to this work

29

30 * Corresponding author

- 31 Dr. Hauke Werner
- 32 Max Planck Institute of Experimental Medicine
- 33 Department of Neurogenetics
- 34 Hermann-Rein-Str. 3
- D-37075 Göttingen, Germany 35
- Tel.: +49 (551) 3899-759; Fax.: +49 (551) 3899-758 36
- 37 E-mail: Hauke@em.mpg.de
- 38

39 Key words

40 Schwann cell, peripheral nervous system (PNS), myelin proteome, neuropathy, Charcot-

41 Marie-Tooth disease (CMT4F), periaxin (PRX), MCT1/SLC16A1, demyelination, axon 42 degeneration, transcriptome

43

44 Word and figure count

- 45 Abstract 149 words; Introduction/results/discussion 4786 words
- 46 6 main figures; 2 figure supplements; 2 main tables; 4 source data files
- 47 48

49 ABSTRACT

50

51 Proteome and transcriptome analyses aim at comprehending the molecular profiles of the 52 brain, its cell-types and subcellular compartments including myelin. Despite the relevance of 53 the peripheral nervous system for normal sensory and motor capabilities, analogous 54 approaches to peripheral nerves and peripheral myelin have fallen behind evolving technical 55 standards. Here we assess the peripheral myelin proteome by gel-free, label-free mass-56 spectrometry for deep quantitative coverage. Integration with RNA-Sequencing-based 57 developmental mRNA-abundance profiles and neuropathy disease genes illustrates the utility 58 of this resource. Notably, the periaxin-deficient mouse model of the neuropathy Charcot-59 Marie-Tooth 4F displays a highly pathological myelin proteome profile, exemplified by the 60 discovery of reduced levels of the monocarboxylate transporter MCT1/SLC16A1 as a novel 61 facet of the neuropathology. This work provides the most comprehensive proteome resource 62 thus far to approach development, function and pathology of peripheral myelin, and a 63 straightforward, accurate and sensitive workflow to address myelin diversity in health and 64 disease. 65

66

67 INTRODUCTION

68

69 The ensheathment of axons with myelin enables rapid impulse propagation, a prerequisite 70 for normal motor and sensory capabilities of vertebrates (1,2). This is illustrated by 71 demyelinating neuropathies of the Charcot-Marie-Tooth (CMT) spectrum, in which mutations 72 affecting myelin genes as MPZ, PMP22, GJB1 and PRX impair myelin integrity and reduce 73 the velocity of nerve conduction in the peripheral nervous system (PNS) (3). 74 Developmentally, myelination by Schwann cells in peripheral nerves is regulated by axonal 75 neuregulin-1 (4,5) and the basal lamina (6-8) that is molecularly linked to the abaxonal 76 Schwann cell membrane via integrins and the dystroglycan complex (9–12). In adulthood, 77 the basal lamina continues to enclose all axon/myelin-units (13), probably to maintain myelin. 78 Beyond regulation by extracellular cues, myelination involves multiple proteins mediating 79 radial sorting of axons out of Remak bundles, myelin membrane growth and layer 80 compaction (14–18). For example, the Ig-domain containing myelin protein zero (MPZ; also 81 termed P0) mediates adhesion between adjacent extracellular membrane surfaces in 82 compact myelin (19). At their intracellular surfaces, myelin membranes are compacted by the 83 cytosolic domain of MPZ/P0 together with myelin basic protein (MBP; previously termed P1) 84 (20,21). Not surprisingly, MPZ/P0 and MBP were early identified as the most abundant 85 peripheral myelin proteins (22,23).

86

87 A system of cytoplasmic channels through the otherwise compacted myelin sheath remains 88 non-compacted throughout life, i.e. the adaxonal myelin layer, paranodal loops, Schmidt-89 Lanterman incisures (SLI), and abaxonal longitudinal and transverse bands of cytoplasm 90 termed bands of Cajal (14,24,25). Non-compacted myelin comprises cytoplasm, cytoskeletal 91 elements, vesicles and lipid-modifying enzymes, and thus numerous proteins involved in 92 maintaining the myelin sheath. The cytosolic channels probably also represent transport 93 routes toward Schwann cell-dependent metabolic support of myelinated axons (26-31).

94

95 Considering that Schwann cells constitute a major proportion of the cells in the PNS, 96 oligonucleotide microarray analyses have been used for mRNA abundance profiling of total 97 sciatic nerves (32,33). Indeed, these systematic approaches allowed the identification of 98 novel myelin constituents including non-compact myelin-associated protein (NCMAP/MP11) 99 (34). Notwithstanding that the number of known peripheral myelin proteins has grown in 100 recent years, a comprehensive molecular inventory has been difficult to achieve because 101 applications of systematic ('omics') approaches specifically to Schwann cells and peripheral 102 myelin remained comparatively scarce, different from studies addressing oligodendrocytes 103 and CNS myelin (35–40). One main reason may be that the available techniques were not

104 sufficiently straightforward for general application. For example, the protein composition of 105 peripheral myelin was previously assessed by proteome analysis (41). However, at that time 106 the workflow of sample preparation and data acquisition (schematically depicted in Figure 107 **1A**) was very labor-intense and required a substantial amount of input material; yet the depth 108 of the resulting datasets remained limited. In particular, differential myelin proteome analysis 109 by 2-dimensional fluorescence intensity gel electrophoresis (2D-DIGE) requires considerable 110 hands-on-time and technical expertise (41,42). While this method is powerful for the 111 separation of proteoforms (43), it typically suffers from under-representation of highly basic 112 and transmembrane proteins. It thus allows comparing the abundance of only few myelin 113 proteins rather than quantitatively covering the entire myelin proteome. Because of these 114 limitations and an only modest sample-to-sample reproducibility, 2D-DIGE analysis of myelin, 115 although unbiased, has not been commonly applied beyond specialized laboratories.

116

117 The aim of the present study was to establish a straightforward and readily applicable 118 workflow to facilitate both comprehensive knowledge about the protein composition of 119 peripheral myelin and systematic assessment of differences between two states, e.g., 120 pathological alterations in a neuropathy model. The major prerequisites were the biochemical 121 purification of myelin, its solubilization with the detergent ASB-14 and the subsequent 122 automated digestion with trypsin during filter-aided sample preparation (FASP). The tryptic 123 peptides were fractionated by liquid chromatography and analyzed by mass spectrometry for 124 gel-free, label-free quantitative proteome analysis. More specifically, we used nano-flow 125 ultra-performance liquid chromatography (nanoUPLC) coupled to an electrospray-ionization 126 guadrupole time-of-flight (ESI-QTOF) mass spectrometer with ion mobility option, providing 127 an orthogonal dimension of peptide separation. The utilized data-independent acquisition 128 (DIA) strategy relies on collecting data in an alternating low and elevated energy mode 129 (MS^E); it enables simultaneous sequencing and quantification of all peptides entering the 130 mass spectrometer without prior precursor selection (reviewed in (44,45)). With their highduty cycle utilized for the acquisition of precursor ions, MS^E-type methods are ideally suited 131 132 to reliably quantify proteins based on peptide intensities. Notably, these methods do not 133 involve the use of spectral libraries in the identification of proteins, different from other DIA 134 strategies. Instead, the achieved high-complexity fragmentation spectra are deconvoluted 135 before submission to dedicated search engines for peptide and protein identification (46.47). In the MS^E mode, this deconvolution involves precursor-fragment ion alignment solely on the 136 137 basis of chromatographic elution profiles; on top, drift times of ion mobility-separated precursors are used in the high-definition (HD)MS^E mode. An expansion of the latter referred 138 to as the ultra-definition (UD)MS^E mode, additionally implements drift time-dependent 139 140 collision energy profiles for more effective precursor fragmentation (48,49).

141

142 Indeed, compared to the previously used manual handling and in-gel digestion, the current 143 workflow (schematically depicted in Figure 1A) is considerably less labor-intense, and 144 automated FASP increases sample-to-sample reproducibility. Moreover, differential analysis 145 by quantitative mass spectrometry (MS) facilitates reproducible quantification of hundreds 146 rather than a few distinct myelin proteins. Together, the present workflow increases the 147 efficacy of assessing the peripheral myelin proteome while shifting the main workload from 148 manual sample preparation and gel-separation to automated acquisition and processing of 149 data. We propose that comprehending the expression profiles of all myelin proteins in the 150 healthy PNS and in myelin-related disorders can contribute to advancing our understanding 151 of the physiology and pathophysiology of peripheral nerves.

152

153 **RESULTS**

154

155 **Purification of peripheral myelin**

156 We biochemically enriched myelin as a light-weight membrane fraction from pools of sciatic 157 nerves dissected from mice at postnatal day 21 (P21) using an established protocol of 158 discontinuous sucrose density gradient centrifugation (41,50), in which myelin membranes 159 accumulate at the interface between 0.29 and 0.85 M sucrose. By immunoblotting, proteins specific for both compact (MPZ/P0, MBP, PMP2) and non-compact (PRX) myelin were 160 161 substantially enriched in the myelin fraction compared to nerve lysates (Figure 1B). 162 Conversely, axonal (NEFH, KCNA1) and mitochondrial (VDAC) proteins and a marker for the 163 Schwann cell nucleus (KROX20/EGR2) were strongly reduced in purified myelin. Together, 164 these results imply that biochemically purified peripheral myelin is suitable for systematic 165 analysis of its protein composition.

166

167 **Proteome analysis of peripheral myelin**

168 It has long been difficult to accurately quantify the most abundant myelin proteins both in the 169 CNS (PLP, MBP, CNP (51)) and the PNS (MPZ/P0, MBP, PRX; this work), probably owing to 170 their exceptionally high relative abundance. For example, the major CNS myelin constituents 171 PLP, MBP and CNP comprise 17, 8 and 4% of the total myelin protein, respectively (51). We 172 have recently provided proof of principle (52) that the mass spectrometric quantification of 173 these high-abundant myelin proteins is accurate and precise when data are acquired in the 174 MS^E data acquisition mode and proteins are quantified according to the TOP3 method, i.e. if 175 their abundance values are obtained based on the proven correlation between the average 176 intensity of the three peptides exhibiting the most intense mass spectrometry response and 177 the absolute amount of their source protein (53,54). Using data acquisition by MS^E we confirmed that CNP constitutes about 4% of the total CNS myelin proteome and that the 178 abundance of CNP in myelin from mice heterozygous for the Cnp gene (Cnp^{WT/null}) compared 179 180 to wild-type mice is 50.7% (±0.4%), in agreement with the halved gene dosage and gel-181 based quantification by silver staining or immunoblotting (52).

182

When applying the MS^E mode to PNS myelin, we quantified 351 proteins with a false discovery rate (FDR) of <1% at peptide and protein level and an average sequence coverage of 35.5% (**Figure 1-source data 1**). While MS^E (labeled in orange in **Figure 1C**) indeed provided a dynamic range of more than four orders of magnitude and thus quantitatively covered the exceptionally abundant myelin proteins MPZ/P0, MBP and PRX, the number of quantified proteins appeared limited when spectral complexity was deconvoluted solely on the basis of chromatographic elution profiles. Accordingly, by using the UDMS^E mode, which

190 comprises ion mobility for additional peptide separation as well as drift time-specific collision 191 energies for peptide fragmentation, proteome coverage was increased about three-fold (1078 192 proteins quantified; average sequence coverage 34.3%; Figure 1-source data 1). However, the dynamic range of UDMS^E (labeled in blue in **Figure 1C**) was found to be somewhat 193 compressed compared to that of MS^E, which can be considered an expectable feature of 194 195 traveling wave ion mobility devices (55), where the analysis of pulsed ion packages leads to 196 a temporal and spatial binning of peptides during ion mobility separation. Indeed, this 197 manifests as a ceiling effect for the detection of exceptionally intense peptide signals, which 198 results in an underestimation of the relative abundance of MPZ/P0, MBP and PRX by 199 UDMS^E.

200

The complementary nature of the MS^E and UDMS^E data acquisition modes led us to 201 202 conclude that a comprehensive analysis of the myelin proteome that facilitates both correct 203 quantification of the most abundant proteins and deep quantitative coverage of the proteome 204 would require analyzing the same set of samples with two different instrument settings for MS^E and UDMS^E, respectively. Considering that instrument time is a bottleneck for the 205 206 routine differential proteome analysis of myelin from mutant mice, we aimed to combine the 207 strengths of MS^E and UDMS^E into a single data acquisition mode. Based on a gene ontology enrichment analysis for cellular components of the 200 proteins of highest and lowest 208 abundance from the UDMS^E dataset, we realized that the 'bottom' of the quantified proteome 209 210 is probably largely unrelated to myelin but dominated by contaminants from other subcellular 211 sources including mitochondria. We thus reasoned that for a myelin-directed data acquisition 212 mode, proteome depth may be traded in for a gain in dynamic range and devised a novel method referred to as dynamic range enhancement (DRE)-UDMS^E, in which a deflection lens 213 214 is used to cycle between full and reduced ion transmission during mass spectrometric scanning. Indeed, DRE-UDMS^E quantified an intermediate number of proteins in PNS myelin 215 216 (554 proteins; average sequence coverage 30.6%; Figure 1-source data 1) while providing an intermediate dynamic range (labeled in green in Figure 1C). We thus consider DRE-217 UDMS^E as the data acquisition mode of choice most suitable for routine differential myelin 218 219 proteome profiling (see below).

220

Overall, we found a high reproducibility between replicates and even among the different data acquisition modes as indicated by Pearson's correlation coefficients for protein abundance in the range of 0.765-0.997 (**Figure 1-supplement 1**). When comparing the proteins identified in PNS myelin using the three data acquisition modes, we found a very high overlap (**Figure 1D**). We also found a high overlap (**Figure 1E**) between the proteins identified in the present study by UDMS^E and those detected in previous proteomic approaches to PNS myelin (41,42), thus allowing a high level of confidence. Together, the three data acquisition modes exhibit distinct strengths in the efficient quantification of exceptionally abundant proteins (MS^E), establishing a comprehensive inventory (UDMS^E) and gel-free, label-free differential analysis of hundreds of distinct proteins (DRE-UDMS^E) in peripheral myelin (see **Figure 1A**). Yet, analyzing the same set of samples by different modes may not always be feasible in all routine applications when considering required instrument time.

234

235 Relative abundance of peripheral myelin proteins

236 Considering that MS^E provides the high dynamic range required for the quantification of the 237 most abundant myelin proteins, we calculated the relative abundance of the 351 proteins identified in myelin by MS^E (Figure 1-source data 1). According to quantitative assessment 238 239 of this dataset, the most abundant PNS myelin protein, myelin protein zero (MPZ/P0), 240 constitutes 44% (+/-4% relative standard deviation (RSD)) of the total myelin protein (Figure 241 2). Myelin basic protein (MBP), periaxin (PRX) and tetraspanin-29 (CD9) constitute 18% (+/-242 1% RSD), 15% (+/-1%) and 1% (+/-0.2%) of the total myelin protein, respectively (Figure 2). For MPZ/P0 and MBP, our quantification by MS^E is in agreement with but specifies prior 243 244 estimations upon gel-separation and protein labeling by Sudan-Black, Fast-Green or 245 Coomassie-Blue, in which they were judged to constitute 45–70% and 2–26% of the total 246 myelin protein, respectively (22,56-58). However, gel-based estimates of the relative 247 abundance of myelin proteins were not very precise with respect to many other proteins. 248 including those of high molecular weight. Indeed, periaxin was identified as a constituent of 249 peripheral myelin after the advent of gradient SDS-PAGE gels (59), which allowed improved 250 migration of large proteins into gels. The present MS^E-based quantification of myelin proteins 251 also extends beyond and partially adjusts an earlier mass spectrometric approach (41). 252 Indeed, the current approach identified and quantified more myelin proteins, probably owing 253 to improved protein solubilization during sample preparation and higher dynamic range of the 254 used mass spectrometer. By MS^E, known myelin proteins (**Table 1**) collectively constitute 255 over 85% of the total myelin protein (Figure 2) while proteins not yet associated with myelin 256 account for the remaining 15% of the total myelin protein.

257

258 Comprehensive compendium and comparison to the transcriptome

To systematically elucidate the developmental abundance profiles of the transcripts that encode peripheral myelin proteins (**Figure 3**), we used our combined proteome inventory of peripheral myelin (**Figure 1-source data 1**) to filter mRNA abundance data of all genes expressed in sciatic nerves. By this strategy, **Figure 3** displays only those transcripts of which the protein product was identified in peripheral myelin rather than all transcripts in the 264 nerve, thereby discriminating myelin-related mRNAs from other mRNAs such as those 265 present in peripheral axons, fibroblasts, immune cells etc. In this assessment we additionally 266 included PMP22 although it was not detected by MS as well as 45 proteins exclusively 267 identified by LC-MS of myelin separated by SDS-PAGE (Figure 1-source data 1). For 268 mRNA abundance profiles, we exploited a recently established RNA sequencing analysis 269 (RNA-Seq; platform Illumina HiSeq 2000) of sciatic nerves dissected form wild type Sprague 270 Dawley rats at embryonic day 21 (E21), P6, P18 and 6 months (60). RNA-Seq provides 271 reliable information about the relative abundance of all significantly expressed genes and is 272 thus not limited to those represented on the previously used oligonucleotide microarrays 273 (41). The raw data (accessible under GEO accession number GSE115930) were normalized 274 (Figure 3-source data 1) and standardized. When comparing the proteome and 275 transcriptome datasets, significant mRNA abundance was detected for all 1046 transcripts 276 for which an unambiguous unique gene identifier was found (Figure 3). 126 transcripts 277 displayed developmentally unchanged abundance levels, i.e., abundance changes below a 278 threshold of 10% coefficient of variation (Figure 3B; Figure 3-source data 1).

279

280 By fuzzy c-means clustering, those 920 transcripts that showed developmental abundance 281 changes were grouped into 5 clusters (Figure 3A; Figure 3-source data 1). Among those, 282 one cluster corresponds to an mRNA-abundance peak coinciding with an early phase of 283 myelin biogenesis (cluster 'P6-UP'), which includes the highest proportion of known myelin 284 proteins (Table 1) such as MPZ/P0, MBP, PRX, cyclic nucleotide phosphodiesterase (CNP), 285 fatty acid synthase (FASN), myelin-associated glycoprotein (MAG), proteolipid protein 286 (PLP/DM20), cell adhesion molecule-4 (CADM4/NECL4), connexin-29 (GJC3), claudin-19 287 (CLDN19) and CKLF-like MARVEL-transmembrane domain containing protein-5 (CMTM5). 288 However, many known myelin proteins clustered together according to their mRNA-289 abundance peak coinciding with a later phase of myelination (cluster 'P18-UP'), including 290 peripheral myelin protein 2 (PMP2), tetraspanin-29 (CD9), tetraspanin-28 (CD81), connexin-291 32 (GJB1), plasmolipin (PLLP), junctional adhesion molecule-3 (JAM3), CD59 and 292 dystrophin-related protein-2 (DRP2). The proportion of known myelin proteins was lower in 293 the clusters corresponding to mRNA-abundance peaks in adulthood (clusters 'late-UP', 'U-294 shaped'). Yet, a considerable number of transcripts displayed abundance peaks at the 295 embryonic time-point (cluster 'Descending'), including carbonic anhydrase 2 (CA2), cofilin-1 296 CFL1), tubulin beta-4 (TUBB4b) and band 4.1-protein B (EPB41L3). Generalized, the 297 clusters were roughly similar when comparing previous oligonucleotide microarray analysis 298 of mouse sciatic nerves (41) and the RNA-Seq analysis of rat sciatic nerves (this study); yet, 299 the latter provides information on a larger number of genes and with a higher level of 300 confidence. Together, clustering of mRNA abundance profiles allows categorizing peripheral301 myelin proteins into developmentally co-regulated groups.

302

303 When systematically assessing the proteins identified in myelin by gene ontology (GO)-term 304 analysis, the functional categories over-represented in the entire myelin proteome included 305 cell adhesion, cytoskeleton and extracellular matrix (labeled in turquoise in Figure 4). When 306 analyzing the clusters of developmentally co-expressed transcripts (from **Figure 3**), proteins 307 associated with the lipid metabolism were particularly enriched in the P6-UP and P18-UP 308 clusters, while those associated with the extracellular matrix (ECM) were over-represented in 309 the U-shaped and Descending clusters (Figure 4). For comparison, known myelin proteins 310 (Table 1) were over-represented in the P6-UP and P18-UP clusters (Figure 4). Together, 311 our proteome dataset provides comprehensive in-depth coverage of the protein constituents 312 of peripheral myelin purified from the sciatic nerves of wild type mice, and comparison to the 313 transcriptome allows identifying developmentally co-regulated and functional groups of 314 myelin proteins. Our data thus supply a solid resource for the molecular characterization of 315 myelin and for discovering functionally relevant myelin proteins.

316

317 Neuropathy genes encoding myelin proteins

318 Heritable neuropathies can be caused by mutations affecting genes preferentially expressed 319 in neurons, Schwann cells or both (3,61-63). To systematically assess which neuropathy-320 causing genes encode peripheral myelin proteins, we compared our myelin proteome 321 dataset with a current overview about disease genes at the NIH National Library of Medicine 322 at https://ghr.nlm.nih.gov/condition/charcot-marie-tooth-disease#genes. Indeed, 31 myelin 323 proteins were identified to be encoded by a proven neuropathy gene (Table 2), a 324 considerable increase compared to eight disease genes found in a similar previous approach 325 (41). Notably, this increase is owing to both the larger size of the current myelin proteome 326 dataset (Figure 1E) and the recent discovery of numerous neuropathy genes by the 327 widespread application of next generation sequencing.

328

329 Pathological proteomic profile of peripheral myelin in a neuropathy model

The results presented thus far were based on analyzing myelin of healthy wild type mice; yet we also sought to establish a straightforward method to systematically assess myelin diversity, as exemplified by alterations in a pathological situation. As a model we chose mice carrying a homozygous deletion of the periaxin gene ($Prx^{-/-}$) (26,64). Periaxin (PRX) is the third-most abundant peripheral myelin protein (**Figure 2**) and scaffolds the dystroglycan complex in Schwann cells. $Prx^{-/-}$ mice represent an established model of Charcot-Marie-Tooth disease type 4F (65–67). Aiming to assess the myelin proteome, we purified myelin from pools of sciatic nerves dissected from *Prx*^{-/-} and control mice at P21. Upon SDS-PAGE separation and silver staining the band patterns appeared roughly similar (**Figure 5A**), with the most obvious exception of the absence of the high-molecular weight band constituted by periaxin in *Prx*^{-/-} myelin. Yet, several other bands also displayed genotype-dependent differences in intensity. As expected, PRX was also undetectable by MS^E in *Prx*^{-/-} myelin, in which most of the total myelin protein was constituted by MPZ/P0 and MBP (**Figure 5B**; **Figure 5-source data 1**).

344

Upon differential analysis by DRE-UDMS^E (Figure 5-source data 2), multiple proteins 345 346 displayed genotype-dependent differences as visualized in a heatmap displaying those 40 347 proteins of which the abundance was reduced or increased with the highest statistical 348 significance in *Prx^{-/-}* compared to control myelin (**Figure 5C**). For example, the abundance of 349 the periaxin-associated dystrophin-related protein 2 (DRP2) was strongly reduced in Prx^{-/-} 350 myelin, as previously shown by immunoblotting (9). Notably, the abundance of multiple other 351 proteins was also significantly reduced in *Prx^{-/-}* myelin, including the extracellular matrix 352 protein laminin C1 (LAMC1; previously termed LAMB2), the laminin-associated protein 353 nidogen (NID1), Ig-like cell adhesion molecules (CADM4, MAG), the desmosomal junction 354 protein desmin (DES), cytoskeletal and cytoskeleton-associated proteins (EPB41L3, MAP1A, 355 CORO1A, SPTBN1, various microtubular and intermediate filament monomers), the 356 monocarboxylate transporter MCT1 (also termed SLC16A1) and the MCT1-associated (68) 357 immunoglobulin superfamily protein basigin (BSG, also termed CD147). On the other hand, 358 proteins displaying the strongest abundance increase in *Prx^{-/-}* myelin included immune-359 related proteins (LGALS3, LYZ2, CTSD), cytoskeletal and cytoskeleton-associated proteins 360 (CAPG, CORO1C, CNN3, several myosin heavy chain subunits), peroxisomal enzymes (CAT, HSD17B4, MDH1) and known myelin proteins (PLLP/plasmolipin, CRYAB, 361 362 GJB1/CX32). For comparison, the abundance of the marker proteolipid protein (PLP/DM20) 363 (69) and the periaxin-associated integrin beta-4 (ITGB4) (12) in myelin was unaltered in Prx^{-/-} 364 myelin. Together, differential proteome analysis finds considerably more proteins and protein 365 groups to be altered in $Prx^{-/-}$ myelin than previously known (**Figure 5C. D-D**^{...}), probably 366 reflecting the complex pathology observed in this model (26,64).

367

368 The monocarboxylate transporter MCT1/SLC16A1 expressed by myelinating 369 oligodendrocytes (70,71) and Schwann cells (28,72) has been proposed to supply lactate or 370 other glucose breakdown products to axons, in which they may serve as substrate for the 371 mitochondrial production of ATP (73–75). In this respect it was striking to find the abundance 372 of MCT1 significantly reduced in peripheral myelin when PRX is lacking (Figure 5C), a result 373 that we were able to confirm by immunoblotting (Figure 5E) and immunolabeling of teased 374 fiber preparations of sciatic nerves (Figure 5F). Notably, reduced expression of MCT1 in 375 Slc16a1^{+/-} mice impairs axonal integrity at least in the CNS (70,76). The reduced abundance of MCT1 thus represents an interesting novel facet of the complex pathology in *Prx^{-/-}* mice. 376 377 Considering that the integrity of peripheral axons may be impaired in Prx^{-/-} mice, we 378 assessed their quadriceps nerves. Indeed, *Prx^{-/-}* mice displayed reduced axonal diameters, a 379 progressively reduced total number of axons and a considerable number of myelin whorls 380 lacking a visible axon (Figure 6), indicative of impaired axonal integrity (77). Yet we note that 381 molecular or neuropathological features other than the reduced abundance of MCT1 382 probably also contribute to the axonopathy in *Prx^{-/-}* mice.

383

Together, gel-free, label free proteome analysis provides a cost- and time-efficient method that provides an accurate, sensitive tool to gain systematic insight into the protein composition of healthy peripheral myelin and its alterations in pathological situations. Indeed, gel-free proteome analysis is particularly powerful and comprehensive compared to 2D-DIGE; the workflow presented here appears readily applicable to other neuropathy models, thereby promising discovery of relevant novel features of their neuropathology.

390

391

392 DISCUSSION

393

394 We used gel-free, label-free quantitative mass spectrometry to assess the protein 395 composition of myelin biochemically purified from the sciatic nerves of wild-type mice, 396 thereby establishing a straightforward and readily applicable workflow to approach the 397 peripheral myelin proteome. The key to comprehensiveness was to combine the strengths of three data acquisition modes, i.e., MS^E for correct guantification of high-abundant proteins, 398 399 UDMS^E for deep guantitative proteome coverage including low-abundant proteins and DRE-400 UDMS^E for differential analysis. We suggest that DRE-UDMS^E provides a good compromise between dynamic range, identification rate and instrument run time for routine differential 401 402 myelin proteome profiling as a prerequisite for a molecular understanding of myelin 403 (patho)biology. We have also integrated the resulting compendium with RNA-Seq-based 404 mRNA abundance profiles in peripheral nerves and neuropathy disease loci. Beyond 405 providing the largest peripheral myelin proteome dataset thus far, the workflow is appropriate 406 to serve as starting point for assessing relevant variations of myelin protein composition, e.g., 407 in different nerves, ages, species and in pathological conditions. The identification of 408 numerous pathological alterations of myelin protein composition in the *Prx^{-/-}* neuropathy 409 model indicates that the method is well suited to assess such diversity.

410

411 Aiming to understand nervous system function at the molecular level, multiple 'omics'-scale 412 projects assess the spatio-temporal expression profiles of all mRNAs and proteins in the 413 CNS including oligodendrocytes and myelin (35-39). Yet, peripheral nerves are also 414 essential for normal sensory and motor capabilities. Prior approaches to the molecular 415 profiles of Schwann cells and PNS myelin thus far, however, were performed >8 years ago 416 (32–34,41,78–80), and the techniques have considerably advanced since. For example, 417 current gel-free, label-free mass spectrometry can simultaneously identify and quantify the 418 vast majority of proteins in a sample, thereby providing comprehensive in depth-information. 419 Moreover, RNA-Seq technology has overcome limitations of the previously used microarrays 420 for characterizing mRNA abundance profiles with respect to the number of represented 421 genes and the suitability of the oligonucleotide probes. The present compendium thus 422 provides high confidence with respect to the identification of myelin proteins, their relative 423 abundance and their developmental mRNA expression profiles. This view is supported by the 424 finding that over 80% of the total myelin proteome is constituted by approximately 50 425 previously known myelin proteins. We believe that the majority of the other identified proteins 426 represent low-abundant myelin-associated constituents in line with the high efficiency of 427 biochemical myelin purification. Doubtless, however, the myelin proteome also comprises

428 contaminants from other cellular sources, underscoring the need of independent validation429 for establishing newly identified constituents as true myelin proteins.

430

431 Do myelin proteins exist that escape identification by standard proteomic approaches? 432 Indeed, some proteins display atypically distributed lysine and arginine residues, which 433 represent the cleavage sites of the commonly used protease trypsin. The tryptic digest of 434 these proteins leads to peptides that are not well suited for chromatographic separation 435 and/or mass spectrometric detection/sequencing, as exemplified by the small hydrophobic 436 tetraspan-transmembrane myelin proteins MAL (81) and PMP22 (82). We can thus not 437 exclude that additional proteins with atypical tryptic digest patterns exist in peripheral myelin, 438 which would need to be addressed by the use of alternative proteases. Moreover, potent 439 signaling molecules including erbB receptor tyrosine kinases (83,84) and G-protein coupled 440 receptors (GPRs) (85-87) display exceptionally low abundance. Such proteins may be 441 identified when applying less stringent identification criteria, e.g., by requiring the sequencing 442 of only one unique peptide per protein. However, lower stringency would also result in 443 identifying false-positive proteins, which we wished to avoid for the purpose of the present 444 compendium. We note that a truly comprehensive spatio-temporally resolved myelin 445 proteome should preferentially also include systematic information about protein isoforms 446 and post-translational modifications, which still poses technical challenges.

447

448 Mutations affecting the periaxin (PRX) gene in humans cause CMT type 4F (65.88–90); the 449 neuropathology resulting from mutations affecting periaxin has been mainly investigated in 450 the *Prx^{-/-}* mouse model. Indeed, *Prx^{-/-}* mice display a progressive peripheral neuropathy 451 including axon/myelin-units with abnormal myelin thickness, demyelination, tomaculae, onion 452 bulbs, reduced nerve conduction velocity (64), reduced abundance and mislocalization of the 453 periaxin-associated DRP2 (9) and reduced internode length (26). Absence of SLIs (64) and 454 bands of Cajal (26) imply that the non-compact myelin compartments are impaired when 455 PRX is lacking. In the differential analysis of myelin purified from Prx^{-/-} and control mice we 456 find that the previously reported reduced abundance of DRP2 (9) represents one of the 457 strongest molecular changes in the myelin proteome when PRX is lacking. Notably, the 458 reported morphological changes in this neuropathy model (9,26,64) go along with alterations 459 affecting the abundance of multiple other myelin-associated proteins, including junctional, 460 cytoskeletal, extracellular matrix and immune-related proteins as well as lipid-modifying enzymes. Thus, the neuropathology in Prx^{--} mice at the molecular level is more complex 461 462 than previously anticipated. It is striking that the abundance of the monocarboxylate 463 transporter MCT1/SLC16A1 that may contribute to the metabolic supply of lactate from myelinating cells to axons (27–31) is strongly reduced in $Prx^{-/-}$ myelin. Considering that 464

465 MCT1 in Schwann cells mainly localizes to Schmidt Lanterman incisures (SLI) (28) and that 466 SLI are largely absent from myelin when PRX is lacking (64), the reduced abundance of 467 MCT1 in Prx^{-/-} myelin may be a consequence of the impaired myelin ultrastructure. Yet, considering that SLI are part of the cytosolic channels that may represent transport routes 468 469 toward Schwann cell-dependent metabolic support of myelinated axons, the diminishment of MCT1 may contribute to reduced axonal diameters or axonal loss in $Prx^{-/-}$ mice, probably in 470 471 conjunction with other molecular or morphological defects. Together, the in depth-analysis of 472 proteins altered in neuropathy models can contribute to an improved understanding of nerve 473 pathophysiology.

474

475 Compared to a previous approach (41), the number of proven neuropathy genes of which the 476 encoded protein is mass spectrometrically identified in peripheral myelin has increased four-477 fold from eight to 32 in the present study. This reflects both that the number of proteins 478 identified in myelin has approximately doubled and that more neuropathy genes are known 479 due to the common use of genome sequencing. We note that our compendium comprises 480 not only myelin-associated proteins causing (when mutated) demyelinating CMT1 (e.g., 481 MPZ/P0, NEFL, PMP2) or intermediate CMT4 (GDAP1, NDRG1, PRX) but also axonal 482 CMT2 (RAB7, GARS, HSPB1). Yet, the expression of genes causative of CMT2 is not 483 necessarily limited to neurons, as exemplified by the classical myelin protein MPZ/P0. 484 Indeed, a subset of MPZ-mutations causes axonal CMT2I or CMT2J (91–95), probably 485 reflecting impaired axonal integrity as consequence of a mutation primarily affecting 486 Schwann cells. We also note that the nuclear EGR2/KROX20 causative of demyelinating 487 CMT1D has not been mass spectrometrically identified in myelin, reflecting that Schwann cell 488 nuclei are efficiently removed during myelin purification.

489

While morphological analysis of peripheral nerves by light and electron microscopy is routine in numerous laboratories, systematic molecular analysis has been less straightforward. Using the sciatic nerve as a model, we show that systematic assessment of the myelin proteome and the total nerve transcriptome are suited to determine comprehensive molecular profiles in healthy nerves and in myelin-related disorders. Myelin proteome analysis can thus complement transcriptome analysis in assessing development, function and pathophysiology of peripheral nerves.

497

498 **MATERIALS AND METHODS**

499

500 Mouse models

501 Prx^{-/-} mice (64) were kept on c57Bl/6 background in the animal facility of the University of 502 Edinburgh (United Kingdom). Genotyping was by PCR on genomic DNA using the forward 503 primers 5'-CAGATTTGCT CTGCCCAAGT and 5'-CGCCTTCTAT CGCCTTCTTGAC in 504 combination with reverse primer 5'-ATGCCCTCAC CCACTAACAG. The PCR yielded a 0.5 505 kb fragment for the wildtype allele and a 0.75 kb product for the mutant allele. The age of 506 experimental animals is given in the figure legends. All animal work conformed to United 507 Kingdom legislation (Scientific Procedures) Act 1986 and to the University of Edinburgh 508 Ethical Review Committee policy; Home Office project license No. P0F4A25E9.

509

510 Myelin purification

A light-weight membrane fraction enriched for myelin was purified from sciatic nerves of mice by sucrose density centrifugation and osmotic shocks as described (41,52). Myelin accumulates at the interface between 0.29 and 0.85 M sucrose. *Prx*^{-/-} and wild type control C57BI/6 mice were sacrificed by cervical dislocation at postnatal day 21 (P21). For each genotype, myelin was purified as three biological replicates (n=3); each biological replicate representing a pool of 20 sciatic nerves dissected from 10 mice. Protein concentration was determined using the DC Protein Assay Kit (Bio-Rad).

518

519 Filter-aided sample preparation for proteome analysis

520 Protein fractions corresponding to 10 µg myelin protein were dissolved and processed 521 according to a filter-aided sample preparation (FASP) protocol essentially as previously 522 described for synaptic protein fractions (96) and as adapted to CNS myelin (52,97). Unless 523 stated otherwise, all steps were automated on a liquid-handling workstation equipped with a 524 vacuum manifold (Freedom EVO 150, Tecan) by using an adaptor device constructed in-525 house. Briefly, myelin protein samples were lysed and reduced in lysis buffer (7 M urea, 2 M 526 thiourea. 10 mM DTT. 0.1 M Tris pH 8.5) containing 1% ASB-14 by shaking for 30 min at 527 37°C. Subsequently, the sample was diluted with ~10 volumes lysis buffer containing 2% 528 CHAPS to reduce the ASB-14 concentration and loaded on centrifugal filter units (30 kDa 529 MWCO, Merck Millipore). After removal of the detergents by washing twice with wash buffer 530 (8 M urea, 10 mM DTT, 0.1 M Tris pH 8.5), proteins were alkylated with 50 mM 531 iodoacetamide in 8 M urea, 0.1 M Tris pH 8.5 (20 min at RT), followed by two washes with 532 wash buffer to remove excess reagent. Buffer was exchanged by washing three times with 533 50 mM ammonium bicarbonate (ABC) containing 10 % acetonitrile. After three additional 534 washes with 50 mM ABC/10% acetonitrile, which were performed by centrifugation to ensure

535 quantitative removal of liquids potentially remaining underneath the ultrafiltration membrane, 536 proteins were digested overnight at 37°C with 400 ng trypsin in 40 µl of the same buffer. 537 Tryptic peptides were recovered by centrifugation followed by two additional extraction steps 538 with 40 µl of 50 mM ABC and 40 µl of 1% trifluoroacetic acid (TFA), respectively. Aliquots of 539 the combined flow-throughs were spiked with 10 fmol/µl of yeast enclase-1 tryptic digest 540 standard (Waters Corporation) for quantification purposes and directly subjected to analysis 541 by liquid chromatography coupled to electrospray mass spectrometry (LC-MS). A pool of all 542 samples was injected at least before and after any sample set to monitor stability of 543 instrument performance.

544

545 Mass spectrometry

546 Nanoscale reversed-phase UPLC separation of tryptic peptides was performed with a 547 nanoAcquity UPLC system equipped with a Symmetry C18 5 µm, 180 µm × 20 mm trap 548 column and a HSS T3 C18 1.8 µm, 75 µm × 250 mm analytical column (Waters Corporation) 549 maintained at 45°C. Injected peptides were trapped for 4 min at a flow rate of 8 µl/min 0.1% 550 TFA and then separated over 120 min at a flow rate of 300 nl/min with a gradient comprising 551 two linear steps of 3-35% mobile phase B in 105 min and 35-60% mobile phase B in 15 min, 552 respectively. Mobile phase A was water containing 0.1% formic acid while mobile phase B 553 was acetonitrile containing 0.1% formic acid. Mass spectrometric analysis of tryptic peptides 554 was performed using a Synapt G2-S quadrupole time-of-flight mass spectrometer equipped 555 with ion mobility option (Waters Corporation). Positive ions in the mass range m/z 50 to 2000 556 were acquired with a typical resolution of at least 20.000 FWHM (full width at half maximum) and data were lock mass corrected post-acquisition. UDMS^E and DRE-UDMS^E analyses 557 558 were performed in the ion mobility-enhanced data-independent acquisition mode with drift 559 time-specific collision energies as described in detail by Distler et al. (48,49). Specifically, for 560 DRE-UDMS^E a deflection device (DRE lens) localized between the quadrupole and the ion 561 mobility cell of the mass spectrometer was cycled between full (100% for 0.4 sec) and 562 reduced (5% for 0.4 sec) ion transmission during one 0.8 sec full scan. Continuum LC-MS 563 data were processed for signal detection, peak picking, and isotope and charge state 564 deconvolution using Waters ProteinLynx Global Server (PLGS) version 3.0.2 (47). For 565 protein identification, a custom database was compiled by adding the sequence information 566 for yeast enclase 1 and porcine trypsin to the UniProtKB/Swiss-Prot mouse proteome and by 567 appending the reversed sequence of each entry to enable the determination of false 568 discovery rate (FDR). Precursor and fragment ion mass tolerances were automatically 569 determined by PLGS 3.0.2 and were typically below 5 ppm for precursor ions and below 10 570 ppm (root mean square) for fragment ions. Carbamidomethylation of cysteine was specified 571 as fixed and oxidation of methionine as variable modification. One missed trypsin cleavage

was allowed. Minimal ion matching requirements were two fragments per peptide, five
fragments per protein, and one peptide per protein. The FDR for protein identification was set
to 1% threshold.

575

576 Analysis of proteomic data

577 For each genotype (*Prx*^{-/-} and wild type control mice sacrificed at P21), biochemical fractions 578 enriched for PNS myelin were analyzed as three biological replicates (n=3 per condition); 579 each biological replicate representing a pool of 20 sciatic nerves dissected from 10 mice. The 580 samples were processed with replicate digestion and injection, resulting in four technical 581 replicates per biological replicate and thus a total of 12 LC-MS runs per condition to be 582 compared, essentially as previously reported for CNS myelin (36,97). The freely available 583 software ISOQuant (www.isoquant.net) was used for post-identification analysis including 584 retention time alignment, exact mass and retention time (EMRT) and ion mobility clustering, 585 peak intensity normalization, isoform/homology filtering and calculation of absolute in-sample 586 amounts for each detected protein (48,49,98) according to the TOP3 quantification approach 587 (53,54). Only peptides with a minimum length of seven amino acids that were identified with 588 scores above or equal to 5.5 in at least two runs were considered. FDR for both peptides and 589 proteins was set to 1% threshold and only proteins reported by at least two peptides (one of 590 which unique) were quantified using the TOP3 method. The parts per million (ppm) 591 abundance values (i.e. the relative amount (w/w) of each protein in respect to the sum over 592 all detected proteins) were log2-transformed and normalized by subtraction of the median 593 derived from all data points for the given protein. Significant changes in protein abundance 594 were detected by moderated t-statistics essentially as described (96,97) across all technical 595 replicates using an empirical Bayes approach and false discovery (FDR)-based correction for 596 multiple comparisons (100). For this purpose, the Bioconductor R packages "limma" (101) 597 and "q-value" (102) were used in RStudio, an integrated development environment for the 598 open source programming language R. Proteins identified as contaminants (e.g. components 599 of blood or hair cells) were removed from the analysis. Proteins with ppm values below 100 600 which were not identified in one genotype were considered as just above detection level and 601 also removed from the analysis. The relative abundance of a protein in myelin was accepted 602 as altered if both statistically significant (q-value <0.05). Pie charts, heatmaps and volcano 603 plots were prepared in Microsoft Excel 2013 and GraphPad Prism 7. Pearson's correlation 604 coefficients derived from log2-transformed ppm abundance values were clustered and 605 visualized with the tool heatmap.2 contained in the R package gplots (CRAN.R-606 project.org/package=gplots). Only pairwise complete observations were considered to 607 reduce the influence of missing values on clustering behavior. The mass spectrometry 608 proteomics data have been deposited to the ProteomeXchange Consortium

609 (proteomecentral.proteomexchange.org) via the PRIDE partner repository (103) with the

- 610 dataset identifier PXD015960.
- 611

612 Gel electrophoresis and silver staining of gels

613 Protein concentration was determined using the DC Protein Assay kit (BioRad). Samples 614 were separated on a 12% SDS-PAGE for 1 h at 200 V using the BioRad system, fixated 615 overnight in 10% [v/v] acetic acid and 40 % [v/v] ethanol and then washed in 30% ethanol (2x 616 20 min) and ddH₂O (1x 20 min). For sensitization, gels were incubated 1 min in 0.012% [v/v]617 $Na_2S_2O_3$ and subsequently washed with ddH₂O (3x 20 sec). For silver staining, gels were 618 impregnated for 20 min in 0.2 % [w/v] AgNO₃ / 0.04% formaldehyde, washed with ddH₂O (3x 619 20 sec) and developed in 3% [w/v] Na₂CO₃ / 0.02% [w/v] formaldehyde. The reaction was 620 stopped by exchanging the solution with 5% [v/v] acetic acid.

621

622 Immunoblotting

623 Immunoblotting was performed as described (104,105). Primary antibodies were specific for 624 dystrophin-related-protein 2 (DRP2; Sigma; 1:1000), peripheral myelin protein 2 (PMP2; 625 ProteinTech Group 12717-1-AP; 1:1000), proteolipid protein (PLP/DM20; A431 (106); 626 1:5000), Monocarboxylate transporter 1 (MCT1/SLC16A1; (107); 1:1000), periaxin (PRX; 627 (59); 1:1000), sodium/potassium-transporting ATPase subunit alpha-1 (ATP1A1; 1:2000; 628 Abcam #13736-1-AP), myelin protein zero (MPZ/P0; (108); kind gift by J. Archelos-Garcia; 629 1:10.000), voltage-dependent anion-selective channel protein (VDAC; Abcam #ab15895; 630 1:1000), basigin (BSG/CD147; ProteinTech Group #ab64616; 1:1000), neurofilament H 631 (NEFH/NF-H; Covance #SMI-32P; 1:1000), voltage-gated potassium channel subunit A 632 member 1 (KCNA1; Neuromab #73-007; 1:1000), EGR2/KROX20 ((109); kind gift by D. 633 Meijer, Edinburgh; 1:1000) and myelin basic protein (MBP; 1:2000). To generate the latter 634 antisera, rabbits were immunized (Pineda Antikörper Service, Berlin, Germany) with the 635 KLH-coupled peptide CQDENPVVHFFK corresponding to amino acids 212-222 of mouse 636 MBP isoform 1 (Swisprot/Uniprot-identifier P04370-1). Anti-MBP antisera were purified by 637 affinity chromatography and extensively tested for specificity by immunoblot analysis of homogenate of brains dissected from wild-type mice compared to Mbp^{shiverer/shiverer} mice that 638 639 lack expression of MBP. Appropriate secondary anti-mouse or -rabbit antibodies conjugated 640 to HRP were from dianova. Immunoblots were developed using the Enhanced 641 Chemiluminescence Detection kit (Western Lightning® Plus, Perkin Elmer) and detected with 642 the Intas ChemoCam system (INTAS Science Imaging Instruments GmbH, Göttingen, 643 Germany).

644

645 Immunolabelling of teased fibers

646 Teased fibers were prepared as previously described (9,110). For each genotype, one male 647 mouse was sacrificed by cervical dislocation at P17. Immunolabelling of teased fibers was 648 performed as described (69). Briefly, teased fibers were fixed for 5 min in 4% 649 paraformaldehyde, permeabilized 5 min with ice-cold methanol, washed in PBS (3x 5 min) 650 and blocked for 1 h at 21°C in blocking buffer (10% horse serum, 0.25% Triton X-100, 1% 651 bovine serum albumin in PBS). Primary antibodies were applied overnight at 4°C in 652 incubation buffer (1.5% horse serum, 0.25% Triton X-100 in PBS). Samples were washed in 653 PBS (3x 5 min) and secondary antibodies were applied in incubation buffer (1 h, RT). 654 Samples were again washed in PBS (2x 5 min), and 4',6-diamidino-2-phenylindole (DAPI; 655 1:50 000 in PBS) was applied for 10 min at RT. Samples were briefly washed 2x with ddH₂O 656 and mounted using Aqua-Poly/Mount (Polysciences, Eppelheim, Germany). Antibodies were 657 specific for myelin-associated glycoprotein (MAG clone 513; Chemicon MAB1567; 1:50) and 658 MCT1/SLC16A1 (107). Secondary antibodies were donkey α-rabbit-Alexa488 (Invitrogen 659 A21206; 1:1000) and donkey α-mouse-Alexa555 (Invitrogen A21202; 1:1000). Labeled 660 teased fibers were imaged using the confocal microscope Leica SP5. The signal was 661 collected with the objective HCX PL APO lambda blue 63.0.x1.20. DAPI staining was excited 662 with 405 nm and collected between 417 nm - 480 nm. To excite the Alexa488 fluorophore an 663 Argon laser with the excitation of 488 nm was used and the emission was set to 500 nm -664 560 nm. Alexa555 was excited by using the DPSS561 laser at an excitation of 561 nm and 665 the emission was set to 573 nm - 630 nm. To export and process the images LAS AF lite and 666 Adobe Photoshop were used.

667

668 mRNA abundance profiles

669 Raw data were previously established (60) from the sciatic nerves of wild type Sprague 670 Dawley rats at the indicated ages (E21, P6, P18; n=4 per time point). Briefly, sciatic nerves 671 were dissected, the epineurium was removed, total RNA was extracted with the RNeasy Kit 672 (Qiagen), concentration and quality (ratio of absorption at 260/280 nm) of RNA samples were 673 determined using the NanoDrop spectrophotometer (ThermoScientific), integrity of the 674 extracted RNA was determined with the Agilent 2100 Bioanalyser (Agilent Technologies) and 675 RNA-Seq was performed using the Illumina HiSeq2000 platform. RNA-Seq raw data are 676 available under the GEO accession number GSE115930 (60). For the present analysis, the 677 fastqfiles were mapped to rattus norvegicus rn6 using Tophat Aligner and then quantified 678 based on the Ensemble Transcripts release v96. The raw read counts were then normalized 679 using the R package DESeq2. The normalized gene expression data was then standardized 680 to a mean of zero and a standard deviation of one, therefore genes with similar changes in 681 expression are close in the euclidian space. Clustering was performed on the standardized

- 682 data using the R package mfuzz. Transcripts displaying abundance differences of less than
- 683 10% coefficient of variation were considered developmentally unchanged.
- 684

685 Venn diagrams

686 Area-proportional Venn diagrams were prepared using BioVenn (111) at <u>www.biovenn.nl/</u>.

687

688 **GO-term**

For functional categorization of the myelin proteome the associated gene ontology terms were systematically analyzed on the mRNA abundance cluster using the Database for Annotation, Visualization and Integrated Discovery (DAVID; <u>https://david.ncifcrf.gov</u>). For comparison known myelin proteins according to literature were added.

693

694 Histological analysis

695 Prx⁻⁻ and control mice were perfused at the indicated ages intravascularly with fixative 696 solution (2.5% glutaraldehyde, 4% paraformaldehyde, 0.1 M sodium cacodylate buffer, pH 697 7.4). Quadriceps nerves were removed, fixed for 2 h at room temperature, followed by 18 h 698 at 4°C in the same fixative, postfixed in OsO₄, dehydrated a graded series of ethanol, 699 followed by propylene oxide and embedded in Araldite. All axons not associated with a 700 Remak bundle were counted and categorized as myelinated or non-myelinated. All myelin 701 profiles lacking a recognizable axon were counted. The total number of axons were counted 702 on micrographs of toluidine blue stained Araldite sections (0.5 µm) of quadriceps nerves. 703 Precise p-values for the quantitative comparison between Ctrl and Prx^{-/-} mice were: Total 704 number of axons (Figure 6B; Student's unpaired t-test): 2 mo p=0.01734; 4 mo p=2.1E-05; 9 705 mo p=0.007625; Number of myelinated axons (Figure 6C; Student's unpaired t-test): 2 mo 706 p=0.00444; 4 mo p=2.12E-05; 9 mo p=0.005766; Number of empty myelin profiles (Figure 707 **6D**; Student's unpaired t-test): 2 mo p=0.004445; 4 mo p=0.001461; 9 mo p=0.000695; 708 Axonal diameters (Figure 6E-G; two-sided Kolmogorow-Smirnow test): 2 mo p=2.20E-16; 4 709 mo p=2.20E-16; 9 mo p=2.20E-16.

- 710
- 711

ACKNOWLEDGMENTS

- We thank J. Archelos-Garcia and D. Meijer for antibodies, T. Buscham and J. Edgar for discussions, L. Piepkorn for support in data analysis, K.-A. Nave for support made possible by a European Research Council Advanced Grant ('MyeliNano' to K.-A.N.) and the International Max Planck Research School for Genome Science (IMPRS-GS) for supporting S.B.S.. FUNDING Our work is supported by the Deutsche Forschungsgemeinschaft (DFG; Grants WE 2720/2-2, WE 2720/4-1 and WE 2720/5-1 to H.B.W. and RO 4076/3-2 to M.J.R.) and the Wellcome Trust (Grant No 0842424 to P.J.B.). **CONFLICT OF INTEREST STATEMENT** The authors declare no conflict of interest.

- 731 **REFERENCES**
- 732
- 733 1. Weil M-T, Heibeck S, Töpperwien M, tom Dieck S, Ruhwedel T, Salditt T, et al. Axonal 734 Ensheathment in the Nervous System of Lamprey: Implications for the Evolution of Myelinating 735 Glia. J Neurosci [Internet]. 2018 Jul 18:38(29):6586–96. Available from: 736 http://www.jneurosci.org/lookup/doi/10.1523/JNEUROSCI.1034-18.2018 737 2. Hartline DK, Colman DR, Rapid Conduction and the Evolution of Giant Axons and Myelinated 738 Fibers. Curr Biol [Internet]. 2007 Jan;17(1):R29-35. Available from: 739 https://linkinghub.elsevier.com/retrieve/pii/S0960982206025231 740 3. Rossor AM, Polke JM, Houlden H, Reilly MM. Clinical implications of genetic advances in 741 Charcot-Marie-Tooth disease. Nat Rev Neurol [Internet]. 2013 Oct 10;9(10):562-71. Available 742 from: http://www.nature.com/articles/nrneurol.2013.179 743 Michailov G V. Axonal Neuregulin-1 Regulates Myelin Sheath Thickness. Science (80-) 4. 744 [Internet]. 2004 Apr 30;304(5671):700-3. Available from: 745 http://www.sciencemag.org/cgi/doi/10.1126/science.1095862 746 5. Taveggia C, Zanazzi G, Petrylak A, Yano H, Rosenbluth J, Einheber S, et al. Neuregulin-1 747 Type III Determines the Ensheathment Fate of Axons. Neuron [Internet]. 2005 Sep;47(5):681– 748 94. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0896627305006926 749 6. Chernousov MA, Yu W-M, Chen Z-L, Carey DJ, Strickland S. Regulation of Schwann cell 750 function by the extracellular matrix. Glia [Internet]. 2008 Nov 1;56(14):1498-507. Available 751 from: http://doi.wiley.com/10.1002/glia.20740 752 7. Petersen SC, Luo R, Liebscher I, Giera S, Jeong S-J, Mogha A, et al. The Adhesion GPCR 753 GPR126 Has Distinct, Domain-Dependent Functions in Schwann Cell Development Mediated 754 by Interaction with Laminin-211. Neuron [Internet]. 2015 Feb:85(4):755–69. Available from: 755 https://linkinghub.elsevier.com/retrieve/pii/S0896627314011660 756 8. Ghidinelli M, Poitelon Y, Shin YK, Ameroso D, Williamson C, Ferri C, et al. Laminin 211 inhibits 757 protein kinase A in Schwann cells to modulate neuregulin 1 type III-driven myelination. Emery 758 B, editor. PLOS Biol [Internet]. 2017 Jun 21;15(6):e2001408. Available from: 759 https://dx.plos.org/10.1371/journal.pbio.2001408 760 9. Sherman DL, Fabrizi C, Gillespie CS, Brophy PJ. Specific Disruption of a Schwann Cell 761 Dystrophin-Related Protein Complex in a Demyelinating Neuropathy. Neuron [Internet]. 2001 762 May;30(3):677-87. Available from: 763 https://linkinghub.elsevier.com/retrieve/pii/S0896627301003270 764 Masaki T, Matsumura K, Hirata A, Yamada H, Hase A, Arai K, et al. Expression of 10. 765 Dystroglycan and the Laminin- α 2 Chain in the Rat Peripheral Nerve during Development. Exp 766 Neurol [Internet]. 2002 Mar;174(1):109-17. Available from: 767 https://linkinghub.elsevier.com/retrieve/pii/S0014488601978562 768 11. Nodari A, Previtali SC, Dati G, Occhi S, Court FA, Colombelli C, et al. 6 4 Integrin and 769 Dystroglycan Cooperate to Stabilize the Myelin Sheath. J Neurosci [Internet]. 2008 Jun 770 25:28(26):6714-9. Available from: http://www.jneurosci.org/cgi/doi/10.1523/JNEUROSCI.0326-771 08.2008

772 Raasakka A, Linxweiler H, Brophy PJ, Sherman DL, Kursula P. Direct Binding of the Flexible 12. 773 C-Terminal Segment of Periaxin to β4 Integrin Suggests a Molecular Basis for CMT4F. Front 774 Mol Neurosci [Internet]. 2019 Apr 9;12. Available from: 775 https://www.frontiersin.org/article/10.3389/fnmol.2019.00084/full 776 13. Hess A, Lansing AI. The fine structure of peripheral nerve fibers. Anat Rec. 1953; 777 14. Sherman DL, Brophy PJ. Mechanisms of axon ensheathment and myelin growth. Nat Rev 778 Neurosci [Internet]. 2005 Sep;6(9):683–90. Available from: 779 http://www.nature.com/articles/nrn1743 780 15. Pereira JA, Lebrun-Julien F, Suter U. Molecular mechanisms regulating myelination in the 781 peripheral nervous system. Trends Neurosci [Internet]. 2012 Feb;35(2):123–34. Available from: 782 https://linkinghub.elsevier.com/retrieve/pii/S0166223611001937 783 Grove M, Brophy PJ. FAK Is Required for Schwann Cell Spreading on Immature Basal Lamina 16. 784 to Coordinate the Radial Sorting of Peripheral Axons with Myelination. J Neurosci [Internet]. 785 2014 Oct 1;34(40):13422–34. Available from: 786 http://www.jneurosci.org/cgi/doi/10.1523/JNEUROSCI.1764-14.2014 787 17. Monk KR, Feltri ML, Taveggia C. New insights on schwann cell development. Glia [Internet]. 788 2015 Aug;63(8):1376–93. Available from: http://doi.wiley.com/10.1002/glia.22852 789 18. Feltri ML, Poitelon Y, Previtali SC. How Schwann Cells Sort Axons. Neurosci [Internet]. 2016 790 Jun 16;22(3):252–65. Available from: 791 http://journals.sagepub.com/doi/10.1177/1073858415572361 792 Giese KP, Martini R, Lemke G, Soriano P, Schachner M. Mouse P0 gene disruption leads to 19. 793 hypomyelination, abnormal expression of recognition molecules, and degeneration of myelin 794 and axons. Cell [Internet]. 1992 Nov;71(4):565-76. Available from: 795 https://linkinghub.elsevier.com/retrieve/pii/009286749290591Y 796 20. Martini R, Mohajeri MH, Kasper S, Giese KP, Schachner M. Mice doubly deficient in the genes 797 for P0 and myelin basic protein show that both proteins contribute to the formation of the major 798 dense line in peripheral nerve myelin. J Neurosci. 1995; 799 21. Nawaz S, Schweitzer J, Jahn O, Werner HB. Molecular evolution of myelin basic protein, an 800 abundant structural myelin component. Glia [Internet]. 2013 Aug;61(8):1364–77. Available 801 from: http://doi.wiley.com/10.1002/glia.22520 802 22. Greenfield S, Brostoff S, Eylar EH, Morell P. PROTEIN COMPOSITION OF MYELIN OF THE 803 PERIPHERAL NERVOUS SYSTEM. J Neurochem [Internet]. 1973 Apr;20(4):1207-16. 804 Available from: http://doi.wiley.com/10.1111/j.1471-4159.1973.tb00089.x 805 23. Brostoff SW, Karkhanis YD, Carlo DJ, Reuter W, Eylar EH. Isolation and partial 806 characterization of the major proteins of rabbit sciatic nerve myelin. Brain Res [Internet]. 1975 807 Mar;86(3):449–58. Available from: 808 https://linkinghub.elsevier.com/retrieve/pii/0006899375908951 809 24. Nave K-A, Werner HB. Myelination of the Nervous System: Mechanisms and Functions. Annu 810 Rev Cell Dev Biol [Internet]. 2014 Oct 11;30(1):503-33. Available from: 811 http://www.annualreviews.org/doi/10.1146/annurev-cellbio-100913-013101 812 25. Kleopa KA, Sargiannidou I. Connexins, gap junctions and peripheral neuropathy. Neurosci Lett

813 [Internet]. 2015 Jun;596:27–32. Available from:

814 https://linkinghub.elsevier.com/retrieve/pii/S0304394014008453

- 815 26. Court FA, Sherman DL, Pratt T, Garry EM, Ribchester RR, Cottrell DF, et al. Restricted growth
 816 of Schwann cells lacking Cajal bands slows conduction in myelinated nerves. Nature [Internet].
 817 2004 Sep;431(7005):191–5. Available from: http://www.nature.com/articles/nature02841
- 81827.Beirowski B, Babetto E, Golden JP, Chen Y-J, Yang K, Gross RW, et al. Metabolic regulator819LKB1 is crucial for Schwann cell-mediated axon maintenance. Nat Neurosci [Internet]. 2014
- 820 Oct 7;17(10):1351–61. Available from: http://www.nature.com/articles/nn.3809
- Bomenech-Estevez E, Baloui H, Repond C, Rosafio K, Medard J-J, Tricaud N, et al.
 Distribution of Monocarboxylate Transporters in the Peripheral Nervous System Suggests
 Putative Roles in Lactate Shuttling and Myelination. J Neurosci [Internet]. 2015 Mar
 11;35(10):4151–6. Available from: http://www.jneurosci.org/cgi/doi/10.1523/JNEUROSCI.3534-
- 825 14.2015
- Kim S, Maynard JC, Sasaki Y, Strickland A, Sherman DL, Brophy PJ, et al. Schwann Cell OGlcNAc Glycosylation Is Required for Myelin Maintenance and Axon Integrity. J Neurosci
 [Internet]. 2016 Sep 14;36(37):9633–46. Available from:
- 829 http://www.jneurosci.org/cgi/doi/10.1523/JNEUROSCI.1235-16.2016
- 830 30. Gonçalves NP, Vægter CB, Andersen H, Østergaard L, Calcutt NA, Jensen TS. Schwann cell
 831 interactions with axons and microvessels in diabetic neuropathy. Nat Rev Neurol [Internet].
 832 2017 Mar 30;13(3):135–47. Available from: http://www.nature.com/articles/nrneurol.2016.201
- 83331.Stassart RM, Möbius W, Nave K-A, Edgar JM. The Axon-Myelin Unit in Development and834Degenerative Disease. Front Neurosci [Internet]. 2018 Jul 11;12. Available from:

835 https://www.frontiersin.org/article/10.3389/fnins.2018.00467/full

- 83632.Nagarajan R, Le N, Mahoney H, Araki T, Milbrandt J. Deciphering peripheral nerve myelination837by using Schwann cell expression profiling. Proc Natl Acad Sci [Internet]. 2002 Jun
- 838 25;99(13):8998–9003. Available from: http://www.pnas.org/cgi/doi/10.1073/pnas.132080999
- 839 33. Le N, Nagarajan R, Wang JYT, Araki T, Schmidt RE, Milbrandt J. Analysis of congenital
 840 hypomyelinating Egr2Lo/Lo nerves identifies Sox2 as an inhibitor of Schwann cell
 841 differentiation and myelination. Proc Natl Acad Sci [Internet]. 2005 Feb 15;102(7):2596–601.
- 842 Available from: http://www.pnas.org/cgi/doi/10.1073/pnas.0407836102

843 34. Ryu EJ, Yang M, Gustin JA, Chang L-W, Freimuth RR, Nagarajan R, et al. Analysis of

- 844 Peripheral Nerve Expression Profiles Identifies a Novel Myelin Glycoprotein, MP11. J Neurosci
 845 [Internet]. 2008 Jul 23;28(30):7563–73. Available from:
- 846 http://www.jneurosci.org/cgi/doi/10.1523/JNEUROSCI.1659-08.2008
- 35. Zhang Y, Chen K, Sloan SA, Bennett ML, Scholze AR, O'Keeffe S, et al. An RNA-Sequencing
 Transcriptome and Splicing Database of Glia, Neurons, and Vascular Cells of the Cerebral
 Cortex. J Neurosci [Internet]. 2014 Sep 3;34(36):11929–47. Available from:

850 http://www.jneurosci.org/cgi/doi/10.1523/JNEUROSCI.1860-14.2014

- 851 36. Patzig J, Erwig MS, Tenzer S, Kusch K, Dibaj P, Möbius W, et al. Septin/anillin filaments
- scaffold central nervous system myelin to accelerate nerve conduction. Elife. 2016;5:e17119.
- 853 37. Sharma K, Schmitt S, Bergner CG, Tyanova S, Kannaiyan N, Manrique-Hoyos N, et al. Cell

854 type- and brain region-resolved mouse brain proteome. Nat Neurosci [Internet]. 2015 Dec 855 2;18(12):1819–31. Available from: http://www.nature.com/articles/nn.4160 856 38. Thakurela S, Garding A, Jung RB, Müller C, Goebbels S, White R, et al. The transcriptome of 857 mouse central nervous system myelin. Sci Rep [Internet]. 2016 May 13;6(1):25828. Available 858 from: http://www.nature.com/articles/srep25828 859 39. Margues S, Zeisel A, Codeluppi S, van Bruggen D, Mendanha Falcao A, Xiao L, et al. 860 Oligodendrocyte heterogeneity in the mouse juvenile and adult central nervous system. 861 Science (80-) [Internet]. 2016 Jun 10;352(6291):1326-9. Available from: 862 http://www.sciencemag.org/cgi/doi/10.1126/science.aaf6463 863 40. De Monasterio-Schrader P, Jahn O, Tenzer S, Wichert SP, Patzig J, Werner HB. Systematic 864 approaches to central nervous system myelin. Cellular and Molecular Life Sciences. 2012. 865 41. Patzig J, Jahn O, Tenzer S, Wichert SP, de Monasterio-Schrader P, Rosfa S, et al. 866 Quantitative and Integrative Proteome Analysis of Peripheral Nerve Myelin Identifies Novel 867 Myelin Proteins and Candidate Neuropathy Loci. J Neurosci [Internet]. 2011 Nov 868 9;31(45):16369–86. Available from: 869 http://www.jneurosci.org/cgi/doi/10.1523/JNEUROSCI.4016-11.2011 870 42. Kangas SM, Ohlmeier S, Sormunen R, Jouhilahti E-M, Peltonen S, Peltonen J, et al. An 871 approach to comprehensive genome and proteome expression analyses in Schwann cells and 872 neurons during peripheral nerve myelin formation. J Neurochem [Internet]. 2016 873 Sep;138(6):830–44. Available from: http://doi.wiley.com/10.1111/jnc.13722 874 43. Kusch K, Uecker M, Liepold T, Möbius W, Hoffmann C, Neumann H, et al. Partial 875 Immunoblotting of 2D-Gels: A Novel Method to Identify Post-Translationally Modified Proteins 876 Exemplified for the Myelin Acetylome. Proteomes [Internet]. 2017 Jan 12;5(4):3. Available 877 from: http://www.mdpi.com/2227-7382/5/1/3 878 44. Neilson KA, Ali NA, Muralidharan S, Mirzaei M, Mariani M, Assadourian G, et al. Less label, 879 more free: Approaches in label-free quantitative mass spectrometry. Proteomics. 2011. 880 45. Distler U, Kuharev J, Tenzer S. Biomedical applications of ion mobility-enhanced data-881 independent acquisition-based label-free quantitative proteomics. Expert Rev Proteomics. 882 2014; 883 46. Geromanos SJ, Vissers JPC, Silva JC, Dorschel CA, Li GZ, Gorenstein M V., et al. The 884 detection, correlation, and comparison of peptide precursor and product ions from data 885 independent LC-MS with data dependant LC-MS/MS. Proteomics. 2009; 886 47. Li GZ, Vissers JPC, Silva JC, Golick D, Gorenstein M V., Geromanos SJ. Database searching 887 and accounting of multiplexed precursor and product ion spectra from the data independent 888 analysis of simple and complex peptide mixtures. Proteomics. 2009; 889 48. Distler U, Kuharev J, Navarro P, Tenzer S. Label-free guantification in ion mobility-enhanced 890 data-independent acquisition proteomics. Nat Protoc [Internet]. 2016 Apr 24;11(4):795-812. 891 Available from: http://www.nature.com/articles/nprot.2016.042 892 49. Distler U, Kuharev J, Navarro P, Levin Y, Schild H, Tenzer S. Drift time-specific collision 893 energies enable deep-coverage data-independent acquisition proteomics. Nat Methods 894 [Internet]. 2014 Feb 15;11(2):167–70. Available from:

895		http://www.nature.com/articles/nmeth.2767
896	50.	Larocca JN, Norton WT. Isolation of Myelin. Curr Protoc Cell Biol [Internet]. 2006
897		Dec;33(1):3.25.1-3.25.19. Available from: http://doi.wiley.com/10.1002/0471143030.cb0325s33
898	51.	Jahn O, Tenzer S, Werner HB. Myelin proteomics: Molecular anatomy of an insulating sheath.
899		Molecular Neurobiology. 2009.
900	52.	Erwig MS, Hesse D, Jung RB, Uecker M, Kusch K, Tenzer S, et al. Myelin: Methods for
901		Purification and Proteome Analysis. In: Methods in Molecular Biology [Internet]. 2019. p. 37-
902		63. Available from: http://link.springer.com/10.1007/978-1-4939-9072-6_3
903	53.	Silva JC, Gorenstein M V., Li G-Z, Vissers JPC, Geromanos SJ. Absolute Quantification of
904		Proteins by LCMS E. Mol Cell Proteomics [Internet]. 2006 Jan;5(1):144–56. Available from:
905		http://www.mcponline.org/lookup/doi/10.1074/mcp.M500230-MCP200
906	54.	Ahrné E, Molzahn L, Glatter T, Schmidt A. Critical assessment of proteome-wide label-free
907		absolute abundance estimation strategies. Proteomics. 2013;
908	55.	Dodds JN, Baker ES. Ion Mobility Spectrometry: Fundamental Concepts, Instrumentation,
909		Applications, and the Road Ahead. J Am Soc Mass Spectrom. 2019;
910	56.	Micko S, Schlaepfer WW. PROTEIN COMPOSITION OF AXONS and MYELIN FROM RAT
911		and HUMAN PERIPHERAL NERVES. J Neurochem [Internet]. 1978 May;30(5):1041–9.
912		Available from: http://doi.wiley.com/10.1111/j.1471-4159.1978.tb12397.x
913	57.	Smith ME, Curtis BM. FROG SCIATIC NERVE MYELIN: A CHEMICAL CHARACTERIZATION.
914		J Neurochem [Internet]. 1979 Aug;33(2):447–52. Available from:
915		http://doi.wiley.com/10.1111/j.1471-4159.1979.tb05174.x
916	58.	Whitaker JN. The protein antigens of peripheral nerve myelin. Ann Neurol [Internet].
917		1981;9(S1):56–64. Available from: http://doi.wiley.com/10.1002/ana.410090710
918	59.	Gillespie CS, Sherman DL, Blair GE, Brophy PJ. Periaxin, a novel protein of myelinating
919		schwann cells with a possible role in axonal ensheathment. Neuron [Internet]. 1994
920		Mar;12(3):497–508. Available from:
921		https://linkinghub.elsevier.com/retrieve/pii/0896627394902089
922	60.	Fledrich R, Abdelaal T, Rasch L, Bansal V, Schütza V, Brügger B, et al. Targeting myelin lipid
923		metabolism as a potential therapeutic strategy in a model of CMT1A neuropathy. Nat Commun
924		[Internet]. 2018 Dec 2;9(1):3025. Available from: http://www.nature.com/articles/s41467-018-
925		05420-0
926	61.	Pareyson D, Marchesi C. Diagnosis, natural history, and management of Charcot-Marie-Tooth
927		disease. Lancet Neurol [Internet]. 2009 Jul;8(7):654–67. Available from:
928		https://linkinghub.elsevier.com/retrieve/pii/S1474442209701103
929	62.	Baets J, De Jonghe P, Timmerman V. Recent advances in Charcot-Marie-Tooth disease. Curr
930		Opin Neurol [Internet]. 2014 Oct;27(5):532-40. Available from:
931		http://content.wkhealth.com/linkback/openurl?sid=WKPTLP:landingpage&an=00019052-
932		201410000-00006
933	63.	Brennan KM, Bai Y, Shy ME. Demyelinating CMT–what's known, what's new and what's in
934		store? Neurosci Lett [Internet]. 2015 Jun;596:14–26. Available from:
935		https://linkinghub.elsevier.com/retrieve/pii/S0304394015000725

- 64. Gillespie CS, Sherman DL, Fleetwood-Walker SM, Cottrell DF, Tait S, Garry EM, et al.
 937 Peripheral Demyelination and Neuropathic Pain Behavior in Periaxin-Deficient Mice. Neuron
 938 [Internet]. 2000 May;26(2):523–31. Available from:
- 939 https://linkinghub.elsevier.com/retrieve/pii/S0896627300811848
- 65. Guilbot A. A mutation in periaxin is responsible for CMT4F, an autosomal recessive form of
 64. Charcot-Marie-Tooth disease. Hum Mol Genet [Internet]. 2001 Feb 1;10(4):415–21. Available
 65. from: https://academic.oup.com/hmg/article-lookup/doi/10.1093/hmg/10.4.415
- 66. Berger P, Niemann A, Suter U. Schwann cells and the pathogenesis of inherited motor and
 sensory neuropathies (Charcot-Marie-Tooth disease). Glia [Internet]. 2006 Sep;54(4):243–57.
 Available from: http://doi.wiley.com/10.1002/glia.20386
- Marchesi C, Milani M, Morbin M, Cesani M, Lauria G, Scaioli V, et al. Four novel cases of
 periaxin-related neuropathy and review of the literature. Neurology [Internet]. 2010 Nov
 16;75(20):1830–8. Available from:
- 949 http://www.neurology.org/cgi/doi/10.1212/WNL.0b013e3181fd6314
- 950 68. Philp NJ, Ochrietor JD, Rudoy C, Muramatsu T, Linser PJ. Loss of MCT1, MCT3, and MCT4
 951 Expression in the Retinal Pigment Epithelium and Neural Retina of the 5A11/Basigin-Null
 952 Mouse. Investig Opthalmology Vis Sci [Internet]. 2003 Mar 1;44(3):1305. Available from:
 953 http://iovs.arvojournals.org/article.aspx?doi=10.1167/iovs.02-0552
- 954 69. Patzig J, Kusch K, Fledrich R, Eichel MA, Lüders KA, Möbius W, et al. Proteolipid protein
 955 modulates preservation of peripheral axons and premature death when myelin protein zero is
 956 lacking. Glia [Internet]. 2016 Jan;64(1):155–74. Available from:
- 957 http://doi.wiley.com/10.1002/glia.22922
- 960 11;487(7408):443–8. Available from: http://www.nature.com/articles/nature11314
- 961 71. Fünfschilling U, Supplie LM, Mahad D, Boretius S, Saab AS, Edgar J, et al. Glycolytic
 962 oligodendrocytes maintain myelin and long-term axonal integrity. Nature [Internet]. 2012 May
 963 29;485(7399):517–21. Available from: http://www.nature.com/articles/nature11007
- 964 72. Morrison BM, Tsingalia A, Vidensky S, Lee Y, Jin L, Farah MH, et al. Deficiency in
- 965 monocarboxylate transporter 1 (MCT1) in mice delays regeneration of peripheral nerves
 966 following sciatic nerve crush. Exp Neurol [Internet]. 2015 Jan;263:325–38. Available from:
 967 https://linkinghub.elsevier.com/retrieve/pii/S0014488614003549
- 968 73. Morrison BM, Lee Y, Rothstein JD. Oligodendroglia: Metabolic supporters of axons. Trends in969 Cell Biology. 2013.
- 970 74. Saab AS, Tzvetanova ID, Nave K-A. The role of myelin and oligodendrocytes in axonal energy
 971 metabolism. Curr Opin Neurobiol [Internet]. 2013 Dec;23(6):1065–72. Available from:
 972 https://linkinghub.elsevier.com/retrieve/pii/S0959438813001888
- 973 75. Rinholm JE, Bergersen LH. White matter lactate Does it matter? Neuroscience [Internet].
 974 2014 Sep;276:109–16. Available from:
- 975 https://linkinghub.elsevier.com/retrieve/pii/S0306452213008464
- 976 76. Jha MK, Lee Y, Russell KA, Yang F, Dastgheyb RM, Deme P, et al. Monocarboxylate

077		
977 078		transporter 1 in Schwann cells contributes to maintenance of sensory nerve myelination during
978 070		aging. Glia. 2019;
979 080	77.	Edgar JM, McLaughlin M, Werner HB, McCulloch MC, Barrie JA, Brown A, et al. Early
980 081		ultrastructural defects of axons and axon-glia junctions in mice lacking expression of Cnp1.
981 082	70	Glia. 2009;
982	78.	Verheijen MHG. Local regulation of fat metabolism in peripheral nerves. Genes Dev [Internet].
983		2003 Oct 1;17(19):2450–64. Available from:
984 085	70	http://www.genesdev.org/cgi/doi/10.1101/gad.1116203
985 086	79.	Buchstaller J. Efficient Isolation and Gene Expression Profiling of Small Numbers of Neural
986 087		Crest Stem Cells and Developing Schwann Cells. J Neurosci [Internet]. 2004 Mar
987 089		10;24(10):2357–65. Available from:
988		http://www.jneurosci.org/cgi/doi/10.1523/JNEUROSCI.4083-03.2004
989	80.	D'antonio M, Michalovich D, Paterson M, Droggiti A, Woodhoo A, Mirsky R, et al. Gene
990 001		profiling and bioinformatic analysis of Schwann cell embryonic development and myelination.
991 002		Glia [Internet]. 2006 Apr 1;53(5):501–15. Available from:
992	04	http://doi.wiley.com/10.1002/glia.20309
993 004	81.	Schaeren-Wiemers N, Bonnet A, Erb M, Erne B, Bartsch U, Kern F, et al. The raft-associated
994 005		protein MAL is required for maintenance of proper axon–glia interactions in the central nervous
995 006		system. J Cell Biol [Internet]. 2004 Aug 30;166(5):731–42. Available from:
996 007		http://www.jcb.org/lookup/doi/10.1083/jcb.200406092
997 000	82.	Adlkofer K, Martini R, Aguzzi A, Zielasek J, Toyka K V., Suter U. Hypermyelination and
998		demyelinating peripheral neuropathy in Pmp22-deficient mice. Nat Genet [Internet]. 1995
999		Nov;11(3):274–80. Available from: http://www.nature.com/articles/ng1195-274
1000	83.	Riethmacher D, Sonnenberg-Riethmacher E, Brinkmann V, Yamaai T, Lewin GR, Birchmeier
1001		C. Severe neuropathies in mice with targeted mutations in the ErbB3 receptor. Nature
1002		[Internet]. 1997 Oct;389(6652):725–30. Available from: http://www.nature.com/articles/39593
1003	84.	Woldeyesus MT, Britsch S, Riethmacher D, Xu L, Sonnenberg-Riethmacher E, Abou-Rebyeh
1004		F, et al. Peripheral nervous system defects in erbB2 mutants following genetic rescue of heart
1005		development. Genes Dev [Internet]. 1999 Oct 1;13(19):2538–48. Available from:
1006	05	http://www.genesdev.org/cgi/doi/10.1101/gad.13.19.2538
1007	85.	Ackerman SD, Luo R, Poitelon Y, Mogha A, Harty BL, D'Rozario M, et al. GPR56/ADGRG1
1008		regulates development and maintenance of peripheral myelin. J Exp Med [Internet]. 2018 Mar
1009	00	5;215(3):941–61. Available from: http://www.jem.org/lookup/doi/10.1084/jem.20161714
1010	86.	Monk KR, Oshima K, Jors S, Heller S, Talbot WS. Gpr126 is essential for peripheral nerve
1011		development and myelination in mammals. Development [Internet]. 2011 Jul 1;138(13):2673–
1012	07	80. Available from: http://dev.biologists.org/cgi/doi/10.1242/dev.062224
1013	87.	Monk KR, Naylor SG, Glenn TD, Mercurio S, Perlin JR, Dominguez C, et al. A G Protein-
1014		Coupled Receptor Is Essential for Schwann Cells to Initiate Myelination. Science (80-)
1015		[Internet]. 2009 Sep 11;325(5946):1402–5. Available from:
1016	00	http://www.sciencemag.org/cgi/doi/10.1126/science.1173474
1017	88.	Kabzinska D, Drac H, Sherman DL, Kostera-Pruszczyk A, Brophy PJ, Kochanski A, et al.

1018 Charcot-Marie-Tooth type 4F disease caused by S399fsx410 mutation in the PRX gene. 1019 Neurology [Internet]. 2006 Mar 14;66(5):745–7. Available from: 1020 http://www.neurology.org/cgi/doi/10.1212/01.wnl.0000201269.46071.35 1021 89. Baránková L, Šišková D, Hühne K, Vyhnálková E, Sakmaryová I, Bojar M, et al. A 71-1022 nucleotide deletion in the periaxin gene in a Romani patient with early-onset slowly progressive 1023 demyelinating CMT. Eur J Neurol [Internet]. 2008 Jun;15(6):548–51. Available from: 1024 http://doi.wiley.com/10.1111/j.1468-1331.2008.02104.x 1025 90. Tokunaga S, Hashiguchi A, Yoshimura A, Maeda K, Suzuki T, Haruki H, et al. Late-onset 1026 Charcot-Marie-Tooth disease 4F caused by periaxin gene mutation. Neurogenetics [Internet]. 1027 2012 Nov 1;13(4):359–65. Available from: http://link.springer.com/10.1007/s10048-012-0338-5 1028 91. Gallardo E, García A, Ramón C, Maraví E, Infante J, Gastón I, et al. Charcot-Marie-Tooth 1029 disease type 2J with MPZ Thr124Met mutation: clinico-electrophysiological and MRI study of a 1030 family. J Neurol [Internet]. 2009 Dec 22;256(12):2061–71. Available from: 1031 http://link.springer.com/10.1007/s00415-009-5251-y 1032 92. Leal A, Berghoff C, Berghoff M, Rojas-Araya M, Ortiz C, Heuss D, et al. A Costa Rican family 1033 affected with Charcot-Marie-Tooth disease due to the myelin protein zero (MPZ) p.Thr124Met 1034 mutation shares the Belgian haplotype. Rev Biol Trop [Internet]. 2014 Dec 1;62(4):1285. 1035 Available from: http://revistas.ucr.ac.cr/index.php/rbt/article/view/13473 1036 93. Tokuda N, Noto Y, Kitani-Morii F, Hamano A, Kasai T, Shiga K, et al. Parasympathetic 1037 Dominant Autonomic Dysfunction in Charcot-Marie-Tooth Disease Type 2J with the MPZ 1038 Thr124Met Mutation. Intern Med [Internet]. 2015;54(15):1919-22. Available from: 1039 https://www.jstage.jst.go.jp/article/internalmedicine/54/15/54 54.4259/ article 1040 94. Duan X, Gu W, Hao Y, Wang R, Wen H, Sun S, et al. A Novel Asp121Asn Mutation of Myelin 1041 Protein Zero Is Associated with Late-Onset Axonal Charcot-Marie-Tooth Disease, Hearing 1042 Loss and Pupil Abnormalities. Front Aging Neurosci [Internet]. 2016 Sep 22;8. Available from: 1043 http://journal.frontiersin.org/Article/10.3389/fnagi.2016.00222/abstract 1044 95. Fabrizi GM, Tamburin S, Cavallaro T, Cabrini I, Ferrarini M, Taioli F, et al. The spectrum of 1045 Charcot-Marie-Tooth disease due to myelin protein zero: An electrodiagnostic, nerve 1046 ultrasound and histological study. Clin Neurophysiol [Internet]. 2018 Jan;129(1):21-32. 1047 Available from: https://linkinghub.elsevier.com/retrieve/pii/S1388245717310854 1048 96. Ambrozkiewicz MC, Schwark M, Kishimoto-Suga M, Borisova E, Hori K, Salazar-Lázaro A, et 1049 al. Polarity Acquisition in Cortical Neurons Is Driven by Synergistic Action of Sox9-Regulated 1050 Wwp1 and Wwp2 E3 Ubiguitin Ligases and Intronic miR-140. Neuron [Internet]. 2018 1051 Dec;100(5):1097-1115.e15. Available from: 1052 https://linkinghub.elsevier.com/retrieve/pii/S0896627318308961 1053 97. Erwig MS, Patzig J, Stever AM, Dibaj P, Heilmann M, Heilmann I, et al. Anillin facilitates septin 1054 assembly to prevent pathological outfoldings of central nervous system myelin. Elife [Internet]. 1055 2019 Jan 23;8. Available from: https://elifesciences.org/articles/43888 1056 98. Kuharev J, Navarro P, Distler U, Jahn O, Tenzer S. In-depth evaluation of software tools for 1057 data-independent acquisition based label-free guantification. Proteomics [Internet]. 2015 1058 Sep;15(18):3140–51. Available from: http://doi.wiley.com/10.1002/pmic.201400396

1059	99.	Silva JC, Denny R, Dorschel C, Gorenstein M V., Li G-Z, Richardson K, et al. Simultaneous
1060		Qualitative and Quantitative Analysis of the Escherichia coli Proteome. Mol Cell Proteomics
1061		[Internet]. 2006 Apr;5(4):589–607. Available from:
1062		http://www.mcponline.org/lookup/doi/10.1074/mcp.M500321-MCP200
1063	100.	Kammers K, Cole RN, Tiengwe C, Ruczinski I. Detecting significant changes in protein
1064		abundance. EuPA Open Proteomics [Internet]. 2015 Jun;7:11–9. Available from:
1065		https://linkinghub.elsevier.com/retrieve/pii/S2212968515000069
1066	101.	Ritchie ME, Phipson B, Wu D, Hu Y, Law CW, Shi W, et al. limma powers differential
1067		expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res [Internet].
1068		2015 Apr 20;43(7):e47–e47. Available from:
1069		http://academic.oup.com/nar/article/43/7/e47/2414268/limma-powers-differential-expression-
1070		analyses-for
1071	102.	Storey JD. The positive false discovery rate: a Bayesian interpretation and the q -value. Ann
1072		Stat [Internet]. 2003 Dec;31(6):2013–35. Available from:
1073		http://projecteuclid.org/euclid.aos/1074290335
1074	103.	Vizcaíno JA, Csordas A, Del-Toro N, Dianes JA, Griss J, Lavidas I, et al. 2016 update of the
1075		PRIDE database and its related tools. Nucleic Acids Res [Internet]. 2016 Jan 4;44(D1):D447-
1076		56. Available from: https://academic.oup.com/nar/article-lookup/doi/10.1093/nar/gkv1145
1077	104.	Schardt A, Brinkmann BG, Mitkovski M, Sereda MW, Werner HB, Nave K-A. The SNARE
1078		protein SNAP-29 interacts with the GTPase Rab3A: Implications for membrane trafficking in
1079		myelinating glia. J Neurosci Res [Internet]. 2009 Nov 15;87(15):3465–79. Available from:
1080		http://doi.wiley.com/10.1002/jnr.22005
1081	105.	de Monasterio-Schrader P, Patzig J, Möbius W, Barrette B, Wagner TL, Kusch K, et al.
1082		Uncoupling of neuroinflammation from axonal degeneration in mice lacking the myelin protein
1083		tetraspanin-2. Glia. 2013;
1084	106.	Jung M, Sommer I, Schachner M, Nave KA. Monoclonal antibody O10 defines a
1085		conformationally sensitive cell- surface epitope of proteolipid protein (PLP): Evidence that PLP
1086		misfolding underlies dysmyelination in mutant mice. J Neurosci. 1996;16(24):7920–9.
1087	107.	Stumpf SK, Berghoff SA, Trevisiol A, Spieth L, Düking T, Schneider L V., et al. Ketogenic diet
1088		ameliorates axonal defects and promotes myelination in Pelizaeus-Merzbacher disease. Acta
1089		Neuropathol [Internet]. 2019 Jul 27;138(1):147–61. Available from:
1090		http://link.springer.com/10.1007/s00401-019-01985-2
1091	108.	Archelos JJ, Roggenbuck K, Scheider-Schaulies J, Linington C, Toyka K V., Hartung H-P.
1092		Production and characterization of monoclonal antibodies to the extracellular domain of P0. J
1093		Neurosci Res [Internet]. 1993 May 1;35(1):46–53. Available from:
1094		http://doi.wiley.com/10.1002/jnr.490350107
1095	109.	Darbas A, Jaegle M, Walbeehm E, van den Burg H, Driegen S, Broos L, et al. Cell autonomy of
1096		the mouse claw paw mutation. Dev Biol [Internet]. 2004 Aug;272(2):470-82. Available from:
1097		https://linkinghub.elsevier.com/retrieve/pii/S0012160604003616
1098	110.	Catenaccio A, Court FA. Teased Fiber Preparation of Myelinated Nerve Fibers from Peripheral
1099		Nerves for Vital Dye Staining and Immunofluorescence Analysis. In: Methods in Molecular

- 1100 Biology [Internet]. 2018. p. 329–37. Available from: http://link.springer.com/10.1007/978-1-
- 1101 4939-7649-2_21
- 1102111.Hulsen T, de Vlieg J, Alkema W. BioVenn a web application for the comparison and1103visualization of biological lists using area-proportional Venn diagrams. BMC Genomics1104[Internet]. 2008;9(1):488. Available from:
- 1105 http://bmcgenomics.biomedcentral.com/articles/10.1186/1471-2164-9-488
- 1106
- 1107

- 1108 FIGURE LEGENDS
- 1109
- 1110

1111 Figure 1. Proteome analysis of peripheral myelin

1112 (A) Schematic illustration of a previous approach to the peripheral myelin proteome (41) 1113 compared with the present workflow. Note that the current workflow allows largely automated 1114 sample processing and omits labor-intense 2-dimensional differential gel-electrophoresis, thereby considerably reducing hands-on time. Nano LC-MS analysis by data-independent 1115 1116 acquisition (DIA) using three different data acquisition modes provides efficient identification and guantification of abundant myelin proteins (MS^E; see Figure 2), a comprehensive 1117 inventory (UDMS^E; see **Figures 3-4**) and gel-free differential analysis of hundreds of distinct 1118 proteins (DRE-UDMS^E; see **Figure 5**). Samples were analyzed in three biological replicates. 1119

(B) Immunoblot of myelin biochemically enriched from sciatic nerves of wild-type mice at postnatal day 21 (P21). Equal amounts of corresponding nerve lysate were loaded to compare the abundance of marker proteins for compact myelin (MPZ/P0, MBP, PMP2), noncompact myelin (PRX), the Schwann cell nucleus (KROX20/EGR2), axons (NEFH, KCNA1) and mitochondria (VDAC). Blots show n=2 biological replicates representative of n=3 biological replicates. Note that myelin markers are enriched in purified myelin; other cellular markers are reduced.

1127 (C) Number and relative abundance of proteins identified in myelin purified from the sciatic nerves of wild-type mice using three different data acquisition modes (MS^E, UDMS^E, DRE-1128 UDMS^E). Note that MS^E (orange) provides the best information about the relative abundance 1129 of high-abundant myelin proteins (dynamic range of more than four orders of magnitude) but 1130 identifies comparatively fewer proteins in purified myelin. UDMS^E (blue) identifies the largest 1131 number of proteins but provides only a lower dynamic range of about three orders of 1132 magnitude. DRE-UDMS^E (green) identifies an intermediate number of proteins with an 1133 1134 intermediate dynamic range of about four orders of magnitude. Note that MS^E with very high 1135 dynamic range is required for the quantification of the exceptionally abundant myelin protein 1136 zero (MPZ/P0), myelin basic protein (MBP) and periaxin (PRX). ppm, parts per million.

(D) Venn diagram comparing the number of proteins identified in PNS myelin by MS^E,
 UDMS^E and DRE-UDMS^E. Note the high overlap of identified proteins.

- (E) Venn diagram of the proteins identified in PNS myelin by UDMS^E in this study compared
 with those identified in two previous approaches (41,42).
- 1141
- 1142

Figure 1-supplement 1. Clustered heatmap of Pearson's correlation coefficients forprotein abundance comparing data acquisition modes.

1145 The heatmap compares the log_2 transformed ppm protein abundance values to assess 1146 peripheral myelin purified from wild type mice using three data acquisition modes (MS^E , 1147 $UDMS^E$, DRE-UDMS^E). The inset shows the color key and the histogram for the values of the 1148 correlation coefficients. Note that the runs cluster with a high overall correlation (>0.75) into 1149 three conditions defined by the acquisition mode, in agreement with the experimental design. 1150 Among the samples analyzed by different acquisition modes, DRE-UDMS^E similarly 1151 correlates with both MS^E and UDMS^E, reflecting its intermediate nature.

11521153

1154 Figure 2. Relative abundance of peripheral myelin proteins

MS^E was used to identify and quantify proteins in myelin purified from the sciatic nerves of wild-type mice at P21; their relative abundance is given as percent with relative standard deviation (% +/- RSD). Note that known myelin proteins constitute >80% of the total myelin protein; proteins not previously associated with myelin constitute <20%. Mass spectrometric quantification based on 3 biological replicates per genotype with 4 technical replicates each (see **Figure 1-source data 1**).

- 1161
- 1162

1163 Figure 3. Developmental mRNA abundance profiles of myelin-associated genes

1164 (A) K-means clustering was performed for the mRNA profiles of those 1046 proteins in our 1165 myelin proteome inventory for which significant mRNA expression was found by RNA-Seg in 1166 the sciatic nerve of rats dissected at ages E21, P6, P18 and 6 months (M6). Note that this 1167 filtering strategy allows to selectively display the developmental abundance profiles of those 1168 transcripts that encode myelin-associated proteins rather than of all transcripts present in the 1169 nerve. Standardized mRNA abundance profiles are shown (n=4 biological replicates per 1170 age). Known myelin genes are displayed in red. For comparison, Pmp22 mRNA was 1171 included although the small tetraspan protein PMP22 was not mass spectrometrically 1172 identified due to its unfavorable distribution of tryptic cleavage sites. Normalized counts for all 1173 mRNAs including those displaying developmentally unchanged abundance are provided in

- 1174 **Figure 3-Source data 1**.
- 1175 **(B)** Numbers of mRNAs per cluster.
- 1176
- 1177

1178 Figure 4. Categorization of annotated protein functions

1179 All proteins identified in peripheral myelin by UDMS^E (turquoise) and the respective 1180 developmental expression clusters (**Figure 3**; shades of red) were analyzed for 1181 overrepresented functional annotations using gene ontology (GO) terms. The graph displays 1182 the percentage of proteins in each cluster that were annotated with a particular function. For 1183 comparison, known myelin proteins were annotated. n.o., not over-represented.

1184 1185

1186 Figure 5. Molecular analysis of myelin in the *Prx^{-/-}* mouse model of CMT4F

1187 **(A)** Myelin purified from sciatic nerves dissected from $Prx^{-/-}$ and control mice at P21 was 1188 separated by SDS-PAGE (0.5 µg protein load) and proteins were visualized by silver 1189 staining. Bands constituted by the most abundant myelin proteins (MPZ/P0, MBP, PRX) are 1190 annotated. Note that no band constituted by PRX was detected in $Prx^{-/-}$ myelin and that 1191 several other bands also display genotype-dependent differences in intensity. Gel shows n=2 1192 biological replicates representative of n=3 biological replicates.

(B) The relative abundance of proteins in myelin purified from *Prx^{-/-}* sciatic nerves as quantified by MS^E is given as percent with relative standard deviation (% +/- RSD). Note the increased relative abundance of MPZ/P0 and MBP compared to wild-type myelin (see Figure 2) when PRX is lacking. Mass spectrometric quantification based on 3 biological replicates with 4 technical replicates each (see Figure 5-source data 1).

- (C,D) Differential proteome analysis by DRE-UDMS^E of myelin purified from Prx^{-/-} and wild-1198 1199 type mice. Mass spectrometric quantification based on 3 biological replicates per genotype 1200 with 4 technical replicates each (see Figure 5-source data 2). (C) Top 40 proteins of which 1201 the abundance is reduced (blue) or increased (red) in peripheral myelin purified from Prx^{-/-} 1202 compared to wild-type mice with the highest level of significance according to the -log₁₀ 1203 transformed q-value (green). In the heatmaps, each horizontal line corresponds to the fold-1204 change (FC) of a distinct protein compared to its average abundance in wild-type myelin 1205 plotted on a log₂ color scale. Heatmaps display 12 replicates, i.e. 3 biological replicates per genotype with 4 technical replicates each. (D-D") Volcano plots representing genotype-1206 1207 dependent quantitative myelin proteome analysis. Data points represent quantified proteins in Prx^{-/-} compared to wild-type myelin and are plotted as the log2-transformed fold-change 1208 1209 (FC) on the x-axis against the -log10-transformed g-value on the y-axis. Stippled lines mark a 1210 -log10-transformed q-value of 1.301, reflecting a q-value of 0.05 as significance threshold. 1211 Highlighted are the datapoints representing the Top 10 proteins displaying highest zdist 1212 values (Euclidean distance between the two points (0,0) and (x,y) with $x = \log_2(FC)$ and y = -1213 log10(q-value) (red circles in **D**), immune-related proteins (purple circles in **D**ⁱ), proteins of 1214 the extracellular matrix (ECM; yellow circles in D") and known myelin proteins (blue circles in 1215 D""). n.d., not detected; n.g., no q-value computable due to protein identification in one 1216 genotype only. Also see Figure 5-supplement 1.
- 1217 **(E)** Immunoblot of myelin purified from $Prx^{-/-}$ and control sciatic nerves confirms the reduced 1218 abundance of DRP2, SLC16A1/MCT1, BSG and PMP2 in $Prx^{-/-}$ myelin, as found by

differential DRE-UDMS^E analysis (in Figure 5C,D). PRX was detected as genotype control;
 PLP/DM20 and ATP1A1 serve as markers. Blot shows n=2 biological replicates per
 genotype.

1222 **(F)** Teased fiber preparations of sciatic nerves dissected from $Prx^{-/-}$ and control mice 1223 immunolabelled for MAG (red) and SLC16A1 (green). Note that SLC16A1 co-distributes with 1224 MAG in Schmidt-Lanterman incisures (SLI) in control but not in $Prx^{-/-}$ nerves, in accordance 1225 with the reduced abundance of SLC16A1 in $Prx^{-/-}$ myelin (**Figure 5C-E**). Also note that, in 1226 $Prx^{-/-}$ myelin, SLI were largely undetectable by MAG immunolabeling.

1227

1228

1229 Figure 5-supplement 1. Clustered heatmap of Pearson's correlation coefficients for 1230 protein abundance comparing genotypes.

1231 **(A)** The heatmap compares the \log_2 transformed ppm protein abundance values from the 1232 DRE-UDMS^E runs to assess peripheral myelin purified from wild type and $Prx^{-/-}$ mice. The 1233 inset shows the color key and the histogram for the values of the correlation coefficients. 1234 Note that the runs cluster with a high overall correlation (>0.85) into two conditions defined 1235 by the genotype, in agreement with the experimental design.

- 1236 (B) Volcano plot representing genotype-dependent guantitative myelin proteome analysis. Data points represent quantified proteins in Prx^{-2} compared to wild-type myelin plotted as the 1237 1238 log2-transformed fold-change (FC) on the x-axis against the -log10-transformed g-value on 1239 the y-axis. Note the different axis scale compared to Figure 5D. Stippled line marks a -log10-1240 transformed q-value of 1.301, reflecting a q-value of 0.05 as significance threshold. 1241 Highlighted is the datapoint for PRX to illustrate that only trace amounts of PRX were detected when assessing *Prx^{-/-}* myelin. ATP2A1, ATP1A4 and PLCD1 were not detected in 1242 *Prx^{-/-}* myelin. 1243
- 1244
- 1245

1246 Figure 6. Progressive loss and reduced diameters of peripheral axons in *Prx^{-/-}* mice

1247 **(A-D)** Genotype-dependent quantitative assessment of light micrographs of toluidine-stained 1248 semi-thin sectioned quadriceps nerve dissected at 2, 4 and 9 months of age reveals

- 1249 progressive loss of peripheral axons in Prx^{-2} compared to control mice.
- (A) Representative micrographs. Arrows point at myelinated axons; asterisk denotes an
 unmyelinated axon; arrowhead points at a myelin whorl lacking a recognizable axon. Scale
 bars, 10 µm.
- 1253 **(B)** Total number of axons per nerve that are not associated with a Remak bundle.
- 1254 **(C)** Total number of myelinated axons per nerve.
- 1255 **(D)** Total number per nerve of myelin whorls that lack a recognizable axon.

- 1256 Mean +/ SD, n=3-4 mice per genotype and age; *P<0.05, **P<0.01, ***P<0.001 by Student's 1257 unpaired t-test.
- 1258 (**E-G**) Genotype-dependent assessment of myelinated axons shows a shift toward reduced 1259 axonal diameters in quadriceps nerves of $Prx^{-/-}$ compared to control mice at 2 months (**E**), 4 1260 months (**F**) and 9 months (**G**) of age. Data are presented as frequency distribution with 0.5 1261 µm bin width. ***, p<0.001 by two-sided Kolmogorow-Smirnow test. For precise p-values see
- 1262 methods section.
- 1263
- 1264

Figure 1-source data 1. Label-free quantification of proteins in wild-type PNS myelin fractions by three different data acquisition modes

1267 Identification and quantification data of detected myelin-associated proteins. Tryptic peptides 1268 derived from four technical replicates (replicate digestion and replicate injection) per three 1269 biological replicate (20 sciatic nerves pooled from 10 animals) were analyzed by LC-MS (12 1270 runs in total). Proteins (FDR < 1%; 2 peptides/protein) and peptides (FDR < 1%; ≥7 amino 1271 acids) were identified by database search against the UniprotKB/SwissProt mouse database 1272 using PLGS. Data were post-processed with the software package ISOQuant to calculate 1273 absolute in-sample amounts for each detected protein based on the TOP3 approach. 1274 Reported abundance values are defined as the relative amount of each protein in respect to 1275 the sum over all detected proteins (ppm: parts per million (w/w) of total protein). Typical 1276 contaminant proteins like keratins were filtered.

- 1277 \rightarrow sheet 1: protein identification details
- 1278 \rightarrow sheet 2: WT myelin proteome by MS^E
- 1279 \rightarrow sheet 3: WT myelin proteome by UD-MS^E
- 1280 \rightarrow sheet 4: WT myelin proteome by DRE UD-MS^E
- 1281 → sheet 5: 45 proteins additionally identified in WT myelin by 1D-gel-LC-MS
- 1282 1283

1284 Figure 3-source data 1. Normalized developmental mRNA abundance data

- 1285 \rightarrow sheet 1: normalized values for all individual 4 biological replicates per age
- 1286 \rightarrow sheet 2: normalized values for biological replicates averaged to give mean per age
- 1287 1288

1289Figure 5-source data 1. Label-free quantification of proteins in PNS myelin fractions1290from *Prx*^{-/-} mice by MSe

- 1291 Identification and quantification data of detected myelin-associated proteins. Tryptic peptides
- 1292 derived from four technical replicates (replicate digestion and replicate injection) per three

1293 biological replicate (20 sciatic nerves pooled from 10 animals) were analyzed by LC-MS (12 1294 runs in total). Proteins (FDR < 1%; 2 peptides/protein) and peptides (FDR < 1%; ≥7 amino 1295 acids) were identified by database search against the UniprotKB/SwissProt mouse database 1296 using PLGS. Data were post-processed with the software package ISOQuant to calculate 1297 absolute in-sample amounts for each detected protein based on the TOP3 approach. 1298 Reported abundance values are defined as the relative amount of each protein in respect to 1299 the sum over all detected proteins (ppm: parts per million (w/w) of total protein). Typical 1300 contaminant proteins like keratins were filtered.

- 1301 \rightarrow sheet 1: protein identification details
- 1302 \rightarrow sheet 2: *Prx*^{-/-} myelin proteome by MS^E
- 1303
- 1304

1305Figure 5-source data 2. Label-free quantification of proteins in PNS myelin fractions1306from WT and *Prx^{-/-}* mice by DRE-UDMSe

1307 Identification and quantification data of detected myelin-associated proteins by DRE-UDMSe. 1308 For each genotype, tryptic peptides derived from four technical replicates (replicate digestion 1309 and replicate injection) per three biological replicate (20 sciatic nerves pooled from 10 1310 animals) were analyzed by LC-MS (24 runs in total). Proteins (FDR < 1%; 2 peptides/protein) 1311 and peptides (FDR < 1%; \geq 7 amino acids) were identified by database search against the 1312 UniprotKB/SwissProt mouse database using PLGS. Data were post-processed with the 1313 software package ISOQuant to calculate absolute in-sample amounts for each detected 1314 protein based on the TOP3 approach. Reported abundance values are defined as the 1315 relative amount of each protein in respect to the sum over all detected proteins (ppm: parts 1316 per million (w/w) of total protein). Typical contaminant proteins like keratins were filtered. The 1317 -log10-transformed q-value was plotted against the log2-transformed fold change to obtain 1318 the volcano plot shown in Figure 5D. As no imputation of missing values was performed, 1319 proteins exclusive for only one of the conditions do not appear in the volcano plot, but are 1320 appended at the end of the list. Criteria for statistically significant regulation were as follows: 1321 fold change of at least 1.5 and q-value below 0.05.

- 1322 \rightarrow sheet 1: protein identification details
- 1323 \rightarrow sheet 2: comparison of WT vs. *Prx*^{-/-} myelin proteome by DRE-UDMS^E
- 1324
- 1325

Protein name	Gene	Reference	TMD	Cluster
2-hydroxyacylsphingosine 1-beta-galactosyltransferase	Ugt8	Bosio et al., 1996	2	P6-up
Syntrophin a1	Snta1	Fuhrmann-Stroissnigg et al., 2012	-	P18-up
Annexin A2	Anxa2	Hayashi et al., 2007	-	Descending
Band 4.1 protein B / 4.1B	Epb4113	Ivanovic et al., 2012	-	Descendin
Band 4.1 protein G / 4.1G	Epb4112	Ohno et al., 2006	-	P6-up
Breast carcinoma-amplified sequence 1	Bcasl	Ishimoto et al., 2017	-	P6-up
Cadherin 1/ E-Cadherin	Cdh1	Fannon et al., 1995	1	P18-up
Carbonic anhydrase 2	Ca2	Cammer et al., 1987	-	Descendin
Catenin a1	Ctnna1	Murata et al., 2006	-	U-shaped
Catenin ß1	Ctnnb1	Fannon et al., 1995	-	Descendin
Caveolin 1	Cavl	Mikol et al., 2002	1	P18-up
CD9, tetraspanin 29	Cd9	Ishibashi et al., 2004	4	P18-p
CD59A	Cd59a	Funabashi et al., 1994	1	P18-up
CD47, integrin-associated signal transducer	Cd47	Gitik et al., 2011	5	P6-up
CD81, tetraspanin 28	Cd81	Ishibashi et al., 2004	4	P18-up
CD82, tetraspanin 27	Cd82	Chernousov et al., 2013	4	P18-up
CD151, tetraspanin 24	Cd151	Patzig et al., 2011	4	P18-up
Cell adhesion molecule 4/ NECL4	Cadm4	Spiegel et al., 2007	1	P6-up
Cell division control protein 42	Cdc42	Benninger et al., 2007	-	P6-up
Cell surface glycoprotein MUC18	Mcam	Shi et al., 1998	1	Descendin
Ciliary neurotrophic factor	Cntf	Rende et al., 1992	-	Late-up
CKLF-like MARVEL TMD-containing 5	Cmtm5	Patzig et al., 2011	4	P6-up
Claudin-19	Cldn19	Miyamoto et al., 2005	4	P6-up
Cofilin 1	Cfl1	Sparrow et al., 2012	-	Descendin
Crystallin α2	Cryab	d'Antonio et al., 2006	-	P18-up
Cyclic nucleotide phosphodiesterase	Cnp	Matthieu et al., 1980	-	P6-up
Sarcoglycan δ	Sgcd	Cai et al., 2007	1	Late-up
Dihydropyrimidinase related protein 1	Crmp1	d'Antonio et al., 2006	-	Descendin
Disks large homolog 1	Dlg1	Cotter et al., 2010	-	Descendin
Dynein light chain 1	Dynll1	Myllykoski et al. 2018	-	P6-up
Dystroglycan	Dagl	Yamada et al, 1994	1	P6-up
Dystrophin/DP116	Dmd	Cai et al., 2007	-	P6-up
Dystrophin-related protein 2	Drp2	Sherman et al., 2001	-	P18-up
E3 ubiquitin-protein ligase NEDD4	Nedd4	Liu et al., 2009	-	Descendin
Ezrin	Ezr	Scherer et al., 2001	-	P6-up
Fatty acid synthase	Fasn	Salles et al., 2002	-	P6-up
Flotillin 1	<i>Flot1</i>	Lee et al., 2014	-	P18-up
Gap junction ß1 protein / Cx32	Gjbl	Li et al., 2002	4	P18-up
Gap junction γ3 protein / Cx29	Gjc3	Li et al., 2002	1	P6-up
Gelsolin	Gsn	Gonçalves et al., 2010	-	Late-up
Glycogen synthase kinase 3ß	Gsk3b	Ogata et al., 2004	-	P6-up
Integrin $\alpha 6$	Itga6	Nodari et al., 2008	1	P6-up
Integrin aV	Itgav	Chernousov & Carey, 2003	1	Descendin
Integrin ß1	Itgb1	Feltri et al., 2002	1	Descendin
Integrin ß4	Itgb4	Quattrini et al., 1996	2	P18-up
Junctional adhesion molecule C	Jam3	Scheiermann et al., 2007	1	P18-up
Laminin α2	Lama2	Yang et al., 2005	-	P6-up
Laminin α4	Lama4	Yang et al., 2005	-	Descendin
Laminin ß1	Lamb1	LeBeau et al., 1994	-	Descendin
Laminin B2	Lamb2	LeBeau et al., 1994	-	P18-up
Laminin γ1	Lamc1	Chen & Strickland, 2003	-	Descendin
Membrane Palmitoylated Protein 6	Мррб	Saitoh et al., 2019	-	P6-up
Microtubule-associated protein 1A	Mapla	Fuhrmann-Stroissnigg et al., 2012	-	P18-up
Microtubule-associated protein 1B	Map1b	Fuhrmann-Stroissnigg et al., 2012	-	P6-up
Mitogen-activated protein kinase 1/ ERK2	Mapk1	Mantuano et al., 2015	-	Descendin
Mitogen-activated protein kinase 3/ ERK1	Mapk3	Mantuano et al., 2015	-	P18-up
Moesin	Msn	Scherer et al., 2001	-	Unchange
Monocarboxylate transporter 1	Slc16a1	Domenech-Estevez et al., 2015	11	P18-up

Myelin associated glycoprotein	Mag	Figlewicz et al., 1981	1	P6-up
Myelin basic protein	Mbp	Boggs, 2006	-	P6-up
Myelin protein 2	Pmp2	Trapp et al., 1984	-	P18-up
Myelin protein zero/ P0	Mpz	Giese et al., 1992	1	P6-up
Myelin proteolipid protein	Plp1	Garbern et al., 1997	4	P6-up
Myotubularin-related protein 2	Mtmr2	Bolino et al., 2004	-	P6-up
Noncompact myelin-associated protein	Ncmap	Ryu et al., 2008	1	P18-up
NDRG1, N-myc downstream regulated	Ndrg1	Berger et al., 2004	-	P18-uP
Neurofascin	Nfasc	Tait et al., 2000	2	P18-up
Nidogen 1	Nid1	Lee et al., 2007	-	Descending
P2X purinoceptor 7	P2rx7	Faroni et al., 2014	-	P6-up
Paxillin	Pxn	Fernandez-Valle et al., 2002	-	P6-up
Periaxin	Prx	Gillespie et al., 1994	-	P6-up
Plasmolipin	Pllp	Bosse et al., 2003	4	P18-up
Profilin 1	Pfn1	Montani et al., 2014	-	Descending
Lin-7 homolog C	Lin7c	Saitoh et al., 2017	-	P6-up
Rac1	Rac1	Benninger et al., 2007	-	U-Shaped
Radixin	Rdx	Scherer et al., 2001	-	Descending
RhoA	Rhoa	Brancolini et al., 1999	-	U-Shaped
Septin 2	Sept 2	Buser et al., 2009	-	Descending
Septin 7	Sept 7	Buser et al., 2009	-	U-Shaped
Septin 8	Sept 8	Patzig et al., 2011	-	P18-up
Septin 9	Sept 9	Patzig et al., 2011	-	P6-up
Septin 11	Sept 11	Buser et al., 2009	-	Descending
Sirtuin 2, NAD-dependent deacetylase	Sirt2	Werner et al., 2007	-	P18-up
Spectrin alpha chain, non-erythrocytic 1	Sptan1	Susuki et al., 2018	-	P18-up
Spectrin beta chain, non-erythrocytic 1	Sptbn1	Susuki et al., 2018	-	P18-up
Tight junction protein ZO-1	Tjp1	Poliak et al., 2007	-	P6-up
Tight junction protein ZO-2	Tjp2	Poliak et al., 2007	-	P6-up
Transferrin	Tf	Liu et al., 1990	2	Late-up
Vimentin	Vim	Triolo et al., 2012	-	Unchanged
Vinculin	Vcl	Beppu et al., 2015	-	Descending

Table 1. Known myelin proteins in the myelin proteome. Proteins mass-spectrometrically identified in peripheral myelin are compiled according to availability of prior references as myelin proteins. Given are the official gene name, one selected reference, the number of transmembrane domains (TMD) and the mRNA abundance profile cluster (see Figure 3).

Protein name	Gene name	OMIM#	Gene Locus	Neuropathy
Monoacylglycerol lipase ABHD12	ABHD12	613599	20p11.21	PHARC
Apoptosis-inducing factor 1	AIFM1	300169	Xq26.1	CMTX4, DFNX5
Na+/K+ -transporting ATPase $\alpha 1$	ATP1A1	182310	1p13.1	CMT2DD
Cytochrome c oxidase subunit 6A1	COX6A1	602072	12q24.31	CMTRID
Dystrophin-related protein 2	DRP2	300052	Xq22.1	CMTX
Dynactin subunit 1	DCTN1	601143	2p13.1	DHMN7B
Dynamin 2	DNM2	602378	19p13.2	CMT2M, CMTDIB
Cytoplasmic dynein 1 heavy chain 1	DYNC1H1	600112	14q32.31	CMT20, SMALED1
E3 SUMO-protein ligase	EGR2	129010	10q21.3	CMT1D, CMT3, CMT4E
Glycine-tRNA ligase	GARS (Gart)	600287	7p14.3	CMT2D, HMN5A
Gap junction B1 protein / Cx32	GJB1	304040	Xq13.1	CMTX1
Guanine nucleotide-binding protein B4	GNB4	610863	3q26.33	CMTDIF
Histidine triad nucleotide-binding protein 1	HINT1	601314	5q23.3	NMAN
Hexokinase 1	HK1	142600	10q22.1	CMT4G
Heat shock protein ß1	HSPB1	602195	7q11.23	CMT2F, DHMN2B
Kinesin heavy chain isoform 5A	KIF5A	602821	12q13.3	SPG10
Prelamin A/C	LMNA	150330	1q22	CMT2B1
Neprilysin	MME	120520	3q25.2	CMT2T, SCA43
Myelin protein zero/ P0	MPZ	159440	1q23.3	CHN2,CMT1B, CMT2I, CMT2J,CMT3, CMTDID, Roussy-Levy syndrome
Myotubularin-related protein 2	MTMR2	603557	11q21	CMT4B1
Alpha-N-acetylglucosaminidase	NAGLU (NAGA)	609701	17q21.2	CMT2V
NDRG1, N-myc downstream regulated	NDRG1	605262	8q24.22	CMT4D
Neurofilament heavy polypeptide	NEFH	162230	22q12.2	CMT2CC
Neurofilament light polypeptide	NEFL	162280	8p21.2	CMT2E, CMT1F, CMTDIG
Peripheral myelin protein 2	PMP2	170715	8q21.13	CMT1G
Peripheral myelin protein 22	PMP22	601907	17p12	CMT1A, CMT1E, CMT3, HNPP,
Ribose-phosphate pyrophosphokinase 1	PRPS1	311850	Xq22.3	Roussy-Levy syndrome Arts syndrome, CMTX5, DFNX1
Periaxin	PRX	605725	19q13.2	CMT4F, CMT3
Ras-related protein Rab 7a	RAB7A	602298	3q21.3	CMT2B
Septin 9	SEPT9	604061	17q25.3	HNA
Transitional ER-ATPase	VCP	601023	9p13.3	CMT2Y
Tryptophan-tRNA ligase, cytoplasmic	WARS	191050	14q32.32	HMN9
Tyrosine-tRNA ligase, cytoplasmic	YARS	603623	1p35.1	DI-CMTC

Table 2. Peripheral myelin proteins identified in PNS myelin involved in neuropathological diseases. Proteins massspectrometically identified in peripheral myelin were analyzed regarding the involvement of the ortholog human gene in neuropathological diseases. PMP22 was added, though it was not identified by MS analyses due to its unfavorable distribution of tryptic cleavage sites. CMT, Charcot-Marie-Tooth disease; DHMN, distal hereditary motor neuropathy; DI-CMTC, dominant intermediate CMTC; DFN, X-linked deafness; HMN, hereditary motor neuropathy; HSAN, hereditary sensory and autonomic neuropathy; HNA, hereditary sensory and autonomic neuropathy; OMIM, Online Mendelian Inheritance in Man; PHARC, polyneuropathy, hearing loss, ataxia, retinitis pigmentosa and cataract; SCA, spinocerebellar ataxia; SPG, spastic paraplegia.

1341